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Abstract 
The development of protecting groups for the NE function of lysine have been 
investigated in order to prevent ambiguous coupling during fragment condensation of 
peptide segments. A number of enzyme cleavable protecting group candidates have 
been synthesised based on phenylacetyl derivatives and conditions for their enzymatic 
removal optimised. The syntheses of various test peptides utilising this class of 
protecting groups have been completed and shown to be suitable for the synthesis of 
small peptides but inappropriate for longer chain polypeptides such as the protein 
ubiquitin (76 amino acids). 
An alternative chemical approach has been investigated with the synthesis, purification 
and deprotection of ubiquitin with six out of seven lysine residues protected as the 
tris(hydroxymethyl)nitromethyl carbamate. The ubiquitin recovered has been purified 
to homogeneity and characterised. 
The total chemical synthesis of deglycosylated human interferon-gamma (dhlFN-y) 
(143 residues) has been achieved by stepwise solid phase synthesis. The affinity for 
carbon of the Na_protecting  group tetrabenzo[a,c,g,i]fluorenyl-17-methoxycarbonyl 
(Thfinoc) has been exploited to expedite the purification of dlilFN-'y. A purification 
protocol has been developed which afforded homogeneous material. 
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Chapter 1: Introduction 
1.1: Solid Phase Peptide Synthesis 
1.1.1: General introduction 
Demand is increasing for both the total synthesis and chemical modification of 
peptides and proteins for research, clinical and industrial purposes. This provides a 
strong incentive for continuous improvement of the general methodology for long 
chain polypeptide synthesis. 
The conceptual breakthrough which stimulated an explosion in long chain polypeptide 
synthesis was the invention of the solid phase method by Merrifield.' In 1963 
Merrifield demonstrated the feasibility of his revolutionary idea by synthesising a 
tetrapeptide through the sequential condensation of protected amino acids from the C-
terminus with the first amino acid covalently bound to an insoluble solid polystyrene 
support. After stepwise assembly the peptide was cleaved from the solid support with 
simultaneous removal of side-chain protecting groups. 
The development of solid phase peptide synthesis (SPPS) greatly facilitated the task 
of peptide formation. The techniques used in stepwise SPPS are simple, particularly 
the purification of resin-bound intermediates by filtration and washing. Also, the 
attachment of a protected peptide to a swollen resin support overcomes the poor 
solubility of protected peptide intermediates. The shortcomings of stepwise SPPS, 
including sequence-dependant difficulties in chain assembly, have to a large extent 
been overcome and are not obstacles to practical peptide synthesis. 
Since its introduction every facet of each stage of solid phase methodology has been 
subjected to detailed scrutiny with a view to optimisation. The resulting technological 
improvements in SPPS, together with a parallel refinement of analytical and 





this method. In addition, the basic principle of the solid phase method has been 
extended to other areas such as oligonucleotide synthesis and the ever expanding field 
of combinatorial libraries. 
1.1.2: Protecting group tactics 
The chemical synthesis of peptides requires the unambiguous formation of an amide 
bond between two amino acids. It is therefore necessary to protect reactive 
functionalities other than those involved in the peptide bond formation. Such 
protection must be reversible without damage to the assembled peptide chain. For 
stepwise SPPS at least two types of protection are necessary: temporary Na 
protection, removable after formation of each peptide bond; and semi-permanent side-
chain protection removable only after assembly of the complete peptide chain. 
There are two main techniques in SPPS which are dictated by the protecting group 
strategy used. The first, is associated with Merrifield '2 and involves N  tert-
butyloxycarbonyl (Boc) (1) protected amino acids in combination with benzyl-based 
side-chain protecting groups. Whereas the second employs N  9-
fluorenylmethoxycarbonyl (Fmoc) 3  (2) protected amino acids and tert-butyl based 
side-chain protection. 
The fundamental operations of the protecting group strategies in Boc and Fmoc SPPS 
are shown in Figure 1. 
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Figure 1 Protecting group strategies in Boc and Fmoc SPPS 
Zgroup=benzyloxycarbonyl; BzI=benzyl; Bu'= tert-butyl; Boc= ten- 
butyloxycarbonyl and Fmoc= 9-fluorenylmethoxycarbonyl 
The N  Boc, benzyl-based side-chain protection strategy relies on the principle of 
graduated acid lability of the protecting groups. The Boc group is cleaved by 
trifluoroacetic acid while the more stable benzyl-based protecting groups require 
stronger acids such as hydrogen fluoride or trifluoromethanesulphomc acid. Themain 
problems encountered with Boc SPPS include the incomplete orthogonality between 
the temporary protecting groups and the semi-permanent protecting groups (which 
include the peptide-polymer link, cleavage of which would result in loss of peptide). 
In addition, the use of strong acids not only requires specialised app artatus but may 
have deleterious effects on the peptide product. 
The development of the base labile Fmoc group 3 and its incorporation into automated 
SPPS4 '5 '6 provided an alternative to Boc synthesis and a truly orthogonal strategy. 
The Fmoc-based strategy uses different mechanisms for removal of the Na  and side-
chain protecting groups. The N  Fmoc group is removed with the mild base, 
piperidine and the tert-butyl based side-chain protecting groups are cleaved with 
trifluoroacetic acid. The general strategy for Fmoc SPPS is outlined in Figure 2. 
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X 	+ 	HO—!_Linker_J-J Polystyrene 
(i) 
—0—f Linker-j Polystyrene 
I (ii) 
1Juv 
monitor R'  
H2N H Linker H Polystyrene 81 
R" 
Repeat n times 	
FflCNH-LC,_.X I (iv) 
81 
NH r. Linker H Polystyrene 
(iii) 
Rn 	R" 	0 
H2N"C-------JNHyL0H Linker H Polystyrene 
(v) 
TARGET SEQUENCE 
Figure 2 General strategy of J'P' Fmoc SPPS: (i) attachment offirst amino acid to 
the resin; (ii) capping with acetic anhydride; (iii) deprotection of Na Fmoc with 
piperidine; (iv) coupling of next N'protected amino acid and (v) simultaneous 
cleavage ofprotecting groups and peptide-resin linkage with aqueous 
trjfluoroacetic acid 
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1.1.3: Role of the resin support 
The term 'solid phase' is actually misleading since the reactions do not take place in, 
or on the surfaces of; solid phases but inside a swollen polymeric network. Several 
requirements for the solid support have been identified' and are summarised below. 
The swollen polymer resin must: 
• possess functionality which allows attachment of the peptide chain 
• be stable to all reaction conditions 
• aid diffusion of reagents and removal of waste products 
• exert a strong solvating effect on the attached peptide chains 
• minimise aggregation between peptide chains 
The solid support, introduced by Merrifield, is a unique copolymer of polystyrene-
divinylbenzene which has been chioromethylated and is in the form of beads. The C-
terminal W Boc protected amino acid salt of the target peptide is then attached to the 
polymer by nucleophilic displacement. The beads of resin are swollen in an organic 
solvent, such as DCM and peptide synthesis takes place inside the swollen polymeric 
matrix. The swollen peptide resin is approximately 80-90% solvent by volume, and 
there are on the order of 1012  growing peptide chains per polymer bead. 
The Merrifield crosslinked-polystyrenes have found widespread use in both Fmoc and 
Boc SPPS. The main drawback with the Merrifield cross-linked polystyrenes is that 
the favoured solvent for swelling the polymeric matrix (DCM) does not fully solvate 
the conjugated peptide chain. Good solvation is crucial because it allows free access 
of reagents to reactive sites resulting in an increase in reaction rates and coupling 
yields for each step. With this objective Sheppard" reasoned that a resin that was 
more compatible with the polarity of the growing peptide chain would be beneficial. 
This led to the introduction of polyamide resins which are now employed in Fmoc- 
sis.9 ' 10 
5 
Introduction 
1.1.4: Resin linkages 
Refinements in SPPS have led to the introduction of specific linkers between the solid 
support and the peptide chain which can be exploited to suit the required synthetic 
strategy. In Fmoc SPPS a more acid labile peptide resin linkage can be used 
compared to the Merrifield PAM" resin (3) used in Boc chemistry. The most popular 
linker used in Fmoc SPPS is the 4-alkoxybenzylalcohol (Wang) linker 12  (4) which is 





HOj1 1 i 	HO..JI11 (3) 	 (4) 
The demand for fully protected peptide fragments for convergent synthesis has led to 
the introduction of a new class of linker in order to leave the t-butyl based protecting 
groups in place (Figure 3). To obtain the protected fragments these linkers are 
cleaved under extremely mild conditions such as very dilute trifluoroacetic acid 13  (5), 




HO,JJ (7) CH2CONBCH2CON }1__j Polystyrene 
Figure 3 Resin linkers cleaved under mild conditions 
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The above resins all give the C-terminal carboxylic acid on cleavage, however 
alternative functionalities can be generated by modifying the linker. For example C-
terminal amides 16  and hydrazides 16" 7 are obtained by utilising a linker such as the 5 
substituted 9-Fmoc aminodibenzocycloheptadiene derivative (8) which is cleaved with 
dilute trifluoroacetic acid. These C-terminal functionalities are important since many 
biologically significant peptides have a C-terminal amide and C-terminal hydrazides 




PolystyreneR = Fni,cNB 
/\ 
 
R = BocNHNH 
0 
(8) 
Photolabile linkers have found widespread use throughout solid phase synthesis. 18 
Photolytic release of peptides offers a method of orthogonal cleavage which 
complements the traditional use of TFA or HF. Recently a new class of ortho-
nitrobenzyl photolabile supports (9) have been introduced with the improvement over 
previous linkers in that they are cleaved faster and liberate methionine-containing 
peptides with minimal oxidation.' 9 
by - Peptide acid 
X=NH 	mo Peptide anile 
Poystyer 
(9) 
1.1.5: Activation and coupling: peptide bond formation 
Efficient peptide bond formation in SPPS requires the generation and aminolysis of 
activated carboxy derivatives via the direct electrophilic acylation mechanism. 20,21 
This requires the replacement of the carboxylic acid hydroxyl group with an 
7 
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electronegative substituent (X), which enhances the electrophilicity of the carbonyl 
carbon thus facilitating attack by the amino component. Activation is necessary 
because ordinary carboxylic acids simply form salts with amines at ambient 
temperature; the transformation of these salts directly into amides requires severe 
heating which is quite incompatible with the presence of other functional groups. 
* Th _ 	
10 R' X H2NR 	- R' NHR  
R NHR 
Figure 4 Direct electrophilic acylation mechanism 2012' 
Ideal chemistry would allow peptide bond formation to be carried out rapidly and 
quantitatively under mild conditions, avoiding side-reactions such as racemisation and 
generating only easily removed by-products. This challenge has stimulated great 
interest, resulting in many and diverse coupling reagents being proposed. 22 Although 
a large number of these reagents have shown subsequent feasibility only a few have 
been routinely applied in Fmoc SPPS and it is these coupling methods that are 
discussed here. 
1.1.5.1: Racemisation during activation and coupling 
A suitable activation and coupling reagent is one which retains the chiral integrity of 
each amino acid on coupling, thus avoiding racemisation. Racemisation is a highly 
undesirable side-reaction which has been closely studied with a view to defining 
conditions under which it is minimal. It is almost exclusively a base-induced reaction 
and in practice is only a matter for serious concern at the activation and coupling 
stages of a synthesis. Fortunately the conditions employed during Fmoc-SPPS mean 
that the risk of racemisation occurring by direct enolisation is very slight indeed. 
However, the main cause of racemisation in peptide synthesis is via the ozazolone 
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Figure 5 Base catalysed racemisation of acyl amino acids via the oxazolone 
mechanism 23 
Racemisation occurs by the cycisation of activated acyl amino acids (10), on 
treatment with base, to give oxazolones (11) and (12). These oxazolones are 
themselves activated carboxylic acid derivatives and thus can react with an amine to 
form a peptide. However, racemisation via the stabilised anion (13) occurs more 
rapidly than aminolysis and both possible epimers (14) and (15) are formed. 
Oxazolone mediated racemisation is fastest with strongly electron withdrawing 
groups, X, and certain methods of coupling have been shown to have lower levels of 
racemisation than others. 
1.1.5.2: Carbodlimides 
Since the introduction in 1955 of N,N'-dicyclohexylcarbodiiniide 24 (DCC) (16) and 
subsequently N,N'-diisopropylcarbodiimide 25  (DIC) (17) these carbodiiniide reagents 
have been used extensively in peptide synthesis. Carbodiimides are very popular 
coupling agents for peptide bond formation either through in situ activation of the 
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carboxyl component in the presence of the amino component, or through the prior 
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Active ester + 
(21) 
Figure 6 Use of carbodiimides for carboxyl activation 
In all cases, the primary activating event is addition of the carboxyl group to the 
carbodiimide functionality to give an 0-acylisourea (18) which is a potent acylating 
agent. 0-Acylisourea formation is rapid, leading to peptide either by immediate 
aminolysis or via a symmetrical anhydride (19) or active ester (20), with the 
concomitant formation of a urea by-product. The N,N'-diisopropyl urea (21), by-
product after DIC activation, is fully soluble in the solvents used in SPPS compared to 
the less soluble N,N'-dicyclohexylurea, thus DIC is the preferred reagent for 
automated synthesis. 
The high reactivity of the 0-acylisourea acylatmg agent can cause several serious 
side-reactions, such as racemisation (section 1.1.5.1), carboxamide dehydration of 

















Figure 7 Carboxamide dehydration of asparagine 
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Figure 8 N-Acyl urea form ation 
These undesirable side-reactions can be alleviated by reacting the 0-acylisourea with 
oxygen nucleophiles to form symmetrical anhydrides and active esters which are less 
reactive acylating agents. 
1.1.5.3: Symmetrical anhydrides 
A breakthrough in SPPS methodology occurred with the development of fully 
automated synthesis involving the separate formation of symmetric anhydrides or 
active esters immediately prior to use. 26  This provided a new dimension in flexibility 
of activation chemistry for SPPS; allowing the use of appropriately activated amino 
acid derivatives in optimal solvents. 
The advantages of symmetrical anhydrides (19) are that they are easily prepared 
(reaction of two equivalents of Fmoc-amino acid with one equivalent of carbodiiniide) 
11 
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and they offer unambiguous aminolysis. However the major drawbacks to their use 
are that firstly only half of the expensive Fmoc-amino acid is incorporated into the 
peptide and secondly carbodiimide promoted side-reactions, such as the dehydration 
of asp aragine/glutamine (Figure 11) and histidine racemisation, 27 are still apparent. 
1.1.5.4: Active esters 
The active esters (20) of N  protected amino acids are easily prepared from one 
equivalent of Fmoc-amino acid and one equivalent of the appropriate alcohol in DIC. 
Thus with this coupling method there is no 'wastage' of amino acid. Also side-
reactions, which normally accompany the coupling step, are minimised due to the 
activated esters being less reactive than the active intermediates discussed previously. 
A commonly used and extremely effective coupling agent is 1-hyciroxybenotnazole 
(HOBt) (24) which was introduced by Komg and Geiger to combat racemisation. 28 
Analogues developed as a consequence of the highly efficient coupling of HOBt esters 
include, 1-hydroxy-7-azabenzotnazole (HOAt) (25)29  and ethyl 1-hydroxy- 1-1,2,3-













Of particular note is the HOCt analogue designed at Edinburgh by Davidson. 30 HOCt 
has been proven to be a superior coupling reagent to HOBt, 33 allowing the stepwise 
SPPS of previously unattainable large proteins such as interferon-y (chapter 3) the 
obese gene 31 and erythropoietin. 33 
1.1.6: Fmoc SPPS side chain protection 
Fmoc-SPPS utilises side chain protection based on t-butyl based protecting groups 
with the notable exceptions of arginine, cysteine and histidine (Tablel). 
12 
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Amino acid Protecting group 
Arg Mtr I Pmc 
Asn/Gin MBH/Tit 
Asp / Glu But esters 
Cys Acm / Trt / SBut 
His ir-Bum/t-Trt 
Lys Boc 
Ser / Thr / Tyr But ethers 
Trp Boc 
Table 1 Side chain protection in Fmoc-SPPS 
1.1.6.1: Arginine protection 
Protecting groups for the strongly nucleophilic guarndino side-chain group of arginine 
have been developed based on ring substituted aiylsulphonyl derivatives, such as 4-
methoxy-2,3,6-trimethylbenzenesulphonyl (Mtr) 34 (27) and 2,2,5,7,8-
pentamethy1chroman-6-sulphonyl (Pmc) 35 '36 (28). 
OCH3 
















The Pmc group is preferred since it is more acid labile. Although the Pmc group is 
cleaved faster, extended TFA cleavage times are still necessary especially in multiple 
arginine sequences. This conflicts with the desire to reduce cleavage times since 
prolonged treatment with TFA may cause shearing of the polypeptide chain. 
Research is currently underway at Edinburgh on the design of a new protecting group 
for arginine37 which will be cleaved faster than Pmc. 35 ' 36 
1.1.6.2: flistidine protection 
Histidine (29) is especially prone to the problem of racemisation which can occur via 
the formation of an oxazolone, 23 (section 1.1.5.1) or through pathways involving the 
side chain imidazole ring of the residue. 27 Although the imidazole ring is only a weak 
base it is strong enough to cause intramolecular proton abstraction by the it nitrogen 
yielding (30) which can then form either the D (31) or L configuration (29). 
R' 	 R 
RN}I"C-X 	RNHC X 
OD 
(29) 	 (30) 
R' 
(31) 
Figure 9 Racemisation of histidine 
Blocking the it nitrogen with tert-butoxymethyl (Bum) (32) has been shown to 
virtually eliminate histidine racemisation. 38 Although Fmoc-His (Bum) is 
commercially available it is often impure and very expensive due to the difficulties in 
synthesising it-protected histidine. A cheaper alternative is to protect the 'r-nitrogen 
with the bulky trity139 (33) group which significantly reduces the basicity of the it 
nitrogen and therefore suppresses proton abstraction from the a-carbon. Although, 
racemisation is not completely eliminated it can be further reduced by coupling with 







"L 'C R 
10 NH c-x 
0 
(33) 
1.1.7: Fmoc SPPS: monitoring 
In solid phase synthesis, purification consists only of filtration and washing of the 
resin-bound intermediates. Due to this, it is necessary to attempt to drive all reactions 
involved in the chain assembly to completion. Information on the coupling 
efficiencies at each cycle allow the chemistry to be improved in general and, if 
necessary, for a particular synthesis. 
Deprotection of the Na Fmoc protected amino acid (34) with base (20% 
piperidine/DMF) by a 13-elimination mechanism results in a dibenzofulvene (35) which 
is quenched with excess piperidine giving a fulvene-piperidine adduct (36). This 
results in a strong UV absorbance at the isosbestic point of 302nm and thus 
monitoring of the deprotection solution provides an estimation of the % coupling of 











Figure 10 Mechanism of Fmoc deprotection 
1.1.8: Fmoc SPPS: acidolytic cleavage 
After the protected peptide chain has been assembled on the resin support, all the 
protecting groups must be removed and the peptide cleaved from the resin support 
releasing the free peptide into solution. Cleavage of peptides containing only the 
standard Nu Fmoc and t-butyl based side-chain protecting groups can be achieved by 
treating with 95% trifluoroacetic acid (TFA)/5% water. 
Introduction 
R 
	 OrE1e  
R?NH , ( 	 (4) 
LH 





Figure 11 Acidolytic cleavage ofpeptide from linker 
However, the cleavage reaction generates stable cations which can attack the electron 
rich side-chains of the amino acids tryptophan, tyrosine and methionine. Such side-
reactions can be minimised by the addition of scavengers including water, 1,2-
ethanedithiol (EDT), thioanisole, anisole and phenol. These reagents work by 
trapping the TFA liberated carbocations before they can interact with the susceptible 
side chains of a-amino acids in the peptide. The scavengers also act as nucleophiles 
in the cleavage step by shifting the mechanism of cleavage from SN 1 towards SN2 for 
certain less acid labile protecting groups e.g. Pmc protected guanidino side chain of 
arginine (28). A possible mechanism is outlined in Figure 12. 
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Figure 12 Acidolytic cleavage of Arg(Pmc) 
1.2: Chemical Synthesis of Proteins 
1.2.1: General introduction 
Recent advances in recombinant DNA technology have made the synthesis of proteins 
possible using biological methods, but the ability to prepare such compounds using 
purely chemical methods remains extremely important. Chemical synthesis allows the 
replacement of key residues in a protein with unnatural amino acids whose chemical 
or structural properties can be tailored to probe specific aspects of protein function. 
In addition, isotopically labelled amino acids can be incorporated at one or more 
positions, thereby allowing highly focused structural studies of the molecule using 
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techniques such as multi-dimensional NMR spectroscopy. Fixed secondary structural 
elements, such as mimics of n-turns, can be introduced and the effects of folding, 
function and stability investigated. Most importantly chemical synthesis permits the 
systematic variation of structure to redesign known proteins with the aim of 
developing second generation products for therapeutic use. Clearly, the generation of 
such protein analogues requires a synthetic strategy over which the researcher has 
complete control at every step in the construction of the target molecule. Fortunately, 
total chemical synthesis meets this criterion and thus exists as a complementary 
approach to genetic engineering in the exploration of protein structure and function. 
The fundamental synthetic protocols developed for the total chemical synthesis of 
proteins are combinations of steps selected from linear solid phase peptide synthesis 
or condensation reactions (either enzymatical or chemical) of presynthesised peptide 
fragments. 
1.2.2: Stepwise synthesis of proteins 
The stepwise synthesis of proteins by the solid-phase method has always been seen as 
a major objective in peptide chemistry. 4 ' However, the main obstacle to the success 
of such syntheses is the generation of unwanted truncated and deletion sequences and 
the subsequent inability to separate these from the desired target protein. 42 The 
physical and chemical similarities of the desired sequence and such impurities mean 
that conventional chromatographic techniques are not usually of high enough 
resolution to afford separation when used individually and lead to poor yields when 
used in combination. These apparent limitations to stepwise SPPS have been 
addressed at Edinburgh by combining (i) the effective coupling reagents DIC/HOCt, 
(ii) a capping step within each cycle using acetic anhydride and (iii) the introduction of 
a labile Naprotecting  group with enhanced chromatographic properties which permit 






Figure 13 Tbfmoc chloroform ate and Tbfmoc protected peptide 
The base labile Ne-protecting group tetrabenzo[a,c,g,i]fluorenyl- 1 7-methoxy carbonyl 
(Tbfinoc)43 (37) was designed in this laboratory to simplify the purification of 
synthetic peptides and proteins produced using Fmoc/t-Butyl-based SPPS. The 
Thfmoc group is incorporated onto the N-terminus of the resin-bound polypeptide 
sequence by reaction with the chloroformate (38). After cleavage of the Thfmoc-
labelled polypeptide from the resin, the desired sequence can then either be purified by 
exploiting the high affinity of the large, essentially planar, aromatic Thfmoc group for 
porous graphitised carbon (PGC) or by using the hydrophobic nature and specific UV 
absorbance (364nni) of the Thfmoc system to simplify the chromatographic 
purification by HPLC. Figure 14 outlines the general philosophy of an integrated 
synthetic/purification protocol for protein synthesis. 
TFA 
o ride 	 I 	
Thc—MT—PB—OH HRe I 
Scavengers + TRUNCATED PEPTIDES 
+ TRUNCATED PEPTIDES 
(i) Affinity 'or (ii) RP.FIPLC 
purification J 	or gel filtration0.  on carbon 
cNi 
I 	 1. Wash out truncations 	A b 
I PURIFIED PE 	I R f 
2. Deprotect Thfmoc 	B in 
(20%pipendinein(1:I) 0 o 
6M Gdm.Cl isopropanol N c + TRUNCATED PEPTIDE 
Figure 14 SPPS and Tbfmoc purification 
20 
Introduction 
Using this methodology stepwise SPPS has been reproducibly applied, in this 
laboratory, to the assembly of proteins including ubiquitin (76 residues) 44 and 
monocyte chemotactic protein-i (MCP- 1)(76 residues). 4' Larger proteins have been 
achieved with the syntheses of ribonuclease A (124 residues), 46 interleukin-3 (11L-3) 
(140 residues)47 and, at Edinburgh, interferon-y (143 residues) (chapter 3), the obese 
gene product (146 residues) 3 ' and erythropoietin (166 residues). 33 These synthetic 
achievments have demonstrated that the synthesis of large proteins is feasible with 
straightforward extensions of existing techniques. Thus the total chemical synthesis 
of other biologically significant proteins by stepwise SPPS is a practical and accessible 
goal. 
1.2.3: Convergent synthesis of proteins 
1.2.3.1: Fragment condensation of fully protected peptides 
As outlined in section 1.2.2 improvements in stepwise SPPS have enabled the 
synthesis and purification of many biologically significant proteins. However, it 
would be misleading to believe that all large peptides or small proteins can now be 
obtained from automatic synthesisers with standardised reaction protocols. An 
alternative to stepwise construction of long peptide chains is to individually synthesise 
small protected peptide segments of the protein in question and then chemically link 
these together to produce the target sequence. This convergent procedure has the 
obvious advantage, in principle, that small peptide fragments are relatively 
straightforward to synthesise and purify. However, in order to achieve unambiguous 
reaction, protection of reactive side chain fünctionalities within each fragment is 
required. There are problems associated with protected peptide intermediates which 
detract from the advantages of this strategy. These are solubility difficulties, 48 
propensity for racemisation during coupling and limited options for purification and 
characterisation of the filly protected fragments. Despite these problems, convergent 
condensation of filly-protected peptide segments has enjoyed notable successes with 
the synthesis of insulin, 49 ribonuclease A5° and prothymosin a 51 
21 
Introduction 
A recent development in the attempt to overcome the insolubility of the protected 
peptides is the introduction, by Sakakibara, of a powerful solvent system which is a 
combination of TFE and chloroform or dichloromethane. 52 This solvent system not 
only dissolves almost all of the sparingly soluble protected peptides but also 
suppresses the racemisation during the coupling reaction. 52  The utility of this new 
solvent system was demonstrated by the synthesis of human midkine (121 residues) by 
the condensation of two fully protected intermediates using water soluble 
carbodiimide in the presence of HOOBt as coupling reagentS. 53  
1.2.3.2: Fragment condensation of unprotected peptides 
The use of highly selective chemistries to link together unprotected peptide fragments 
can avoid the requirement for side-chain protection. Such a concept was successfully 
demonstrated by Kent in the complete synthesis of an MV-1 protease analogue (99 
residues). 54 By replacing the peptide bond at the fusion site with a thioester linkage, 
unprotected synthetic fragments of the enzyme were linked together to directly yield a 
protein analogue which exhibited full enzymatic activity. The chemo selective ligation 
was achieved by a nucleophilic reaction at low pH (pH 3-5) between the thioacid-
containing fragment (39) and the corresponding bromoacetylated fragment (40) 
(Figure 15). 
H-Pro' .......... 11e50-NHCH2COSH 	+ 	BrCH2 CO-Phe'3 ........ Phe99-OH 
(39) 	 (40) 
6M Guanidine.HC1 
4, pH 4.3 
H-Pro' ........... lle'°-NH-CH2-LCo-S-]- CH, -CO-Phe .......... Phe 99-OH 
Figure 15 Chemoselective ligation of an HIV-1 protease analog 
The main disadvantages associated with this technique are the instability of the 
thioester pseudo-peptide bond at physiological pH and the fact that this structural 
motif results in the introduction of an altered backbone into the protein. However, 
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this method of backbone engineering has been exploited for the rapid assembly of a 
four-helix bundle on a templating peptide. 55 
1.2.3.3: Enzyme catalysed ligation 
Many of the difficulties associated with protein synthesis strategies can be 
circumvented by enzymatic coupling procedures. Proteolytic enzymes, particularly 
serine proteases, have been used extensively in peptide synthesis because of their 
selectivity, ability to function under mild reaction conditions and minimal requirements 
for protecting groups. Although it might seem counterintuitive to attempt to 
synthesise a protein using a protease, problems due to proteolytic degradation of the 
final peptide product by the enzyme can be minimised by manipulating the reaction 
conditions or through genetic engineering. An example of a suitable enzyme is lysine 
endoproteinase which preferentially cleaves at the carboxyl side of lysine residues. 56 
Thus coupling of segments can only be carried out for carboxyl components with a 
lysine residue in the C-terminal position. To prevent the protease dismantling peptide 
bonds at another lysine sites in the peptide the other lysine residues in the 
unassociated fragments must be protected during the enzymatic synthesis. 
Significant progress in the area of enzyme-driven ligation has been achieved by 
Nakatsuka through specific genetic engineering of the serine protease subtilisin. 57 A 
double mutation of subtilisin converts the protease into an acyl transferase called 
subtiligase which, importantly, has greatly diminished proteolytic activity compared 
with the wild-type enzyme. Replacement of the active-site serine with a cysteine 
residue results in efficient acylation of the enzyme by peptides esterilled at their C-
terminus with a glycolate-phenyl-alanine amide group (41) . 18  A second active-site 
mutation relieves steric crowding, allowing subsequent deacylation of the enzyme-
peptide thioester intermediate (42) by the N-terminus of the second peptide fragment. 
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Figure 16 Subtiligase-catalysed ligation 
Near quantitative yields have been obtained for reactions between model esters and 
dipeptide nucleophiles. 59 The total synthesis of ribonuclease A was achieved in good 
yield and high purity by subtiligase-catalysed ligation of six peptide segments ranging 
in length from 12 to 30 residues. 58 Ribonuclease A mutants containing the unnatural 
amino acid 4-fluorohistidine were also prepared allowing the mechanism of catalysis 
to be probed. Given that the incorporation of multiple unnatural amino acids in 
precise positions in a protein backbone is not currently possible using recombinant 
technologies, this application of subtiligase illustrates the potential utility of chemical 
approaches to total protein synthesis. 
1.2.3.4: Native chemical ligation 
An important extension of the chemical ligation approach has recently been 
introduced by Kent and coworkers that results in the straightforward generation of 
proteins with native backbone structures from fully unprotected peptide building 
blocks . 60 Referred to as native chemical ligation, the method utilises the reaction of a 
peptide bearing a thioester at its carboxyl terminus (43) with another unprotected 
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peptide segment containing an N-terminal cysteine residue (44) to give a thio ester-
linked intermediate (45). Without change in the reaction conditions this intermediate 
undergoes spontaneous intramolecular reaction to form a native peptide bond at the 
reaction site. Consequently, the target full-length polypeptide is obtained in the 
desired final form without further manipulation. 










Figure 17 Native chemical ligation 
As with their enzyme-driven counterparts, the native chemical ligation strategies can 
be performed in aqueous media, but have the added advantage of being tolerant to 
organic solvents6 ' and to solubilising agents such as urea and guanidine. 54 The 
ligations can also be performed in the presence of all the functionalities commonly 
found in proteins, including free cysteine sulfhydryls. The only disadvantage of native 
chemical ligation is the necessity for a cysteine residue at the coupling site. Although 
this technique has been demonstrated to be successful a more general approach to 
fragment coupling would be desirable. 
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1.2.3.5: Azide method 
One of the most successfIil methods of fragment condensation encompassing the 
minimal protection strategy and retaining a peptide amide bond is the azide procedure. 
Azide condensations are advantageous in that once the azide has been selectively 
introduced at the C-terminus it is only necessary to have the strongly nucleophilic Na 
terminal amino function, the N amino functions of lysine and the sulfhydryl functions 
of cysteine protected . 62 Azide activation is relatively racemisation free and the 
starting materials are easily prepared. 
Acyl azides can be generated by the diazotisation of a hydrazide using nitrous acid or 
alkyl nitrites. This requires three consecutive steps for peptide bond formation: 
hydrazide formation (46), azide formation (47) and then aminolysis resulting in union 
of the two peptide fragments to give the target peptide. 
0 	 0 	 0 	HNR' 	0 II 
R- -OH 	 R-C-NHN412 	 R-C-N3 	 R--N-R' 
(46) 	 (47) I 
H 
Figure 18 Peptide bond formation via azide 
The formation of the hydrazide of a peptide has been achieved by the development of 
hydrazine resin linkers. 16,17  This has eliminated the need for hydrazinolysis and the 
associated problem of removal of Fmoc from the N-terminus by hydrazine. The 
hydrazine resin linker (48) should selectively incorporate the hydrazide to the C-










Figure 19 Formation ofpeptide hydrazide via a linker 
The method of Honzl-Rudinger is applied to convert the hydrazide to the a2ide. 63 
The peptide hydrazide (49) is reacted with an alkyl nitrite, such as t-butyl nitrite, 
generating an N-nitroso intermediate (50) which loses water to form the 
corresponding peptide azide (51).64 
PEPI1DE 	 + ONO____ 	HC1 	IPEPTIDE HC--No 
DMF/dioxane 
(49) 
PEP11DEH-N3 	 IPEFFIDE ff——N=N-0H 
(51) 	 (50) 
Figure 20 Azide formation via the Honzl-Rudinger meth od63  
The azide (51) is normally not isolated and after neutralisation of the acid is 
immediately reacted with the amino component of the other peptide fragment. 
However, the azide itself is prone to side reactions such as amide formation which 








Figure 21 Rearrangement of the N-nitroso intermediate to form an amide 
The other side reaction is the Curtius rearrangement in which the isocyanate (54) is 
formed which can then react with the amine component to form a urea derivative 
(55). These problematic side reactions can be suppressed by maintaining the 
temperature at -10 0C. 65 
PEPTIDE 	 JPEPTIDE }-N=C=O 






Figure 22 Urea formation via Curtius rearrangement of the azide 
Notwithstanding these side reactions, the azide method is a very effective technique 
for the union of minimally protected peptide fragments. However, the successful 
marriage of Fmoc SPPS and azide condensations requires the development of a new 
protecting group methodology. It is necessary to protect the strongly nucleophilic W 
function of lysine and the sulfhydiyl function of cysteine. Protection is required both 
throughout the synthesis of the peptide fragment itself and during the condensation of 
the peptide fragments to form the desired protein. It would obviously be preferable to 
develop protecting groups that are introduced with the amino acids during peptide 
chain assembly. This is a difficult problem since the protecting groups must not only 
be orthogonal to the basic Fmoc removal conditions but must also be stable to the 
acidic resin peptide cleavage. In addition to these stringent requirements the 
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protecting groups should impart solubility to the fragments and ultimately be cleaved 
under mild conditions. 
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Chapter 2: NcLysine  protecting groups 
2.1: General introduction 
Solid phase peptide synthesis, azide condensations and enzymatic fragment coupling 
all necessitate the protection of the NE  amino function of lysine. Protection is required 
both throughout the synthesis of the peptide fragment itself and during coupling of the 
peptide fragments to form the desired protein. The requirements for the design of 
such a protecting group are stringent and may be summarised as follows. The group 
should: 
o be orthogonal to acid labile side chain protecting groups and the C-terminal ester 
bond to the resin 
• survive repeated Fmoc deprotections during peptide assembly on the resin 
• attribute solubility to the synthetic peptide fragment and protein product 
• be amenable to deprotection under mild conditions which are compatible with 
protein chemistry 
be straightforward to introduce onto the lysine side chain 
be relatively cheap to produce. 
2.1.1: Objective 
A specific goal requiring an exacting chemical strategy is the chemical synthesis of 
novel branched proteins such as ubiquitm conjugates. Ubiquitin is a highly conserved 
(76 amino acids, 8565 Da) protein found in all eukaryotes 66 both as a free protein and 
covalently attached to other proteins. In collaboration with Professor Mayer, at The 
University of Nottingham, interesting branched ubiquitin derivatives have been 
identified. The chemical synthesis of these derivatives is required to allow different 
aspects of ubiquitin metabolism to be investigated. In particular they could be used to 
probe the cellular roles played by the 26S proteasome complex. The 26S proteasome 
is a multisubunit protease which is a new therapeutic target for the pharmaceutical 
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industry with inhibitors having applications in the treatment of disorders such as 
metabolic acidosis-induced muscle wasting. 67 
Di-ubiquitin has been chosen as the first target molecule and is formed through an 
isopeptide bond between the c amino group of lysine-48 and the C-terminal glycine of 
another ubiquitin molecule (Figure 23). To ensure selectivity of the amide bond to be 
formed between these two residues it is necessary to protect the other lysine residues 
in the unassociated fragments. 
76G 
1 	 76 
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Figure 23 Synthesis of di-ubiquitin 
The successful chemical synthesis of di-ubiquitin demands a protecting group for the 
N amino function of lysine which allows 2nd order differentiation between different 
lysine residues. Therefore, the objective of this research was the development of a 
novel F, amino protecting group for lysine. This involved the discovery and synthesis 
of an appropriate lysine derivative and its incorporation into Fmoc SPPS. A test 
peptide was utilised for optimising the protection and deprotection conditions before 
moving to the large ubiquitin system. 
2.1.2: Examples of existing N'-lysine protecting groups 
Notable accomplishments in protecting group strategy for lysine have been the 
development of groups such as the 1 -(4,4-dimethyl-2,6-dioxocyclohex- 1 -ylidine)ethyl 
or Dde group (56).68  The Dde group has been employed in the synthesis of branched 
peptides69 and is efficiently removed by 2% hydrazine in DMF. However, when 
model peptides containing Lys(Dde) were subjected to 20% piperidine in DMF a 
3.2% loss of Dde was observed after 2 hours and 6.6% after 4 hours. Although this 
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loss is considered sufficently low to validate this protection strategy for short chain 
peptide synthesis it may prove inappropriate in the synthesis of longer chain 
polypeptides (>100 residues). 
FnrcNH CO2H 
(56) 
Another protecting group offering 2nd order differentiation of lysine is the Alloc 
group (57)7O However, this group is deprotected by treatment with Pd(0) metal, a 
slow reaction requiring specialised argon equipment and often leaves the products 
contaminated with Pd . 69  An additional drawback is that the reaction cannot be 
monitored. The 2-adamantyloxycarbonyl (2-Adoc) group (58) has also been 
developed for F--amino protection of lysine in convergent solid phase peptide 
synthesis. 7 ' This group is stable to both piperidine and TFA but is cleaved by the 
strong acids trifluoromethanesulfonic acid (TFMSA) or anhydrous BF in a few 
minutes at 0°C. 





The presence of aromatic and hydrophobic groups within post cleavage protecting 
groups is limited since they drastically reduce the solubility of the fragments they 
protect. This problem is particularly significant for large peptides which would be 
rendered insoluble by these groups making purification and further reactions 
exceedingly difficult. Although many protecting groups have been described in the 
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literature none adequately flulfil the aforementioned requirements for the successful 
synthesis and condensation of large peptide fragments. 
2.2: Design of an enzyme cleavable lysine protecting group 
Numerous chemical methods have been developed for the introduction of protecting 
groups which can be cleaved under the mildest of conditions. 72 ' 73 Recently there has 
been renewed interest in using biocatalyts for functional group protection and 
deprotection in the field of peptide synthesis 74 and in other areas. 75 In addition to 
their stereodiscriniinating properties, enzymes offer the opportunity to carry out 
highly chemo selective and regio selective transformations. They generally operate 
under physiological conditions and in many cases combine a high selectivity for the 
reactions they catalyse and the structures they recognise with a broad substrate 
tolerance. Therefore, the application of biocatalysts offers a viable alternative to 
classical methods of functional group protection and deprotection. 
2.2.1: Penicillin G acylase 
Penicillin G acylase (E.C. 3.5.1.11), from Escherichia co/i, is an enzyme used 
industrially to hydrolyse benzylpenicillin (59) to yield phenylacetic acid (60) and 6-
aminopenicillanic acid (61) (the 13-lactam nucleus which is the basis for a wide range 
of semi-synthetic pemcillins) (Figure 24). 76,77  The enzyme is highly specific at the 
aromatic carbonyl side of the amide bond, yet highly tolerant of substrates varying in 















Figure 24 Penicillin acylase hydrolysis ofpenicillin G to form 
6-aminopenicillanic acid and phenylacetic acid 
Its potential in peptide synthesis was first demonstrated by Brtnik et a!, who utilised 
the enzyme as a selective hydrolysis reagent for NC_phenylacetyl  lysine in the solution 
synthesis of vasopressin (9 residues). 79 On completion of the synthesis the W -
phenylacetyl protected lysyl peptide (62) was deprotected by incubation with 
penicillin acylase to yield the lysyl derivative (63) (Figure 25). This synthesis 
demonstrated the possible utility of the enzyme in protecting group strategies and also 
the advantage of a protecting group connected by an amide bond (which should be as 







Figure 25 Penicillin acylase hydrolysis of Nphenylacetyl lysyl residue 
A major problem associated with N lysyl protection is the loss of protonation sites, 
and hence solubility. Previous work at Edinburgh established that the insolubility of 
peptides containing phenylacetyl protected lysine caused problems both in the 
purification and in the final enzymatic cleavage step. 80 The deprotection of the 
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phenylacetyl group was found to require several days incubation with the enzyme 
utilising conditions (40-50 °C, pH 7.1-8.5) which were not compatible with many 
peptides, especially those which readily hydrolyse or oxidise. 
2.2.2: Structure and modelling studies of penicillin G acylase 
One important reason for studying the enzyme is its extensive use by the 
pharmaceutical industry to produce large quantities of 6-aminopenicillanic acid (61), 
the starting point for the chemical manufacture of semi-synthetic penicillins. It has 
already been discovered that the substitution of a hydroxyl group in the 4 position of 
the benzene ring, to give 4-hydroxybenzyl penicillin, increases the rate of hydrolysis. 81 
Knowledge of the enzyme's mechanism and the structural basis of its specificity may 
make it possible to further extend its range of substrates and to convert it to a 
synthase useful for enzymatic synthesis. With this impetus, the crystal structure of 
penicillin acylase has recently been resolved by Professor Dodson at York 
University. 82  The mature enzyme is a heterodimer of 20,500 and 69,000Da consisting 
of closely intertwined A and B chains (209 and 566 amino acids respectively). 
The structures of the enzyme crystallised with phenylacetic acid (a competitive 
inhibitor) and phenylmethylsuiphonyl fluoride (PMSF) have also been determined 
allowing the binding site for the side chain of the substrate to be located. The phenyl 
moiety of each of these inhibitors points towards the interior of the protein; into a 
mainly hydrophobic cleft lined with many aromatic residues and hydrophobic side 
chains. The increased rate of hydrolysis of substrates with a hydroxyl group at the 4 
position of the benzene ring can be rationally explained by close examination of the 
structure of the active site. At the mouth of the binding pocket is a 0 l serine residue 
which is responsible for the hydrolysis of the amide bond and at the back of the cleft 
there is a second serine (Figure 26). The side chain of this serine residue should 
interact favourably with the hydroxyl group, drawing the substrate into the active site 
and holding it there during hydrolysis. 
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Figure 26 Molecular model ofphenylacetic acid in the active site of 
penicillin G acylase. The phenylacetic acid molecule is shown as aline drawing 
and the nearby residues as 'ball-and-stick' representations. 
Figure 26 shows a molecular model of phenylacetic acid in the active site illustrating 
that insertion of groups at positions other than the 4 position would interfere with the 
hydrophobic phenylalanine residues. This would cause a worse fit of the substrate 
into the active site and hence a dramatic reduction in the rate of hydrolysis. 
Consequently, the best substrate for the enzyme is one in which only the functional 
group at the 4 position is altered. The 4-hydroxybenzyl penicillin substrate could be 
modified for protecting group strategy to give the corresponding N-4-
hydroxyphenylacetyl lysine protecting group (Lys-Hopa) (64). The addition of a 
hydroxy group in the 4 position should improve the protecting group in two ways. 
Firstly, by making it more hydrophilic it should be more solubilising than the 
phenylacetyl group (Phenac) (65) and, secondly, by creating a better substrate for the 








Incorporation of the lysine derivative (64) into Fmoc SPPS methodology requires the 
phenolic group to be protected during peptide synthesis preventing it coupling via its 
hydroxy function to activated amino acids. The t-butyl ether derivative, used to 
protect tyrosine, was thought to be suitable due to its structural similarities with 
tyrosine. 	This would result in the amino acid derivative 
butoxyiphenylacetyl-lysine (Fmoc-Lys-Bupa) (66) being incorporated during peptide 
chain assembly. Subsequent cleavage of the peptide from the resin would regenerate 
the Hopa protected lysyl peptide which, after fragment condensation, could be fully 





Pallin attempted to synthesise (66) and despite encountering synthetic problems a 
pentapeptide, H-Phe-Gly-Lys-Ala-Gly-OH, incorporating the Bupa lysyl derivative 
was synthesised . 80  This was tested against the same peptide sequence which 
contained the Phenac protected lysine (65). The results obtained were very exciting 
since not only was the Hopa peptide more soluble but the Hopa group was 
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deprotected faster than the Phenac group. These results revealed that the Hopa 
protecting group possessed the desired features of increased solubility and fast 
removal required for fragment coupling reactions. Unfortunately, the synthesis of the 
Bupa lysine derivative proved irreproducible 33  and a new protecting group was 
required. 
The subsequent proposal was to replace the t-butyl group with a methoxy group 
forming the 4-methoxyphenylacetyl protecting group (Mepa) (67). This group was 
chosen since the synthesis should be more accessible and molecular modelling studies 
had shown that it was structurally compatible with the active site. It was hoped that 
the oxygen at the 4 position would still be available for hydrogen bonding at the active 




In order to investigate the scope and limitations of the Mepa protecting group the 
same peptide sequence employed by Pallin was synthesised. As before the 
corresponding Phenac peptide was also synthesised as a control. The Phenac 
protected peptide (68) was deprotected much faster than the Mepa peptide (69) 
(approximate half-life of 6.5 hours versus 22 hours for the Mepa group). This 
disappointing result highlighted the substrate specificity of the enzyme and implied 
that the largest group tolerable in the 4 position of the phenylacetyl was a hydroxyl. 
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Figure 27 Penicillin G acylase deprotection of Phenac and Mepa protected lysyl 
pen tap eptides 
2.2.3: Strategy for development of a new enzyme cleavable N-Lysine protecting 
group 
The experiments utilising the Mepa group (67) and the findings by Robertson33 and 
Pallin8° indicated that the presence of the 4-hydroxyphenylactyl (Hop a) moiety (64) 
was a crucial requirement. The Hopa group was desirable since it is the best substrate 
for the enzyme and also imparts the greatest solubility to the protected peptide. 
Accordingly the strategy adopted was to develop a protecting group which would 
yield the Hopa moiety after the peptide resin cleavage. The following reactions 
describe the efforts made to meet this strategy. 
2.2.3.1: N-4-benzyloxyphenyIacetyl protected lysine 
The use of benzyl ethers as protecting groups for phenols is well documented  .83  It 
was decided to employ a benzyl ether derivative to protect the hydroxy function thus 
allowing the Hopa derivative to be incorporated onto the side chain of lysine. 
Consequently the next target protecting group was a 4-benzyloxyphenylaceiyl group 
(Bepa) (70). 
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CO2H 
(70) 
The protected lysine residue should therefore be introduced as the amino acid 





This would result in a Bepa lysine (72) being incorporated into the peptide on the 
resin. Cleavage from the resin using TFA would yield the Hopa lysyl derivative (64), 
which could itself be cleaved using penicillin G acylase affording the N amino 
deprotected peptide as in Figure 28. 
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Figure 28 Two stage deprotection of Bepa protecting group 
In general benzyl ethers are prepared from a phenol by treating an alkaline solution of 
the phenol with a benzyl halide. 84 Synthesis of the derivative was achieved by the 
following synthetic route. Firstly the 4-hydroxyphenylacetic acid methyl ester (73) 
was reacted with benzyl bromide to give the benzyl ether (74), which was then 
hydrolysed to remove the ester group yielding benzyloxyphenylacetic acid (70). 
OH 00 
BzlBr 	0 	LIDH 
	





Figure 29 Synthesis of4-hydroxyphenylacetic acid 
Palm 80 found that the most favourable synthetic route to Fmoc-Lys-Bupa (66) was 
one which involved the Bupa moiety being coupled to a copper lysine complex. This 
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with copper means the two a-fiinctionalities of lysine engage in chelate formation 
allowing specific reaction at the c-amino group. Thus the Bepa moiety is coupled, via 
its acid chloride (75), to a copper lysine complex (76) resulting in copper[W-4-
benzyloxyphenylacetyl lysine] 2 (77) (Figure 30). 
Q Q 
Oxay1 chloride 
0  0 
CO2H 	 Cod 
(70) 	 (75) 
NH 
:77) 
Figure 30 Synthesis of Copper[N'-4benzy1oxyphenyIacetyI IysineJ 2 
Extraction of the copper from the insoluble complex was achieved by sonicating a 
mixture of (77) in a saturated solution of the disodium salt of 
ethylenediaminetetraacetic acid (EDTA). 85 The introduction of Fmoc using 9- 
fluorenylmethylsuccmimidyl carbonate (Fmoc-ONSu), 86 to give the Fmoc-Lys-Bepa 
(71) was reasonably straightforward. 
To investigate the efficacy of the Bepa protecting group the same trial pentapeptide 
was synthesised so that a comparison of solubility and deprotection could be made 
with the Phenac and Mepa protecting groups. 
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When the pentapeptide with the Bepa protected lysine (72) was cleaved from the resin 
the desired Hopa protected peptide (64) was obtained as in Figure 28. After 
purification the (Phe-Gly-Lys(Hopa).Ala-Gly) peptide (64) was dissolved in Tris 
buffer at pH 8. 1, before the enzyme penicillin G acylase was added and the reaction 
incubated at 37°C with gentle agitation. The acylase (kindly supplied by SmithKline 
Beecham Pharmaceuticals Ltd.) was bound to a resin which enabled easy purification: 
the enzyme could simply be filtered from the reaction solution. The deprotection of 
the peptide to give the free NE  amino lysyl derivative was monitored by analytical 
HPLC and was considerably faster than for the Phenac peptide (68). Figure 31 shows 
HPLC traces of the deprotection of the Phenac and Hopa protected peptides after one 
hour. 
I 





(Phe-Gly-Lys(Phenac)..Ala-Gly) (68) (Phe-Gly-Lys(Hopa)-Ala-cjly) (64) 
Figure 31 HPLC traces ofpenicillin acylase deprotection of Phenac and Hopa 
protected pentapeptides after 1 hour 
An approximate half life of 4 hours was calculated compared to the 6.5 hours for the 
Phenac deprotection. in addition, the Hopa protected peptide eluted earlier than the 
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Phenac protected peptide. Thus not only is it deprotected faster but it is also more 
hydrophilic (Table 2). 
Protecting group Half life 
(hours) 
itt (mins), %B 
(See Figure 31) 
Mepa 22 17,49% 
Phenac 6.5 17,49% 
Hopa 4 12,38% 
Table 2 Half lives and HPLC retention times for lysine protecting groups 
This was a very promising result. However, the HPLC trace of the product after the 
TFA resin cleavage revealed three peaks (a, b & c (R =12, 18 & 20mins)) (Figure 
32). These were trapped and submitted for MALDI MS. Peak (a) was the correct 
mass for the Hopa peptide and peaks (b) and (c) corresponded to the mass of the 
peutapeptide with the lysine Bepa protected. 
Figure 32 HPLC with MALDIMS results for peptides (a), (b) and (c) obtained 
after TFA resin cleavage 
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The peptides represented by peaks (b) and (c) must be isomers whose presence can be 
explained by examination of the mechanism of TFA cleavage. TFA-acidolysis of the 
benzyl ether (78) occurs via a mechanism involving alkyl-oxygen fission due to the 
stability of the intermediate carbocation thus formed (Figure 33). This process is 
hampered if the liberated benzyl carbonium ion (79) is involved in deleterious side 
reactions, the most obvious being recombination with the hydroxy function of Hopa 
(80) to reform the Bepa peptide (78). It is conceivable that the benzyl carbomum ion 
could also be attached at the 3 position on the benzene ring resulting in a compound 














Figure 33 TFA acidolysis of benzyloxyphenyl acetyl group 
To minimise this side reaction scavengers, and in particular phenol, must be present to 
quench the reactive benzylcarbonium ion. Various scavenger mixtures were 
investigated and the optimum cleavage and deprotection protocol was found to be: 
crystalline phenol, 1,2-ethanedithiol, thioanisole, water and TFA. Cleavage of the 
benzyl ether was followed by HPLC and was virtually complete after 3 hours. 
It was proposed that modifying the protecting group itself would further improve the 
rate of cleavage of the benzyl ether. The introduction of a 4-methoxy or even a 4-
methyl group should increase the stability of the benzyl cation. Since the cleavage of 
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the C-O bond is encouraged by the stability of the carbocation inclusion of such 









The next protecting group was therefore a 4-methoxy substituted benzyl ether (82). 
The synthesis was analogous to the unsubstituted Bepa group. However, as with the 
Bupa group (66) problems arose during the synthesis of the acid chloride. The acid 
chloride (84) was prepared by reacting the 4-(4'-methoxybenzyloxy)phenylacetyl 
moiety (82) with oxalyl chloride in benzene. The reaction was followed by JR and 
when it had gone to completion the benzene was evaporated in vacuo to remove any 
unreacted oxalyl chloride and HC1 formed. The 4-methoxy derivative was obviously 
unstable because a colour change was noted and by lit the acetyl chloride peak at 
1800 cm 1 had disappeared. It was postulated that the HC1 present in the reaction 
mixture breaks up the acid chloride (84) when the solution is concentrated to dryness. 
To overcome this problem the reaction mixture was reduced to half its original 
volume and reacted undiluted with the copper lysine (76) (Figure 30). Despite 
carrying out this reaction at pH 10, to neutralise any remaining HCI, the acid chloride 
did not successfully couple to the free W amino of the copper lysine (76). This was 
evident since, after extracting the copper, a white insoluble product was obtained 
which was identified as lysine.HC1 (nip. 245°C; no aromatics by NMR & no 
chromophore by UN). 
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A small amount of copper[NL4(4'methoxybenzy1oxy)phenylacetyl lysine] 2 was 
obtained which was carried through to give Fmoc-Lys-(4-methoxy)Bepa (86) and 
characterised. However, it was concluded that the presence of the 4-methoxy group 
resulted in the destabilisation of the acid chloride (84) and the 4-methoxy substituted 
benzyl ether (82) was deemed not to be a viable protecting group. 
oj: x 
uN 
- ' —(oNWCO2H 
XOMe (86) 
X=Me (88) 
The 4-methyl substituted benzyl ether (83) formed a more stable acid chloride (87) 







The 4-methyl-Bepa pentapeptide (89) was synthesised and concurrent TFA cleavages, 
with identical scavenger mixtures, were carried out on 4-methyl-B epa and Bepa 
protected pentapeptides. Samples of the cleavage mixture were removed after 1, 2 
and 3 hours and analysed by HPLC. After 1 hour the formation of the desired Hopa 
group from both protected pentapeptides was observed by analytical HPLC (Rt 
l2mins., %B 38). The rate of cleavage was more than twice as fast for the 4-methyl-
Bepa peptide (89). This was a promising result which agreed with our supposition. 
However, after 3 hours the Bepa group had almost fully cleaved, whereas for the 
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4-methyl-Bepa there was no ftirther cleavage after 1 hour. It was speculated that 
although the initial cleavage was faster an equilibrium between the 4-methylbenzyl 
cation (90) and the 4-hydroxyphenylacetyl group (80) was being set up. Therefore, 
the 4-methylbenzyl cation (90) was in fact too stable and thus not effectively removed 
by the scavenger mixture. Figure 34 shows a comparison of the stability of the benzyl 
cations. 
CH3 
CL ç CI q 
CH2 	 +CH2 	 CH2 	 CH2 
(92) 	 (79) 	 (90) 	 (91) 
Increasing stability of benzyl cation 	 11 
Figure 34 Comparison of stability of benzyl cations 
The next proposal was to destabilise the benzyl cation by the addition of halogen 
atoms onto the benzene ring (92). This cation should be more easily removed by 
scavengers thus pushing the deprotection reaction to completion. Research using 2,6-
dichlorobenzyl ethers to protect tyrosine had revealed only a low incidence of 
alkylation at the 3-position of tyrosine during acidolysis. 87 This hypothesis was tested 
by synthesising 4-(2,6-dichlorobenzyloxy)phenylacetyl protected lysine. 
Unfortunately, this molecule was very insoluble and therefore not compatible with 
automated solid phase peptide synthesis and thus this protecting group was 
abandoned. 
From these investigations it was concluded that the Bepa group (70) was the most 
promising protecting group. This was due to its straightforward synthesis, 
compatibility with the automated peptide synthesiser and it gave the cleanest route to 
the Hopa protected lysine derivative. It was therefore decided to probe the scope and 
limitations of the Bepa protecting group by utilising it in the synthesis of the protein 
ubiquitin. 
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2.2.4: Incorporation of Bepa protected lysine into ubiquitin 
As stated in Section 2.1.1 an application for the new N  lysine protecting group is to 
provide 2nd order differentiation between different lysine residues to permit the 
synthesis of di-ubiquitin. Consequently, to test the new protection strategy a ubiquitin 
derivative incorporating the Bepa protecting group was synthesised. 
1 	 10 	 20 
Met Gin ILe Phe Val Lye Thr Leu Thr Gly Lye Thr lie Thr Leu Glu Val Giu Pro Ser 
30 	 40 
Asp Thr lie Giu Asn Val Lye Ala Lye lie Gin Asp Lye Giu Gly Tie Pro Pro Asp Gin 
50 	 60 
Gin Arg Leu lie Phe Ala Giy Lye Gin Leu Giu Asp Giy Arg Thr Leu Ser Asp Tyr Aen 
70 	 76 
Ile Gin Lye Giu Ser Thr Leu His Leu Val Leu Arg Leu Arg Giy Giy 
Figure 35 Amino acid sequence of bovine ubiquitin 
Ubiquitin is a small protein (76 residues) containing seven lysine residues (Figure 35). 
In order to manipulate the orthogonality of the system the strategy was to protect six 
lysines with the Bepa group (70) and to protect the remaining lysine, at position 48, 
with Boc (1). After solid phase synthesis the ubiquitin derivative (93) could then be 
cleaved from the resin using TFA and scavengers. The TFA cleavage should remove 
the acid labile Boc group at lysine-48 and cleave the benzyl ether protecting the other 
six lysine residues leaving them Hopa protected to give [6,11,27,29,33&63-
Lys(Hopa)]ubiquitin (Ub(Hopa) 6) (94). 






j IoPa 	I1opa 	ropa -Iopa ropa 2 481 1 	76 Met------- Lys------- Lys------ -Lys-------Lys-------Lys ------ Lys-------Lys---G, 
(94) 
Figure 36 Schematic of the synthesis of 16,11,2 7,29,33& 63-Lys(Hopa)Jubiquitin 
Ub (HOP  a) 6 
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2.2.5: Chemical synthesis of Ub(Hopa) 6 
The ubiquitm derivative was constructed as outlined in the experimental section 
without any drop in the coupling efficiency on introduction of Bepa protected lysine. 
On completion of the synthesis the resin-bound Fmoc protected Ub(Bepa) 6 (95) was 
somcated in the presence of acetic anhydride/HOBt/DIEA in DCM in order to cap 
any remaining free amino groups. The N-terminal Fmoc group was then removed and 
the purification group Thfmoc 43 (37) introduced at the N-terminus to give Thfmoc-
Ub(Bepa)6-resin (96). 
The next step was to cleave the protein from the resin and simultaneously remove all 
side chain protecting groups with the exception of the six Lys(Bepa) residues which 
were only partially cleaved to Lys(Hopa). The was achieved by utilising the TFA and 
scavenger cocktail selected from the studies on the Bepa pentapeptide (72) (Section 
2.2.3). After 4.5 hours the resin was removed by filtration and the filtrate 
concentrated in vacuo to a yellow oil. The crude Thflnoc-Ub(Hopa) 6 (97) was 
isolated from the oil by precipitaion with 2% v/v 3-mercaptoethanol in diethyl ether at 
0°C. 
2.2.6: Affinity purification of Ub(Hopa) 6 using Tbfmoc on PGC 
During solid phase peptide synthesis acetylated truncates accumulate on the resin due 
to incomplete coupling steps and these need to be separated from the desired peptide 
sequence. This can be achieved by derivatising the N-terminus with the base labile 
Thfnioc group prior to cleaving the peptide from the resin. Then exploiting the 
hydrophobicity of the Thfmoc group to implement separation of the Thfmoc-peptide 
from the truncates. Another advantage of using Thfmoc for purification is that this 
group can also be utilised as a N' protecting group for subsequent fragment coupling 
reactions. 
As outlined in Section 1.2.2 two methods of purification have been developed for 
Thflnoc-peptides. These are either affinity purification on porous graphitised carbon 
(PGC) or alternatively reverse phase HPLC which enables separation through the 
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increased retention time of the Tbfmoc-peptide compared to the truncates. For the 
purification of Tbflnoc-Ub(Hopa) 6 (97) the Thflnoc/PGC purification was chosen in 
preference to reverse phase HPLC since studies by Wilken 88 had shown limited 
recovery of ubiquitin analogues when using the latter method. 
Thfmoc-Ub(Hopa)6 (97) was solubilised in 6MGdniCl, diluted with isopropanol and 
centrifuged to remove a small amount of insoluble material. PGC was added to the 
supernatant and the mixture was vortexed for 10 minutes to allow (97) to be adsorbed 
onto the PGC. The PGC was washed to remove truncated peptides and finally the 
protein was cleaved from Thfmoc by vortexing the PGC with a 10% piperidine 
solution and then centrifuging the PGC to a pellet. The supernatant was neutralised 
with acetic acid, the isopropanol removed in vacuo and the protein/guanidine solution 
was desalted by gel filtration to afford Ub(Hopa) 6 (98). Figure 37 shows the HPLC 
profiles of crude Thfmoc-Ub(Hopa) 6 (97) and Ub(Hopa) 6 (98) obtained after the 
Thfmoc/PGC purification. 
IU 
F 	 '-- 	 - F 
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MmLe. MnUes 
crude Tbfmoc-Ub(Hopa) 6 (97) Ub (HOP  a)6  (9 8) 
Figure 37 HPLC traces of crude Tbfmoc-Ub(Hopa) 6 (97) and Ub(Hopa) 6 (98) 
The AAA, MALDI MS and N-terminal sequencing of (98) were as required, however 
the analytical RP HPLC was broad. This was probably due to the presence of the 
Hopa groups which would alter the conformation of the protein preventing it from 
folding in its native structure. In fact synthetic ubiquitin has to undergo a folding 
protocol before it is folded in its correct conformation. 88 Therefore the next goal was 
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to remove the Hopa groups, fold the protein and show that the ubiquitin obtained was 
analogous to native ubiquitin. 
2.2.7: Attempted enzymatic deprotection of Ub(llopa) 6 (98) 
To confirm that the new protectionldeprotection strategy can be successfully 
translated from small peptide models to protein fragments all the Hopa groups must 
be removed to generate ubiquitin. Hence Ub(Hopa) 6 (98) was incubated with 
immobilised penicillin G acylase utilising the conditions that had been successful for 
the trial pentapeptide (Tns buffer, pH 8.1 at 37 0C). Again the reaction was monitored 
by analytical HPLC but no deprotection was observed after 14 days. 
Similar experiments by Brown, on an enzyme cleavable cysteine protecting group, had 
revealed that the protein could be adsorbed onto the solid support used to immobilise 
the enzyme. 89 This adsorption was due to the fact that the solid support was based on 
an ion exchange material which very quickly bound any free basic protein present in 
solution. 90 Although Ub(Hopa)6 (98) is not basic, due to the lysine residues being 
capped, the free ubiquitin is basic with a p1 of 8.5 and it was therefore surmised that 
any ubiquitin that had been deprotected or even partially deprotected would have been 
bound to the resin support. Therefore a second immobilised enzyme was obtained 
which utilised a polymeric solid support and the removal of the lysine protecting 
groups was attempted once more. HPLC monitoring indicated a slight shift in the 
retention time of the peak which remained broad. This peak was isolated and 
analysed by MALDI MS and gave essentially an identical mass spectra to Ub(Hopa) 6 
(98). Further attempts to deprotect the lysine residues by employing soluble enzymes 
also failed. 
The optimum conditions for catalysis by immobilised penicillin acylase have been 
reported as pH 7-8.5 at 50°C. Above 55 °C there is a rapid loss of activity and the 
soluble enzyme loses activity faster than the immobilised enzyme. 9 ' Thus the 
deprotection reactions were incubated at the elevated temperature of 50°C, but with 
no success. 
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The fact that Ub(Hopa) 6 (98) was only sparingly soluble in the aqueous media 
employed would also limit the deprotection rates. In an attempt to overcome this 
disadvantage solubility- enhancing organic cosolvents, in particular DMF and DMSO 
were added. In their presence, however, the enzyme was denatured to a major extent 
and again no deprotection was achieved. 
The failure of the enzyme mediated deprotection can be rationalised if the rate of the 
forward reaction, to produce the free amino function of lysine and 4-
hydroxyphenylacetic acid (99), is slower than the reverse reaction (Figure 38). The 
equilibrium of the hydrolysis reaction might not go to completion due to product 
inhibition. A possible explanation is that the macromolecules of Ub(Hopa) 6 (98) can 
not effectively interact with the active sites of penicillin acylase as effectively as the 
small molecules of 4-hydroxyphenylacetic acid (99). The effective collision frequency 
of Ub(Hopa)6 with penicillin acylase is thus much lower than 4-hydroxyphenylacetic 
acid with penicillin acylase. Therefore, the hydrolysis can only be completed when the 













(63) 	 (99) 
Figure 38 Hydrolysis equilibrium 
This same difficulty was encountered by Wang in the deprotection of N-
phenylacetylated insulin using immobilised penicillin G acylase. 92 However, Wang 
successfiully removed the liberated phenylacetic acid shifting the hydrolysis reaction 
towards deprotection. This was achieved by the inclusion of a column of strong basic 
ion exchange resin connected to a column packed with the immobilised enzyme. The 
N-phenylacetylated insulin solution was then circulated through the two columns 
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which had been equilibrated with the same buffer at 37 °C. The by-product, 
phenylacetic acid, was adsorbed by the basic resin allowing complete deprotection of 
the insulin. Attempts to reproduce these ingenious reaction conditions resulted in the 
Ub(Hopa)6 (98) becoming adsorbed onto the ion exchanger and no removal of the 
Hopa protecting group was observed. 
Another attempt to sequester the 4-hydroxyphenylacetic acid (99) and thus favour the 
forward reaction of the hydrolysis equilibrium was the addition of lysine to the 
reaction solution. Experiments utilising the Hopa protected pentapeptide (64) had 
revealed that the conditions which furnished the fastest deprotection were when the 
peptide was incubated with the immobilised enzyme in Tris buffer, pH 8.1 at 37 °C 
with 50mM lysine.HC1. The lysine acts as a substrate for the reverse reaction i.e. 
between 4-hydroxyphenylacetic acid and an amine group. The small size of the lysine 
molecule compared to the protein means that it is more accessible to the active site 
and is thus more likely to react with 4-hydroxyphenylacetic removing it from the 
equation. However when these same reaction conditions were applied to the 
deprotection of the Hopa group in lJb(Hopa) 6 (98) they failed. 
The 40 residue ubiquitin fragment [63-Lys(Hopa)]ubiquitin-(36-76) (100) was also 
incubated with penicillin G acylase in an attempt to deprotect just one Lys(Hopa) but 
those reactions also failed. However two Hopa protecting groups were incorporated 
into a peptide fragment for an azide fragment coupling reaction to obtain the 32 
residue peptide hormone Salmon Calcitonin I (SCT). 3 Robertson then successfully 
deprotected the two Hopa groups using the conditions employed for the Hopa 
pentapeptide (64). The deprotection was complete in 48 hours whereas there was no 
deprotection for Ub(Hopa) 6 (98) or [63-Lys(Hopa)]ubiquitin-(36-76) (100) using 
exactly the same conditions. Therefore Bepa is a suitable protecting group for use in 
the azide fragment condensation technique for small peptides (Ca. 30 residues) but it is 
not applicable for larger peptide systems. 
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The failure to translate the enzymatic deprotection methodology from small peptides 
to proteins can be justified by examination of the crystal structure of penicillin G 
acylase (Figure 39). The three dimensional crystal structure of the enzyme shows that 
the catalytic serine residue, at the N-terminal of the B chain, is buried deep in the 
centre of the molecule. Clearly the relative inaccessibility of the active site means that 
whilst small unstructured molecules can easily access the binding pocket larger protein 
molecules (which will adopt some degree of structure under the reaction conditions) 
will have difficulty. The lower collision frequency of the protein with the active site 
of the enzyme will result in either incomplete deprotection or a shift in the equilibrium 
to favour the reverse reaction. 
Figure 39 MOLSRIPT representation of the three dimensional crystal structure 
of penicillin G aq'lase. (left) The A chain is shown in red wrapped around the 
B chain (blue), the side chain atoms of the active serine are shown at the apex 
of the deep depression at the centre and (right) an orthogonal view. 
Variation of the structure of the substrate can significantly enhance the efficiency of 
penicillin acylase catalysed reactions. This approach of "substrate tuning" has been 
successfully employed for substrates of penicillin G acylase, 93 however it will not 
overcome the problems of steric hindrance encountered here. A strategy which might 
serve to conquer the problems would be the modification of the enzyme by genetic 
engineering. For example, if the active site could be made more accessible instead of 
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buried deep in the protein then the enzymatic deprotection of protected proteins may 
yet be possible. However, until such time as that, a new protecting group for lysine 
must be developed. 
2.3: Design of a chemically cleaved N lysine protecting group 
2.3.1: Tris(hydroxymethyl)nitromethane (Tnm) derivatives as protecting groups 
in peptide synthesis 
Research by Corner into a novel linker system for fragment condensation had lead to 
the evolution of a compound that was stable to Fmoc SPPS, partially cleaved by 
aqueous TFA and finally removed under basic conditions. 94 This 
tris(hydroxymethyl)nitromethane (Tnm) derivative (101) was then successfully applied 
as a protecting group for acid functionalities where the 1,3-diol would be protected as 
the acetal (102) during SPPS (Figure 40). 
o
>O2N 0 H 
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Figure 40 Tnni protection of acidfunctionality 
After the success of the Turn group in the protection of acid functions, it was decided 
to assess its potential as a protecting group for the N amino function of lysine. The 
protection being in the form of the carbamate derivative of Turn (103). 
RNH AO!  C><rD 
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A comprehensive study by Corner incorporating different Tam derivatives into model 
systems led to the optimisation of the lysine protecting group . 94 Consequently the 
new lysine derivative which is introduced during assembly of a peptide is Na9F moc 
N- 1: 5-dioxaspiro-5 5-undecane-3-nitro-3-methoxycarbonyl-lysine (104). 
o 02N 
HN 




As the acetal (105) this protecting group is stable to the basic deprotection conditions 
of Fmoc SPPS. After assembly of the peptide is complete the acetal is cleaved during 
the TFA resin cleavage to yield the 1,3-diol (106) which can easily be removed by 
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—NH CO— 
(106) 
Figure 41 TFA acido4'sis of aceta! (105) to 1,3-diol (106) 
The synthesis of (104) was achieved by the synthetic route outlined in Figure 42. 
Cyclohexanone and tris(hydroxymethyl)nitromethane were refluxed in toluene using a 
Dean and Stark apparatus. The resulting alcohol (107) was attached to Fmoc-Lysine 
by firstly activating the alcohol as the chloroforrnate and then converting it to the 
more stable pentafluorophenylcarbonate (108). 
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Figure 42 Synthetic route for (104) 
2.3.2: Incorporation of Tnm protected lysine into ubiquitin 
Corner successfully incorporated the Turn group into model peptides and 
demonstrated its facile removal. The deprotection protocol utilised by Corner was to 
sonicate the Tnni protected peptide in DMSO/borate buffer pH 8.75 for thirty 
minutes. 94  These were very promising results involving one Trim protected residue 
but the crucial test was the synthesis of the ubiquitin derivative with six lysines Tnm 
protected. If the Trim protecting group could succeed where the enzyme- cleavable 
group had failed, its utility as a protecting group for fragment coupling experiments 
would be vindicated. 
The ubiquitm derivative incorporating the six Tam protected lysines and lysine-48 
Boc protected was successfully constructed as outlined in the experimental section. 
An indication that the synthesis proceeded extremely well was obtained from the 
deprotection profile of the synthesis (Graph 1). The deprotection profile is not 
quantitative, it shows coupling percentages of greater than 100% which are probably 
associated with changes in the extent of resin swelling during the svnthesis. 9 The 
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profile is analogous to those obtained from other syntheses of ubiquitm inferring that 










G R H E N L D 	I Q 	D/.E SET L F 
RESIDUES 
Graph 1 Deprotection profile for Ub(Tnm) 6 
After solid phase synthesis a trial TFA resin cleavage was carried out to ensure that 
the acetal (105) was in fact cleaved to the 1,3-diol (106) (Figure 41). The product 
obtained was examined by MALDI MS and identified as the Tnm diol 
[6,1 l,27,29,33&63-Lys(Tnrn)]ubiquitin (Ub(Tnm) 6) thus the first stage of the 
deprotection was successful. It was noted that this ubiquitin derivative was filly 
soluble compared to the Ub(Hopa) 6 (98) which was only partially soluble under the 
same conditions. Thus the Turn group attributes solubility to the protected fragment 
which is an essential requirement for the lysine protecting group. However the 
principal demand is that the Trim group can be easily removed under mild conditions. 
The next objective was therefore to remove the Trim groups, fold the protein and 
show that the ubiquitin obtained was analogous to native ubiquitin. 
2.3.3: Purification of Ub(Tnm) 6 and deprotection of Trim groups 
2.3.3.1: Affinity purification of Ub(Tnm) 6 using Tbfmoc 
The resin-bound Fmoc protected Ub(Tnm) 6 (109) was sonicated with capping 
solution before the N-terminal Fmoc group was removed and replaced with Thfmoc 
(37) to give Thflnoc-Ub(Tnm)6-resin (110). The protein was then cleaved from the 
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resin with the simultaneous removal of all side chain protecting groups and the 
generation of six 1,3-diol Tam protected lysines (106). The same cleavage conditions 
used for the Thfmoc-Ub(Bepa) 6-resin (96) were employed and crude Thfmoc-
Ub(Tnm)6 (I 11) was isolated as a white fluffy solid. 
The Thfmoc group can be deprotected by treating the Thflnoc-peptide with 10% 
piperidine in 6MGdm.Cl/isopropanol. It was envisaged that these basic conditions 
would also deprotect the base labile Tnm group (106) making the Tbfluioc/PGC 
protocol a combined purification and deprotection step. The crude Thfmoc tagged 
Ub(Tnm)6 (111) was solubilised in the minimum amount of 6MGdm.Cllisopropanol 
and vortexed with charcoal. Previous Thfmoc purifications had used PGC as the 
adsorption medium but it was replaced by chromatographic grade charcoal which is 
much cheaper and equally effective. The Thfmoc-Ub(Tnm) 6 (111) was adsorbed onto 
charcoal which was then washed to remove acetylated truncates. Once the truncated 
peptides had been removed the next step was to deprotect the Thfmoc and the six 
Turn. groups. This was achieved by vortexing the charcoal with 10% piperidine in 
ÔMGdm.Cllisopropanol for ten minutes. After which the charcoal was centrifuged to 
a pellet the protein containing supernatant decanted off and neutralised to pH 4.5. 
The protein solution was reduced in vacuo to remove isopropanol and desalted by gel 
filtration and lyophilised to give Ub(112). Figure 43 shows HPLCs of Ub(112) and 
crude Thfmoc-IJb(Tnm) 6 (111). The AAA and MALDI MS were as required for fi.illy 
deprotected ubiquitin and analysis by HPLC showed that lJb(1 12) co-eluted with 
Ub(bovine). This was an excellent result which proved the efficacy of the Tnm 
protectionldeprotection strategy. 
(24 A 	 14
364nm  
crude Tbfmoc-Ub(Tnm) 6 (111) 	Ub(112) 
Figure 43 Analytical HPLCs of crude Tbfmoc-Ub(Tnm) 6 (]]])and Ub(112) 
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Although it only takes ten minutes to deprotect the Thfinoc and Tnm groups by 
vortexing with 10% piperidine in 6MGdm. Cllisopropanol the pH may be as high as 13 
or 14. Hence a milder method of purification and deprotection was also employed 
which involved separating the Thflnoc-(Tnm) 6 (111) from any truncated peptides 
utilising size exclusion gel filtration with a Sephadex G50 (fine) column. The Thfmoc 
containing fractions were pooled and lyophilised to give purified Thftnoc-Ub(Tnm) 6 
(113). The non-Thfmoc fractions (114) (truncations) were also pooled, lyophilised 
and examined by MALDI MS. This permitted the truncated peptide sequences to be 
identified and with this knowledge subsequent syntheses of ubiquitin may be 
improved. 
To deprotect the Ththoc and Trim groups the purified Thfmoc-Ub(Tnm) 6 (113) was 
dissolved in 6M Gdm. Clltris base pH 8.8 and sonicated at room temperature for 1.5 
hours. The protein solution was then desalted by gel filtration and lyophilised to give 
Ub(115) which was equivalent to Ub(112). 
The HPLC profiles of Ub(112) and Ub(115) were broader than that of native 
ubiquitin. (Figure 44). This was explained by the presence of oxidised ubiquitin which 
eluted slightly earlier than native ubiquitin. Oxidised protein is formed if the 
methionine at position 1 is oxidised to the suiphoxide during the purification protocol. 
The broad HPLC profile was also because the synthetic ubiquitin was not folded 
correctly. It has been shown by Wilken that Thfmoc purification causes ubiquitin to 
adopt a non-native structure. 88 However the native fold can be accessed via the use 
of cation exchange chromatography. 
2.3.3.2: Reduction and folding of Ub(112) 
A portion of lJb(112) was dissolved in a 10% wlv solution of N-
methylmercaptoacetamide (MIMA) in aqueous acetic acid and incubated at 37 °C. The 
reduction reaction was monitored by HPLC and after 24 hours the protein solution 
was diluted and applied to a CM-Sepharose CL6B cation exchange column. The 
separation is based on the reversible adsorption of positively charged protein 
N'-Lysine protecting groups 
molecules to a negatively charged matrix. The protein sample initially binds to the 
matrix and selective separation and elution of protein is achieved by application of a 
pH gradient followed by a salt gradient. This resulted in the isolation of Ub(116) 
which had a much sharper HPLC profile than Ub( 112) before the cation exchange 
chromatography (Figure 44) thus indicating that cation exchange chromatography 
was crucial for the correct folding of ubiquitin. In addition, the HPLC profile and 
MALDI MS revealed that the ubiquitin obtained, Ub(116), was pure and 
indistinguishable from Ub (bovine). 
a 
2O 
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(a) Ub(112) (b) Ub(116) (c) Ub(bovine). 
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Figure 45 MALDIMS of Ub(116) and Ub(bovine) 
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The secondary structure content of Ub(116) was investigated using far UV circular 
dichroism (CD). Figure 46 shows the CD spectra for Ub(116) and Ub(bovine) and it 
is apparent that they have very similar profiles. 
8.000E+00 . IIIII,lIlllllTIIlllllIll?llllt!IIIttt$II I IPIIIIIIIIIIII I4 IIIIIII 4 
Ub(boune) 
\ \ 
CO 	N Uh(116) 	 - 
-6.000E+00 .1111 iIII,LIIIII 	 4iiuiti j,siiSli 	 ......... 
95.0 	 WLnm 250.0 
Figure 46 Far (TV circular dichroism spectra for Ub(116) and Ub(bovine) 
The CD analysis at pH 7 indicated both reduced a-heicity from 17% ± 1.6% in 
Ub(bovine) to 11% ± 1.5% in Ub(116), and an increased n-sheet of 60% ± 2.8% in 
Ub(116) versus 53% ± 2.6% in Ub(bovine). These results were comparable to other 
CD analysis obtained by Wilken for synthetic ubiquitin. 88 The deviations in the CD 
analysis between the synthetic material and Ub(bovine) may be largely due to a 
concentration effect since any salt present in the synthetic material would alter the dry 
weight and hence the concentration. The CONTIN procedure used to estimate the 
secondary structure is a limited program which is very dependent on concentration. 
However the CD analysis did indicate a similar secondary structure in Ub(116) and 
Ub(bovine). 
63 
N'-Lysine protecting groups 
2.3.3.3: Non-Tbfmoc purification protocol 
To confirm the general application of the purification/deprotection strategy for Tnm 
protected peptides a non-Thfmoc protocol was also investigated. The NaFmoc 
group was removed from (109) and the protein cleaved from the resin using the same 
cleavage conditions employed for its Thfmoc counterpart. The precipitated Ub(Tnm) 6 
(117) was purified by size exclusion gel filtration using a Sephadex G50 (fine) column 
to afford Ub(Tnm) 6 (118) and the Tnm groups removed by sonicating (118) in 6M 
Gdm.Clltrizma base pH 8.8 for 1.5 hours. The protein recovered contained fully 
deprotected ubiquitin, Ub(119), but also present were truncated peptides of similar 
mass to ubiquitin. Thus gel filtration using a Sephadex G50 column was not 
sufficiently resolving to allow separation of ubiquitin from large truncated peptides. 
It was hoped that FPLC size exclusion would afford better resolution. An aliquot of 
(117) was sonicated in 6MGdniCl, centrifuged and the supernatant loaded onto a 
SuperdexTM 75 HR 10/30 column. However the Ub(Tnm) 6 (120) which eluted was 
identical to that obtained from gel filtration using the Sephadex column. 
2.3.4 Utilisation of Tnm group in azide fragment condensation 
The utility of the Tnm protecting group for fragment coupling reactions has recently 
been demonstrated by Robertson with the condensation of small fragments of the 
protein erythropoietin. 33 The hexapeptide azide fragment (121) was successfully 
coupled to a fragment containing a Tnm protected lysine residue (122). The Tnm 
group was stable to the reaction conditions and is thus suitable for use in azide 
fragment couplings. The protected peptide (123) was isolated by preparative HPLC 
and the Tnm N8 and Fmoc Na  protecting groups were removed simultaneously with a 
10% piperidine solution to give the fully deprotected peptide (124). 
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Fmoc-NH-Thr-Leu-Arg-Ala-Leu-GIy-N H2N-A-GIn-Lys-Glu-AIIe-Ser-Pro-Pro-Asp-Ala-Ala-OH 
(121) 	 I 	 I 	(122) 
DIE Aj 
Tnni 
107 	 125 
Frnoc-NH-Thr-Leu-Arg-Meu-G1y-a-G1n-Lys-Glu-a-I1e-Ser-Pro-Pro-Asp-A1a-A1a-OH 
I  10% pipendine/ I 	Tn 
I ni (123) 
30%CH3CN/H2c 
107 	 I F 125 
H2N-Thr-Leu-Arg-Ala-Leu-GIy-Gln-Lys-Glu-Ala-Ile-Ser-Pro-Asp-Ala-AJa-OH 
(124) 
Figure 47 Azide fragment coupling of two peptide fragments utilising the Tnm 
protecting group for lysine 
2.4: Conclusions and future work 
Bepa was successfully incorporated into Fmoc SPPS of peptides and proteins and 
afforded the Lys-Hopa moeity after the TFA resin cleavage. However, although the 
Hopa moiety is a suitable protecting group for use in azide fragment condensations 
for small peptides (ca. 30 residues) it is not applicable for larger peptide systems. 
It has been demonstrated that the Trim group is a viable protecting group for the N 
amino function of lysine. It attributes solubility to the protected peptide fragment, is 
stable to the conditions required for fragment condensations and is easily deprotected. 
From the investigations on Ub(Tnm) 6 it was apparent that derivatising the N-terminal 
with Thfmoc facilitated purification of the protein. The Thfmoc/charcoal protocol 
allowed the acquisition of synthetic ubiquitin which was homogeneous and 
indistinguishable from bovine ubiquitin. The Thfmoc group also permitted the protein 
to be purified by gel filtration keeping the Tnm groups in place which would 
obviously be desirable for the coupling of purified protected protein fragments. The 
facile deprotection of the Tnm group was also achieved using basic solution. 
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Now that the Turn protectionldep rot ection strategy has been validated then coupling 
of two ubiquitin fragments can be attempted. This work is presently being undertaken 
by Wang96 at Edinburgh. The strategy for the synthesis of di-ubiquitin utilises the 
azide method (Section 1.2.3.5) for fragment condensation. This means that a second 
ubiquitin fragment would be synthesised with all seven lysine residues Tnm protected 
and with a hydrazide linker at the C-terminal. Thus after resin cleavage a Tam 
protected ubiquitin with an activated acyl azide at the C-terminal could be produced. 
This would then be coupled to the first fragment via the free N amino group at 
lysine-48 forming Tam protected di-ubiquitin. The Trim groups should then be 
removed by treatment with base to yield a branched protein with a peptide linkage 
involving the F,-amino group of lysine. 
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Chapter 3: Stepwise SPS of deglycosylated human 
interferon-gamma 
3.1: General introduction 
3.1.1: Protein chemistry 
The upsurge of interest in protein chemistry, has to a large extent, been stimulated by 
the establishment of a biotechnology industry based on the production of genetically 
engineered proteins. Generally, biotechnology drugs (biopharmaceuticals) are 
molecules or derivatives of molecules that originate from living organisms and exert a 
biological effect, 97  for example growth hormone, the interferons and insulin. Since 
these drugs are large complex molecules that are often charged their delivery into the 
body at levels that are effective but non-toxic, is a demanding goal. In fact drug 
delivery of such substances is thought to represent the potential Achilles' heel for the 
biotechnology industry. 98 Currently, with few exceptions, drug delivery is by 
transdermal injection, however the skin is a formidable barrier, and some researchers 
remain sceptical about the usefulness of transdermal delivery routes. Nevertheless 
transdermal technology, namely sonophoresis, has been used to deliver therapeutic 
doses of proteins such as insulin, y-interferon and erythropoeitin across the skin. 99100 
Sonophoresis, which involves applying low-frequency ultrasound, shows great 
promise however it requires further testing to optimise its performance. 
The biotechnology industry has benefited from modem molecular biology techniques, 
such as cloning and cDNA sequencing of genes, which have made available amino 
acid sequence data of proteins. In many cases, the proteins themselves have never 
been isolated and their properties are largely or completely unknown. Chemical 
synthesis of peptide fragments, or of the whole molecule, can be used to explore the 
structure and function of such gene products. These studies may lead to the 
identification of the most active protein fragment which would enable proteins to be 
redesigned as second generation products for human pharmaceutical use. 
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3.1.2: Interferon-gamma 
Human interferon-gamma (hIFN-y) is a potent cytokine produced naturally by 
activated T cells and natural killer cells.' 0"02 Although originally isolated based on its 
antiviral activity, hIFN-'y also exhibits powerful antiproliferative and 
immunomodulatory activities. These biological activities are essential for developing 
appropriate cellular defences against a variety of infectious agents. In addition hJFN-'y 
may play a key role in multiple sclerosis' 03 and the onset of inflammatory reactions. 
Therefore hIFN-y is an important therapeutic protein and thus an ideal synthetic target 
for SPS. 
The amino acid sequence of kIFN-y was originally deduced from a cDNA clone which 
predicted the existence of a signal sequence followed by 146 amino acids starting with 
the tripeptide sequence Cys-Tyr-Cys.' °4 However, the amino-terminus of mature 
hIFN-'y, purified from induced peripheral blood lymphocytes, differed from the 
sequence predicted by cloning. In natural hIFN-'y the first three residues, Cys-Tyr-
Cys, were missing to give a 143 amino acid polypeptide chain and the amino-terminus 
consisted of a pyroglutamate residue (Figure 48). 105 In addition, natural hJFN-y was 
shown to consist of a mixture of molecules, all with identical amino-termini, but they 
displayed some variability in glycosylation and heterogeneity at the carboxyl-termini 
with the longest polypeptide being 138 amino acids. 101,106  The heterogeneity at the 
carboxyl-terminus was proposed to be the result of peptidase digestion either during 
or after secretion of the protein. 105 
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1 	 10 	 20 
Gin Asp Pro Tyr Val Lye Giu Ala Glu Aen Leu Lys Lys Tyr Phe Asn Ala Gly His Ser 
* 	 30 	 40 
Asp Val Ala Asp Aen Gly Thr Leu Phe Leu Gly lie Leu Lye Asn Trp Lye Giu Giu Ser 
50 	 60 
Asp Arg Lye lie Met Gin Ser Gin lie Val Ser Phe Tyr Phe Lye Leu Phe Lys Asn Phe 
70 	 80 
Lye Asp Asp Gin Ser lie Gin Lys Ser Val Giu Thr lie Lye Giu Asp Met Asn Val Lye 
90 	 * 	 100 
Phe Phe Aen Ser Aen Lys Lys Lys Arg Asp Asp Phe Giu Lye Leu Thr Asn Tyr Ser Val 
110 	 120 
Thr Asp Leu Asn Val Gin Arg Lys Ala lie His Giu Leu lie Gin Val Met Ala Giu Leu 
130 	 140 
Ser Pro Ala Ala Lye Thr Giy Lye Arg Lye Arg Ser Gin Met Leu Phe Arg Giy Arg Arg 
143 
Ala Ser Gin 
* N-Linked glycosylation sites 
Figure 48 Amino acid sequence of hIFN-y showing glycosylation sites 
hJFN-y has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 
of its 143 amino acid long mature polypeptide chain (Figure 48). There is 
considerable heterogeneity in the core glycosylation of hIFN-y with the molecules 
containing 0, 1 or 2 glycan residues. 107 The biologically active h1FN-y is a 
homodimer. There are no cysteine residues in the mature hIFN-y and thus the 
polypeptide lacks intramolecular disulphide bonds. 
The expression of hIFN-y in Escherichia coil'08' 109 has resulted in the preparation of 
large quantities of highly purified recombinant hJFN-y. As a result recombinant hJFN-
y has been fully characterised, is licensed for clinical use and detailed studies of 
structure-function relationships have been initiated. The three-dimensional structure 
of recombinant hJFN-y has been resolved (Figure 49 (a)).' 1° The protein is primarily 
a helical., with six helices in each subunit that comprise 62% of the structure; there is 
no 0 sheet. The six helices are labelled A-F from the N-terminus. Helix F is packed 
in a cleft created by helices A, B, C and D. With the exception of the AB loop, the 
helices are linked by short loops of 3 to 5 residues. The subunits are associated to 
each other in an antiparallel fashion and the molecules have multiple interactions along 
the polypeptide chains, forming a compact, relatively globular symmetrical dimeric 
structure. 
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Figure 49(a) Domain structure of rhIFN-y. 
Residues 1 -84 from chain 1 (yellow) and residues 85-132 (cyan) from chain 2. 
Figure 49(b) Complex between rhIFN-y and its soluble high-affinity receptor." 
Receptor 1 (green) receptor 2 (yellow). Potential N-linked glycosylation sites are 
also shown. 
Expression of biological activity appears to be mediated through binding to specific 
cell-surface receptors,' 2 which have now been cloned. 113  The KIFN-y dimer has two 
receptor binding-sites and it can simultaneously bind to two receptor molecules 
(Figure 49 (b)).' 14 All four potential N-linked glycosylation sites are located on the 
surface of the hWN-y dimer." ° Glycosylation is apparently not required for 
dimerisation of the subunits, since recombinant hWN-y produced in EscherEchia co/i 
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forms dimers which are biologically active."' Glycosylation may, however protect 
hIFN-y against cellular proteases and prolong its survival time in the circulation. 116 
Both carboxyl-terminal truncation and glycosylation do not appear to affect either 
quaternary structure or biological activity of 117 , 118 In fact the removal of a 
limited number of carboxy-terminal residues dramatically enhances the biological 
activity. "9 Maximal enhancement was found with the deletion of 9 to 10 amino acids 
but the polypeptide is rendered inactive on the removal of more than 14 residues. 
From these results Dobeli proposed that hIFN-y is synthesised as a preprotein and 
that its activity is modulated by proteolytic digestion." 9 Such post-translational 
modifications require further investigation to determine if there are other fragments 
with increased biological activity. The preparation of truncated hIFN-y molecules 
with greater than 11 deleted residues requires an extreme expenditure of DNA 
synthesis, due to unfavourable cleavage sites for restriction enzymes. "9 An 
alternative route to obtain carboxy-terminally truncated hIFN-7 is proteolytic 
digestion by enzymes. However, even highly specific enzymes usually lead to a wide 
spectrum of fragments which are difficult to purify. Therefore, a major advantage of 
chemically produced hIFN-y is that the amino acid sequence can be specifically 
modified to synthesise the most biologically active protein fragment and will avoid C-
terminal heterogeneity. 
3.2: Objectives 
The aim of this project was to construct deglycosylated hIFN-y (143 amino acids, 
16.8kDa) by applying solid phase peptide synthesis. Gin hIFN-y was synthesised 
because it is the first processed product which spontaneously cydises to give the 
pyroglutamic N-terminus. On completion of the synthesis, the aim is to develop an 
effective purification protocol to obtain homogeneous synthetic protein. The 
attainment of pure protein will allow the biological activity to be determined and 
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should lead to crystallisation and structural data. Finally both the glycosylated form 
of hIFN-7 and stabilised, modified analogues could be synthesised. 
3.3: Chemical synthesis of deglycosylated hIFN-y (dhIFN-'y) 
The pioneering stepwise syntheses of the obese gene product, 31 erythropoietin 33 and 
the catalytic domain of Stromelysin' 2° have demonstrated that the methodology in this 
laboratory can be applied to larger polypeptide systems. The use of the superior 
coupling agent HOCt (26) was crucial, permitting the synthesis of proteins previously 
unattainable using HOBt (24). 
The stepwise assembly of the dhJFN-y sequence (Figure 48) was carried out on a 
0. immol scale using Fmoc-GIn(Trt), functionalised Wang resin and an ABI 430A 
peptide synthesiser. The amino acids were single coupled as their active HOCt esters 
with the exception of the last 44 residues which were double coupled. It was hoped 
that double coupling from Ile-44 to Gin- 1 would reduce the formation of large 
truncations and increase the yield of the desired sequence. From the deprotection 
profile the stepwise SPS of dhlFN-y appeared to have proceeded extremely well with 
no obvious large drops in the percentage coupling of the amino acids (Graph 2). 
Graph 2 Deprotection profile for dhIFN-y 
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The success of the synthesis was confirmed by submitting resin-bound protein for 
amino acid analysis. The values obtained from the amino acid analysis were in good 
agreement with the expected composition (Table 3). 
Amino acid Found Expected 
Asx 22.4 20 
Tbr 5.4 5 
Ser 10.0 11 
Gix 21.0 18 
Pro 3,7 2 
Gly 5.3 5 
Ala 7.7 8 
Cys 0 0 _ 
Val 9.3 8 
Met 2.3 4 
Ile 7.9 7 
Leu 12.0 10 
Tvr 3.9 4 
Phe 12.0 10 
His 2.7 2 
Lys 20.4 20 
Am 6.3 8 
Table 3 A.A.A. of resin bound dhIFN-y 
The SPS of dhlFN-y was carried out on only one occasion consequently limited 
material was available to determine the best purification strategy. The following 
sections describe the efforts made to characterise the product and to identify a suitable 
purification protocol to obtain homogeneous protein. 
3.4: Purification of dhIFN-y 
As outlined in Section 1.2.2 the main obstacle to the success of stepwise SPS of 
proteins can be attributed to the generation and subsequent inability to separate 
closely related sequences from the target protein. Protracted chromatographic 
purification is usually required to isolate the protein, and it is sometimes even 
impossible to separate the desired protein from the physically and chemically similar 
truncated sequences. Derivatisation of the free N-terminus of the resin-bound 
polypeptide with the Thfmoc group (37) allows differentiation between the target 
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sequence and any acetylated truncations. Thflnoc methodology is one technique that 
can be utilised in the purification of dhIFN-y but it was decided to examine the 
methods employed for the purification of natural and recombinantly produced hTFN-y. 
3.4.1: Literature purification of hLFN-y 
The partial purification of IFN-y from human peripheral leukocytes was reported in 
1981 by Yip using sequential chromatographic separations. 121  Subsequently natural 
hIFN-y was purified to homogeneity utilising a concanavalin A-Sepharose column and 
RP HPLC.' °5 Concanavalin A binds molecules which contain ct-D-mannose and a-D-
glucose therefore it is exploited as a means to separate and purify glycoproteins. In 
1986 Miyata reported a purification procedure for natural hIFN-y based on 
monoclonal antibody affinity chromatography which gave essentially quantitative 
recovery of the protein. 122  Both purification procedures resulted in two active species 
with apparent molecular weights of 20,000 and 25,000, as judged by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), corresponding to mono and 
di-glycosylated hIFN-y respectively. 
The purification of recombinant dhlIFN-y produced in Escherichia coil has also been 
achieved utilising antibody affinity chromatography. 123  However, Dobeli utilised 
sequential chromatographic techniques to purify dhIFN-y and the carboxy-terminally 
truncated analogues.' 19 First Döbeli applied the crude extract to a silica gel column 
then the eluate containing the dhJFN-y was pumped through two hydrophobic 
interaction columns followed by a cation exchange column and finally a desalting step 
using a Sephadex column. Although this appears a somewhat lengthy procedure the 
protein obtained was homogeneous by SDS-PAGE and biologically active. 
The protein produced by recombinant methods is not glycosylated and is therefore 
analogous to the dhlFN-y which was synthesised by SPS. The objective of this 
research was not only to develop a purification protocol for dhlFN-y but also one that 
could be applied to the general purification of other proteins. Consequently the 
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research of Dobeli was applicable since it did not involve specialised antibodies but 
instead employed standard purification techniques available in most laboratories. 
3.4.2: Proposed strategy for the purification of dhLFN-'y 
The proposed purification strategy for IFN-y encompassed standard peptide 
purification techniques and those used to purify recombinantly produced dhlFN-y and 
is outlined below: 
• Attachment of Thfmoc 
• Cleavage from resin 
• Thfmoc/charcoal purification 
• FPLC size exclusion 
• Hydrophobic interaction chromatography (MC) 
• Isoelectric focusing (1FF) 
• Denaturing and folding 
• Ion exchange chromatography 
3.4.3: Affinity purification of dhIFN-y using Tbfmoc on charcoal 
On completion of the synthesis, the resin-bound Fmoc protected dhJFN-y (125) was 
somcated in the presence of acetic anhydridefHOBtfDlEA in DCM in order to cap 
any free amino groups. The N-terminal Fmoc group was then removed and Thfmoc 
introduced at the N-terminus. The next step was to cleave the Thfmoc labelled 
dhIFN-y (126) from the resin and simultaneously remove all side chain protecting 
groups. It was desirable to ascertain the minimum time that afforded complete 
cleavage since subjecting the protein to TFA for a long period of time might cause 
cleavage of the polypeptide chain although this has not been proven. Therefore a trial 
resin cleavage was carried out in order to establish the optimum time. This was 
accomplished by stirring a portion of the resin-bound material in a scavenger cocktail 
of TFA, EDT, thioanisole, water and phenol. Samples of the cleavage mixture were 
analysed by HPLC after 3.5 hours and every half an hour after that until 6 hours had 
75 
SPS of interferon-gamma 
passed. After 4.5 hours there was no further change in the HPLC profile and thus 4.5 
hours was taken as the optimum cleavage time. 
A large scale resin cleavage was then performed on (126) and after 4.5 hours the resin 
was removed by filtration and the crude protein was precipitated from the filtrate with 
diethyl ether. The crude Thfinoc labelled protein (127) was isolated by centrifugation 
and lyophilisation. 
Thfmoc adsorption methodology, using charcoal as the solid phase, was applied as the 
primary purification of Thfmoc-dlilIFN-y (127). Denaturing conditions (6MGdm.Cl) 
were used, as outlined in the experimental section. The Thfinoc purified dliJFN-
y/guanidine solution (128) obtained was examined by RP-HPLC and observed as a 
single broad peak (Figure 50). 
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Figure 50 HPLC profiles of crude Tbfmoc-dhIFN-y (127) and dhIFN-y (128) 
The dkIFN-y (128) was characterised by N-terminal sequencing, amino acid analysis, 
MALDI MS and SDS-PAGE. These techniques confirmed that the dhWN-y sequence 
had been synthesised correctly and the latter two techniques allowed the purity of the 
material to be assessed. The MALDI MS and SDS-PAGE reproducibly revealed 4 
components of approximate molecular weight 16.8, 14.3, 13.2 and 10.5kDa (Figure 
51). 
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Molecular weight of Lane: 1 	2 	3 
standards in Lane 1 std. (127) (128) 
Figure 51 SDS-PA GE of Tbfmoc-dhIFN-y (127) and dhIFN-y (128) 
It was proposed that the impurities revealed by the SDS-PAGE gel and mass spectra 
could have arisen from three sources. Firstly the acetylated truncated materials may 
not have been removed during the washing of the charcoal, perhaps because they 
themselves had bound to the charcoal via aromatic side chains. Or secondly the 
protein may have been sheared during the TFA resin cleavage. If the protein 
backbone was cut from the C-terminus then truncated fragments that were tagged 
with Thfmoc would be carried through the purification protocol. The impurities 
could also have arisen from deletion sequences. Deletion peptides are similar to 
truncated peptides but, unlike truncated sequences they are not acetylated during the 
capping step. This could occur during the synthesis if the resin swelling is not 
sufficient to expose all the free amino functions for coupling. However, later in the 
synthesis the extent of resin swelling might alter and the amino functions would again 
become available for coupling. Thus deletions could be formed that are missing 
residues from the middle of the desired sequence. When Thfmoc is incorporated onto 
the N-terminus of the target sequence the deletion sequences, which have not been 
capped, would also be labelled with Thfmoc and carried through the purification 
protocol. 
3.4.4: FMC ,purification of dhWN-7 (128) by gel filtration 
The next purification technique employed was FPLC gel filtration adopting the 
principle of size exclusion (largest molecular weight elutes first). dliIFN-'y (128) was 
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loaded onto a Superdex Tm 75 column which was then eluted isocratically with 6M 
Gdm.Cl. Fractions absorbing at 280mn were examined by analytical HPLC. 
Fractions 8-15 eluted with the correct retention time (Rt= 17. 2mins., 51 %B) however 
fractions 8-10 gave the sharpest HPLC profiles (Figure 52). 
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Figure 52 HPLCs of dhIFN-y (128) (fraction 11) and dhIFN-y (129) (fractions 
8,9) 
Individual fractions were desalted, examined by SDS PAGE PhastGel and mass 
spectra obtained. Fraction 8 and 9 were seen to consist of 3 components of 
approximate molecular weight 16.8, 14.3, 13.2kDa. Whilst the later fractions gave 
the same composition as dhJFN-y (128). Fractions 8 and 9 were combined to give 
dliWN-y (129) and used for subsequent purification steps. Figure 53 shows the SDS-
PAGE Phast gel of dhIFN-'y (129) (fractions 8,9) and dkWN-y (128) (fraction 1 1). 




6.3 8kDa–* Moab 
Molecular weight Lane: 1 	2 	3 
of 	standards 	in std. (129) (128) 
Lane 1  
Figure 53 SDS-PA GE of dhIFN-y (129) (fractions 8,9) and dhIFN-y (128) 
(fraction 11) 
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3.4.4.1: Molecular weight determination of dhLFN-y (128) by FPLC 
The FPLC experiments could also be used to determine the molecular weight of the 
eluted protein and hence gain further evidence that the correct sequence relating to 
dklFN-y had been synthesised. This was achieved by loading known molecular 
weight standards (Ovalbumin, Mwt 43, Chymotrypsinogen A, MWt 25 and 
Ribonuclease A, MWt 13.7kDa) onto the column and measuring their elution 
volumes. A graph was then plotted of the elution volume parameters (kAy) of the 
standard versus the logarithm of their molecular weight. Where kAyis calculated from 
the following equation: 
kAy = Ve - Vo 
Vt - Vo 
where Ve = elution volume, Vt = column bed volume and Vo = column void volume 
The kAy value for dhlFN-y was calculated from the FPLC experiments and the 
logarithm of its molecular weight was found from the graph (Graph 3) allowing the 
molecular weight of dkIFN-y to be determined. The logMWt value calculated for 
dhJFN-y was 4.2256 which compared well with the expected value of 4.2247. 
Graph 3 Plot of logMwt vs kA 
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3.4.5: Folding of dhlFN-'y (129) 
To be biologically active, all proteins must adopt specific folded three-dimensional 
structures. These thermodynamically favoured structures are maintained by relatively 
weak interatomic forces such as hydrogen bonding, hydrophobic interaction and ionic 
interactions. 124 
Many recombinant proteins have been successfully folded and their activity recovered 
using the following folding procedure. After isolating solid protein pellets from the 
cell, the protein is solubilised in a strong denaturant such as Gdm.Cl or urea. The 
denaturant concentration is then reduced by dilution or dialysis to allow the protein to 
refold to its native state. The protein can aggregate during refolding and, thereby, the 
recovery of active protein is reduced. Several approaches have been investigated to 
reduce aggregation, one of which is inclusion of folding aids in the dilution 
buffer. 125,126  The addition of the cosolvent, polyethylene glycol (PEG), to the dilution 
buffer has been shown to enhance refolding of active recombinant proteins including 
rhlFN-y.' 27 Cleland's results indicate that PEG is probably binding to specific 
segments of the protein to prevent aggregation and hence increase the recovery of 
active protein. 127 
The experimental conditions of Cleland were utilised for dklFN-y (129)127  and the 
folding was monitored by analytical HPLC. It must be noted that the protein sample 
contained three components, as determined by SDS-PAGE and MALDI MS, and the 
purpose of the experiment was to test the literature folding protocol. The HPLC 
profile did become sharper which implied that the protein was folded (Figure 54). 
However conclusive evidence that the protein had folded in the correct configuration 
can only be obtained if the biological activity is tested. 
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Figure 54 RP HPLC of dhIFN-y (129) after folding 
3.5: Characterisation of dhIFN-y (129) (3 components 16.8, 14.3 and 
13.2 kDa) 
At this stage it was decided to filly characterise the protein, dkWN-y (129), obtained 
after FPLC size exclusion and folding to obtain evidence that the correct sequence 
had been constructed. 
3.5.1: Tryptic digest and mass spectrometry data 
The acquisition of MALDI MS for the entire sequence of synthetic proteins, such as 
ertbropoietin and the obese gene has proved problematic however, mass spectra were 
obtained for dhlFN-y. Mass spectrometry data for dhIFN-y (16. 8kDa) revealed the 
presence of three main components at 16.8, 14.3 and 13.2kDa (Figure 55). 
Figure 55 MALDIMS of dhLFN-y (129) 
81 
SPS of interferon-gamma 
A technique employed to acquire accurate mass spectra data is the hydrolysis of the 
intact protein into smaller fragments which can readily be examined by MALDL MS. 
The most suitable proteolytic enzyme was trypsin since it has only two cleavage sites 
(cuts at the C-terminus of Lys and Arg) which should minimise the number of 
fragments obtained. Also it should be able to withstand the denaturing conditions 
required for the reaction. The hydrolysis was carried out in 3M Gdm.Cl solution 
since dialysis of the protein into low salt had resulted in its precipitation. 
Protein digestion followed by MS analysis of the mixture showed evidence for five 
main sites of cleavage. Not all possible cuts were observed but the molecular mass of 
some of the predicted fragments would have been too small to detect by MALDI MS. 
The results are shown in Table 4 below: 
Table 4 MALDIMS data obtained from tiyptic digest 
From the tryptic digest results there was no evidence for the presence of the N-
terminal amino acids (1-12). It was important to know that the synthesis had 
proceeded to the end in order to confirm that this was not simply a deletion sequence 
which had been purified, thus other methods had to be employed to analyse this 
portion. 
3.5.2 Sequencing analysis 
The intact protein was then sequenced from the N-terminus ' 28 in an attempt to 
characterise this part of dhWN-y. This was performed by Edman degradation 
labelling the N-terminus with phenyl isothiocyanate.' 29 
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A total of 15 rounds of Edman degradation were performed satisfactorily on dhJFN-y 
(129). Thus confirming the correct sequence of the N-terminal region and providing 
more evidence that the correct material had been synthesised. 
3.5.3: Western blot analysis 
Western blotting 130  using monoclonal mouse anti-hIFN-y antibody (kindly supplied by 
Department of Pathology, University of Edinburgh) was carried out on dhIFN-y 
(129). The bands obtained were compared with a set of molecular weight markers 
and the gel showed that the antibody was active for the synthetic dhIFN-y (129). The 
bands were within the correct molecular weight for dhIFN-y (-17kDa) (Figure 56). 
No lower molecular weight bands were present but a band at higher molecular weight 
was observed (-34kDa). This could be due to the presence of the dimer of dliIFN-y 
which could have formed due to a greater concentration of dhIFN-y compared to 
SDS. 131 
—34kDa -* S 
-17kDa--+ . 
Figure 56 Western blot analysis of dhIFN-y (129) 
3.5.4: Far UV circular dichroism 
Crystallographic studies on human WN-y" ° and rabbit IFN-y' 32 confirmed the high a-
helical content of 60-70% which had been predicted on the basis of UV circular 
dichroisni' 33 ' 134 The secondary structure content of dlilFN-y (129) was investigated 
using far UV circular dichroism (Figure 57). 
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Figure 57 Far UV circular dichroism spectrum of dhlFN-y (129) 
The CD analysis at pH 7 indicated a-helicity of 44% ± 0.49. This result implied that 
the protein had folded and some secondary structure was present in the dhJFN-y (129) 
sample. 
3.6: Further purification of dhIFN-y 
Thus FPLC size exclusion had purified the dhJFN-y from 4 components to 3 
components. However, this technique was not of sufficient resolution to afford 
further separation. It was thought that although the 3 components were similar in size 
they might possess different charges and different hydrophobicities, therefore 
techniques such as IEF, ion exchange or hydrophobic interaction chromatography 
might be more applicable. 
3.6.1: Hydrophobic interaction chromatography (HIC) of dhlFN-y (128) 
Hydrophobic interaction chromatography (HIC) is employed to separate substances 
on the basis of their varying strength of hydrophobic interaction with hydrophobic 
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groups attached to the uncharged gel matrix. For HIC the sample is applied in a 
solution of high ionic strength. Bound proteins are then eluted by reducing the 
hydrophobic interaction. This can be achieved by reducing the concentration of ions 
in the buffer with a decreasing salt gradient. 
An aliquot of dhJFN-'y/6M GdmCl solution (128) was slowly diluted with the initial 
buffer: 0.7M ammonium sulfate in 10mM sodium borate buffer, pH8.0. The mixture 
was loaded onto a Phenyl Sepharose column and eluted with the initial buffer and then 
with successively reduced concentrations of ammonium sulphate and finally only 
10mM sodium borate buffer. Fractions absorbing at 280nm were combined, 
concentrated and desalted. The material obtained, (dhlFN-y (130)), was characterised 
and the composition of the protein found to be the same as dhJFN-y (128) i.e 4 
components were present. 
3.6.2: Cation exchange chromatography of dhIFN-y (129) 
The purification protocol employed for recombinant dkIFN-y involved using cation 
exchange chromatography. 116 Hence it was decided to apply this technique to the 
purification of the synthetic protein. 
Problems were encountered with this technique due to precipitation of the protein in 
the low salt buffers required to load the protein onto the column. The presence of 
even 0. 1M salt concentations resulted in the protein being washed off the column 
without binding. 
As a general method the dhlFN-yI6M GdniCl (129) was slowly dialysed against 
native buffers (50mM IVIES buffer, pH 6.0 or 50mM phosphate buffer, pH 6.0) to fold 
the protein and desalt the solution to concentrations of :! ~0. 1M 6M GdmCl. The 
protein/buffer solutions were loaded onto a cation exchange column (Resource S) 
which had been equilibrated with the appropriate buffer. The column was then eluted 
with a linear NaC1-gradient of 0- 1M NaCl with monitoring at 280nm. Fractions 
absorbing at 280nm were concentrated and both the filtrate and retentate were 
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examined by analytical RP HPLC, SDS PAGE and MALDI TOF MS. None of the 
cation exchange experiments afforded any protein pure or otherwise. It was inferred 
that the protein either bound irreversibly to the column or was not retained and 
washed off It was noted that a significant amount of material was lost, due to 
precipitation when the protein was dialysed from the 6MGdm.Cl solution. 
3.6.3: Isoelectric focusing (IEF) of dhLFN-y (129) 
Separation of proteins by isoelectric focusing is based on the fact that all proteins 
have a pH-dependent net charge. When a protein is electrophoresed through an 
established pH gradient, it will migrate until it reaches the pH where the net charge on 
the protein is zero; at that point it will stop migrating and is said to be focused at its 
isoelectric point or p1. The Rotofor® cell consists of a focusing chamber which is 
divided into 20 compartments each holding one fraction. After the protein has been 
focused, the solution in each compartment can be collected without mixing using the 
harvesting apparatus. 
An aliquot of dhIFN-y/6M GdniCl (129) was slowly dialysed against 1M urea 
solutions before being loaded into the focusing chamber of the Rotofor® cell. The 
run was monitored by observing the voltage increase over time and was judged to be 
completed after 4 hours when the voltage stabilised. The twenty fractions obtained 
were examined by HPLC and the protein containing fractions were characterised by 
SDS-PAGE and MALDI MS. The material obtained, dhlFN-y (131), was 
characterised and the composition of the protein was found to be the same as dhlFN-y 
(129) i.e 3 components were present. 
3.6.4: Preparative electrophoresis of dhIFN-y (128) 
dhlFN-yI6M GdmCl solution (128) (4 components) was desalted, lyophilised and 
dhlFN-y (0.5mg) loaded onto a preparative polyacrylamide gel. Low molecular 
weight markers were loaded as a reference lane next to 10 sample elution lanes and 
the gel electrophoresed. After electrophoresis, the reference lane and the adjacent 
sample lane were cut out and stained, followed by destaining. The stained and 
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unstained gels were aligned and the band correspoding to dhlFN-y (Mwt 16.8 kDa) 
was identified on the stained gel. The location of the dhIFN-y band on the unstained 
gel was then estimated by extrapolating from the stained gel. The dhlFN-y band was 
excised and eluted into lml elution buffer for 5 hours using the Model 422 Electro-
Eluter. 
After elution the sample was dialysed (centricon 3000) against 10mM sodium 
phosphate buffer, pH 7.5 to remove SDS and to concentrate the protein. The eluted 
protein dh]FN-7 (132) was examined by SDS-PAGE and a single band corresponding 
to a molecular weight of 16.8kDa was observed (Figure 58). 




Lane: 1 	2 	3 Molecular weight of 
(132) (128) 	std standards in Lane 3, 
Figure 58 SDS-PA GE of dhIFN-y (132) and dhIFN-y (128) 
The eluted protein dhIFN-y (132) was submitted for N-terminal sequencing and the 
first two amino acids (Gin and Asp) were satisfactorily identified. Further rounds of 
Edman degradation were not obtained because of the low sequencing yield. This 
suggested that the N-terminus was blocked. The N-terminal sequence has previously 
been reported with a pyroglutamic residue at the N-terminus. 105 Thus these results 
are consistent with the presence of a N-terminal pyroglutamate since it is resistant to 
Edman degradation. 
The isolation of purified dhJFN-y, represented by a single clean band on the SDS-
PAGE gel was an excellent result. Preparative electrophoresis is therefore effective 
for the purification of proteins with impurities of similar mass which cannot be 
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separated by standard chromatographic techniques. Manipulaton of this technique 
should result in milligram quantities of purified protein being obtained which could be 
used for biological testing and structural studies. 
3.7: Conclusions and recommendations 
The initial studies outlined in this text have revealed that the total synthesis of 
interferon-gamma is accessible by SPS. The protein has been successfully purified to 
homogeneity by a combination of chromatographic techniques and the application of 
preparative electrophoresis. The synthesis and purification of dkIFN-7 should be 
repeated to acquire sufficient pure protein for biological testing, crystallisation and the 
attainment of structural data. 
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Chapter 4: Experimental 
4.1: Notes 
All amino acids were purchased from either Bachem or Novabiochem or were 
synthesised as described in the text. All amino acids were of the L configuration. 
Bachem supplied the 4-alkoxybenzylalcohol functionalised polystyrene resin (Wang). 
Peptide synthesis grade dimethylformamide (DMF), 1,4-dioxan and pip eridine were 
supplied by Rathbum Chemicals. N-N'-Diisopropylethylamine (DIEA) and 
trifluoroacetic acid (TFA) were peptide synthesis grade and purchased from Applied 
Biosystems (ABI). 1-Hydroxyl-4-ethoxycarbonyl- 1,2,3-triazole (HOCt) and 
tetrabenzo[a,c,g,i]fluorenyl- 17-methoxycarbonyl (Thfinoc) were synthesised within 
the research group. Porous graphitised carbon (PGC) was supplied by Shandon 
Scientific. Ubiquitin (bovine) was purchased from Sigma. 
Melting points were recorded in open capillaries using a Buchi 510 oil immersion 
melting point apparatus. Optical rotations were measured on' a AA1000 polarimeter 
(Optical Activity Ltd.) using a 10.0cm cell in the solvent indicated in the text. 
Analytical thin layer chromatography (t.l.c.) was performed using aluminium sheets 
precoated with silica gel 60F 254 (Merck) in the solvent systems indicated in the text. 
Compounds were visualised using suitable combinations of the following methods: 
ultraviolet (UV) absorption at 254nm; ninhydrin test for free amino groups; Mary's 
spray [4,4'-bis(dimethylamino)thphenylcarbinol] for free carboxylic acid functions. 
Infrared spectra were recorded on a BlO-RAD SPC 3200 instrument in solution or as 
a liquid film as indicated. UV spectra were recorded on a Varian Cary 210 double 
beam spectrophotometer, a Unicam UV/vis double beam spectrophotometer or a 
Perkin Elmer, single beam spectrophotometer in the solvents described in the text. A 
Coming ion analyser 150 was used for all pH measurements. Somcation was carried 
out in a Decon FS300b sonic bath. High and low resolution fast atom bombardment 
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mass spectra (FAB MS) were measured on a Kratos MS50TC instrument, using 
either thioglycerol, 3-nitrobenzyl alcohol or glycerol as matrix. Matrix assisted laser 
desorption ionisation mass spectra (MALDI) time of flight mass spectra (TOF MS) 
were recorded on a PerSeptive Biosystems Voyager Tm BiospectrometryTM  
Workstation using either a-cyano-4-hydroxycinnamic acid or 3,5-dimethoxy-4-
hydroxycinnamic acid as matrix. Calculated masses were based on average isotope 
composition and were derived using the program ADDMASS. Proton NMR spectra 
were recorded on either a Jeol FX-60 (60 MHz) or a Brucker WP-200 (200 MHz). 
Carbon-13 NMR spectra were recorded on a AC250 (60MHz) instrument in the 
solvents indicated in the text. Circular dichroism (CD) spectra were recorded at 20 °C 
on a JASCO J600 spectropolarimeter (University of Stirling) in the solvents stated. 
Elemental analyses were performed on a Perkin-Elmer 2400 CHIN elemental analyser. 
Amino acid analyses (AAA) were perfomed on a LKB 4150 alpha amino acid analyser 
on the hydrolysate obtained after heating samples in 6M HC1 at 110 °C in sealed 
Carius tubes at the times indicated in the text. Protein sequencing was performed on 
an ABI 477A sequencer at the Welmet sequencing facility, University of Edinburgh. 
Polyacrylamide molecular weight gels were run using 20% homogeneous SDS gels 
(Pharmacia) on a LKB Pharmacia PhastGel electrophoresis system, and developed 
using coomassie blue staining. High performance liquid chromatography (HIPLC) was 
carried out using either an ABI system comprising 2xl406A solvent delivery systems, 
a 1480 injector/mixer and a 1783 detector/controller, or a Gilson system comprising 
2006 solvent delivery systems, an 81 1C dynamic mixer, an 805 manometric module, 
a 119 UV/vis detector and a Gilson 715 software-driven gradient controller. 
Components were eluted from various columns, as described in the text, by a linear 
gradient of acetomtrile (far UV grade, Rathburn Chemicals) in MilJi-Q grade water, 
where both solvents contained 0.1% v/v of HPLC grade TFA (Fisons). Fast protein 
liquid chromatography (FPLC) was carried out on a Pharmacia FPLC system with 
Liquid Chromatography Controller LCC-501 Plus using a Superdex 751-JR 10/30 
column and the conditions stated in the text. Gel filtration and cation exchange 
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chromatography were carried using Pharmacia!LKB apparatus comprising 2xLKB 
2138 UVICORDS, a Pharmacia 2132 Microperpex peristaltic pump, an LKB 2112 
redirac fraction collector and where appropriate a Pharmacia Gm gradient mixer. 
4.2: Solid Phase Peptide Synthesis 
All polypeptides were synthesised on an ABI 430A automated peptide synthesiser 
with on line UV monitoring using an ABI 758A detector. All polypeptides were 
synthesised using the 9-fluorenylmethoxycarbonyl (Fmoc) strategy of N  protection. 
This involves the complementary use of orthogonal acid labile side chain protection 
and an acid labile peptide-resin linker. 
4.2.1: Side chain protecting groups used in Fmoc SPPS 
The side chain protecting groups used were as follows: tert-butyl (But)  ethers for 
serine, threonine and tyrosine; But  esters for aspartic and glutamic acid; 'r-
triphenylmethyl (Trt) for histidine; 2,2,5 ,7,8-pentamethylchroman-6-sulphonyl (Pmc) 
for arginine. The carboxamide side chains of asparagine and glutamine were 
incorporated as either the 4,4'-dimethoxybenzhydryl (MIBH) or tnphenylmethyl (Trt) 
derivatives as indicated in the text. Lysine was incorporated as either the tert-
butyloxycarbonyl (Boc), phenylacetyl (Phenac), 4-methoxyphenylacetyl (Mepa), 4-
benzyloxyphenylacetyl (Bepa), 4-(4'-methylbenzyloxy)phenylacetyl (MeBepa) or the 
Nc 1, 5-dioxaspiro- 5: 5 -undecane- 3 -nitro- 3 -methoxycarbonyl (Tnm) derivatives as 
indicated in the text. 
4.2.2: Coupling of the C-terminal amino acid onto 4-alkoxybenzylalcohol 
(Wang) resin 
The C-terminal Fmoc-amino acid (6 equivalents) was dissolved in DMF (lOmi) with 
N,N'-diisopropylcarbodiimide (DIC) (3 equivalents). The solution was sonicated for 
15 minutes at room temperature before adding it to 4-alkoxybenzylalcohol 
functionalised polystyrene (Wang) resin which had been preswollen in a minimum 
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amount of DMF with a catalytic amount of 4-(N,N'-dimethylamino)-pyridine 
(DMAP). The mixture was sonicated for 2 hours at room temperature. The 
functionalised resin was then removed by filtration and sequentially washed with 
DMF, DCM and diethyl ether before being dried in vacuo. 
If a low resin loading was required the procedure was modified as follows: 3 
equivalents of the Fmoc-amino acid and 1.5 equivalents of DIC were used. After 
adding to the Wang resin and the DMAP, the mixture was allowed to stand at room 
temperature for 1.5 hours. 
4.2.3: Determination of resin loading 
The loading efficiency was determined by sonicating a sample of the dried Fmoc-
amino acid resin (3-5mg) in 20% v/v piperidine/DMF in a lOml volumetric flask for 
20 minutes. The UV absorbance of the supernatant was then measured at 302nm and 
the loading calculated using the Beer-Lambert Law (6302=15400 for fulvene-
piperidine adduct). The values for resin functionality (mmol/g) and percentage 
coupling obtained are listed in the text. 
4.2.4: Automated SPPS 
Synthetic procedures were preprogrammed into the ABI 430A synthesiser prior to 
the commencement of each synthesis. The first (C-terminal) amino acid was 
attached to the Wang resin manually (section 4.2.2) and then transferred to the 
reaction vessel for automated peptide synthesis. A synthetic cycle, resulting in the 
coupling of a single amino acid, involved recurring capping, deprotection and 
coupling steps with thorough washing of the resin after each step. Each cycle was 
then repeated in order to build up the desired sequence of amino acids, in a stepwise 
manner, from the C-terminus to the N-terminus. The preprogrammed synthetic 




Any unreacted amino functions were capped using acetic anhydride (0.5M), DIEA 
(0.125M) and HOBt (0.2% w/v) in DMIF/1,4-dioxan (1:1, lOml) with vortexing for 
10 minutes. The reaction vessel was drained and the resin washed with six portions of 
DMF:1,4-dioxan(l:l). 
Deprotection 
The Na  Fmoc protecting group was cleaved using 20% v/v piperidine in DMF/1,4-
dioxan (1:1, lOmi) for 6 minutes. An aliquot of the deprotection filtrate was passed 
through an UV detector with on line integration in order to quantify the amount of 
fulvene-piperidine adduct present at 302mm. Thus allowing the percentage coupling 
of each amino acid to be estimated. The deprotection step was then repeated a 
further two times, but with vortexing for 1.5 minutes to ensure complete removal of 
the Fmoc group. Finally the resin was washed with 6 portions of DMF/1,4-dioxan 
(1:1). 
Coupling 
The next amino acid residues were incorporated in one of two ways; either using the 
HOBt method or the HOCt method: 
The HOBt method used double couple cycles. The first coupling cycle utilised a 
preformed symmetrical anhydride and the second a preformed HOBt ester. The 
exceptions to this were asp aragine, glutamine and histidine, which were coupled twice 
as their HOBt esters and glycine which was coupled only once as its symmetrical 
anhydride. The symmetrical anhydride was formed, in the activator vessel, by reacting 
the Fmoc-amino acid (immol) with DIC (0.5mmol) in DMF/1,4-dioxan (1:1, 8m1) for 
10 minutes before being transferred to the reaction vessel containing the resin. The 
mixture was vortexed for 30 minutes before the resin was drained and washed with 
four portions of DMF/1,4-dioxan (1:1). The resin was then vortexed for a second 30 
minute period with the Fmoc-ammo acid HOBt active ester (preformed from the 
Fmoc-amino acid (0.5mmol), HOBt (0.5mmol) and DIC (0.5mmol)) before being 
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drained and washed with four portions of DMF/1,4-dioxan (1:1). For certain difficult 
couplings the coupling time was extended. 
The HOCt method utilised the Fmoc-amino acid HOCt active ester in a single couple 
cycle. The only exception was histidine which was coupled as the HOBt active ester 
(HOBt (immol) was placed in the cartridge with histidine (immol) prior to synthesis). 
The HOCt active ester was preformed as for the HOBt active ester except that a 
immol scale was used. 
4.2.5: Loading Tbfmoc onto the peptide-resin 
Using the Fmoc loading test (4.2.3) the resin functionality (mmollg) of the peptide-
resin was calculated. Thfmoc chioroformate (3 equivalents) was dissolved in DCM 
and the solution added to the dry resin followed by DIEA (3 equivalents). The 
mixture was sealed and sonicated in the dark for 3 hours with occasional mixing. The 
resin bound Thfmoc-peptide was filtered, washed copiously with DCM then diethyl 
ether, dried in vacuo and a Thfmoc load test carried out. The resin was swollen in 
1,4-dioxan and stored in the freezer until required. 
4.2.6: The Tbfmoc loading test 
Dry Tbflnoc-peptide-resin (3-5mg) was sonicated in 20% v/v pip endine/l,4-dioxan in 
a lOmI volumetric flask for 15 minutes. The UV absorbance of the supernatant was 
measured at 364nm and the values for resin functionality (mmollg) and percentage 
loading of Thfmoc were calculated using the following equations: 
Resin functionality (mmol/g) = [0.613 x Abs at 364nm] / weight of resin (mg) 




4.3: Experimental Details 
4.3.1: Synthesis of enzyme cleavable lysine protecting groups 
Copper[Iysinej 2 (76) 
Basic copper carbonate (66g, 0.3mol) was added to a boiling solution of lysine 
monohydroclilonde (36.8g, 0.2mol) in water (500m1). The suspension was refluxed 
for 3 hours, hot filtered to remove excess insoluble copper carbonate and washed with 
cold water (30m1). The filtrate was evaporated in vacuo to yield the title compound as 
a blue solid (50g. 83%). 
Copper NE4_methoxyphenylacety1 lysineJ 2 
4-Methoxyphenylacetic acid (8g, 48mmol) was stirred in sodium dried benzene 
(45m1), at 0°C, under an atmosphere of dry nitrogen. Freshly distilled oxalyl chloride 
(6.1g. 48mmol) was added followed by DMF (0. lml). The reaction flask was fitted 
with a drying tube and the mixture stirred for 1 hour, until all the gas had evolved. 
The benzene was removed in vacuo to yield the acid chloride as a yellow oil which 
was not isolated. o 	(C6H6)/cm' 3090 (ArCH), 1800 (COd), 1611 & 1512 
(aromatic C=C). The acid chloride (8.8g, 48mmol) was dissolved in 1,4-dioxan 
(lOmi) and added dropwise over a period of 1 hour to a solution of copper[lysine] 2 
(76) (7.2g, 20.4mmol) in water (50m1). Throughout the experiment the pH was kept 
constant at 10.0 with 10% sodium carbonate. The product precipitated from solution 
as the reaction progressed, after 1 hour the blue precipitate was removed by filtration, 
washed copiously with water and dried in vacuo to give the title compound as a blue 
solid (7.9g, 5 1%). 
NC4MethoxyphenyIacetyl lysine (67) 
Dry, finely powdered, copper[N 5-4-methoxyphenylacetyl lysine1 2 (5. 7g, 8. 8mmol) 
was suspended in a stirred solution of ethylenediaminetetraacetic acid disodiuxn sal 
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precipitate of NE4methoxyphenylacetyl lysine was filtered from the blue, copper 
containing, solution. The precipitate was washed copiously with water and dried in 
vUcuo to give the title compound as a white solid (3.4g, 67%), nip. 241-242 °C; 
Found: C, 61.20; H, 7.53; N, 9.52; C 15H23N204 requires C, 61.16; H, 7.63; N, 9.39%; 
m/z (Found: MH, 295.16562 ± 0.5 ppm C 15H24N204 requires 295.16578); u,, 
(CHBr3)/(cm 1 ) 3271 (NH), 1668 (COOH), 1635, (CO amide I), 1540 (CO amide II), 
1513 (aromatic C=C); X. (MeOH)/mn 283 (/dm 3moF 1 cm 2528), 276 (2940); 6H 
(200MHz; D20) 1.11-1.69 (81-, m, CH2 x 4, Lys), 2.85-2.9 (3H, m, CH2Ar & aCH), 
3.58 (311. s, OCH3), 6.69-7.09 (411, m, aromatic); 6C (200MHz; D 20) 22.04, 31.45, 
34.23, 40.06 (CH2 x 4, Lys), 55.33 (OCH3), 55.55 (aCH), 113.86 & 130.01 
(aromatic CH), 129.66 (quat. aromatic), 156.91 (quat. aromatic C-OMe), 168.23 
(amide CO); m/z (FAB) 295 (MH, 100%). 
Na9FluorenyImethoxycarbonylNE4_methoxyphenylacetyl lysine 
NL4Methoxypheny1acety1 lysine (3. ig, 10.5mmol ) was stirred in water (50m1) and 
triethylamine (1. ig, 10.5mmol) in 1,4-dioxan (SOml) was added. To this solution was 
added 9-fluorenylmethylsuccinimidyl carbonate (3.4g, 10. immol) and the mixture 
stirred overnight. The reaction mixture was diluted with water (100m!) acidified to pH 
2.0 using 2M HCI. The resulting precipitate was extracted into ethyl acetate, washed 
with water then brine, dried (MgSO 4) and the solvent removed in vacuo to give a 
white solid. Recrystallisation from ethyl acetate/diethyl ether gave the title compound 
as a white powder (3.7g. 68%); nip. 144°C; t1c. (DCMIMeOH, 80:20) R f 0.33; 
Found C, 69.56; H, 6.45; N, 5.38; C301132N206 requires C, 69.75; H, 6.24; N,.5.42%; 
m/z (Found: MI-P 517.23388 ± 1 ppm; C 301133N206 requires 517.23384); U. 
(CHBr3)/(cm 1 ) 3411, 3337 (NH), 1745 (urethane CO), 1692, (CO amide I), 1552 
(CO amide II), 1600 & 1512 (aromatic C=C); A (MeOH)/nm 302 (F/dm 3moF'cm-1 
6186), 290 (5928), 267 (20103); 6H (200 MHz, d6-DMSO) 1.37 (411, m, CI-12 x 2, 
Lys), 1.62-1.70(211, m, CH2CH,  Lys), 3.02-3.04 (2H, m, CH-NH,  Lys), 3.31 (21-1, s, 
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COC112-Ar), 3.70 (3H, s, OCH3), 3.90-3.93 (114, in, aCH, Lys), 4.23-4.31 (311, 
ni3OCfl2  & CH, fluorenyl), 6.83-7.99 (1411, in, aromatics & NH x 2), 12.6 (IH, br., 
OH); 8C (200 MHz, d6-DMSO ) 23.24, 28.80, 30.56, 38.59 (CI-12 x 4, Lys), 41.69 
(CH2CO) 46.80 (aCH, Lys), 53.91 (CH, fluorenyl), 55.09 (OCH3), 65.74 (0H2 , 
fluorenyl), 113.73, 120.24, 125.42, 127.20, 127.78, 130.02 (aromatic CH), 128.59 
(quat. aromatic, ç-CH), 140.85, 143.94 (quat. fluorenyl, C's), 156.33, 157.96 
(CO20H & quat. aromatic, C-OMe) 170.43 (amide CO), 174.14 (urethane CO); m/z 
(FAB) 517 (MEft, 100%); [a]D=+7 0, c=0.1 in MeOH. 
Methyl 4-beuzyloxyphenylacetate (74) 
To a solution of methyl 4-hydroxyphenylacetate (73) (6.6g, 40mmol) and benzyl 
bromide (10.3g. 60mmol) in DMF (lOOm!) was added potassium carbonate (11.1g. 
80mmol) and the resulting mixture was heated at 60°C for 7 hours and at room 
temperature overnight. The reaction mixture was filtered and the filtrate concentrated 
in vacuo to give a yellow oil. The residue was dissolved in diethyl ether, washed with 
a 1M HC1 solution, then brine, dried (MgSO 4) and the solvent removed in vacuo. The 
orange residue was recrystallised from n-hexane to yield the title compound as a white 
powder (7.8g, 76%); m..p. 58-59°C (lit 135 58.5-590C); t.1.c. (DCM) Rf 0.5; Found C, 
74.67; H, 6.58; calculated for C, 6H,603 C, 74.95; H, 6.29%; m/z (Found: MH 
257.11776; C 16H1703 requires 257.11777); o (CHBr3)/cm-' 3100 (ArCH), 1730 
(CO2Me), 1612 & 1511 (aromatic CC); X. (MeOH)/nm 282 (cldm3moF'cm' 
1997), 276 (2355); 6H (200 M}Iz, CDC13) 3.57 (211, s, CH2 CO), 3.68 (311, s, OCH3), 
5.05 (211, s, 0CH, ), 6.92-7.44 (911, in, aromatics); 6C (200 MIHz, CDC1 3) 40.17 
(CHC0), 51.88 (OCH3), 69.88 (CH20), 114.81, 127.32, 127.85, 128.45, 130.16 
(aromatic CH), 126.19 & 136.85 (quat. aromatic, c-CH2), 157.80 (quat. aromatic, C-
0)172.21 (CO 2Me); m/z (FAB) 256 (Mt, 100%). 
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4-.Benzyloxyphenylacetic acid (70) 
To a solution of methyl 4-benzyloxyphenylacetate (74) (7.0g. 27.3mmol) in 
ácetone:water (50m1, 4:1) was added lithium hydroxide (1.7g, 41mmol) in water 
(30m1) and the mixture stirred for 2 hours. The white precipitate which formed was 
filtered off, washed with ethyl acetate suspended in water (lOOml) and acidified to pH 
3 using 2M HC1. The resulting precipitate was extracted into ethyl acetate, washed 
with water and brine, dried (MgSO 4) and the solvent removed in vacuo to yield a 
white solid. The title compound was recrystaffised from ethyl acetate (5.2g. 79%), 
nip. 124°C (lit 13-1 114°C); t.Lc. (DCM!MeOH, 80:20) R f 0.60; Found C, 74.48; H, 
6.10; calculated for C 15H1403 C, 74.36; H, 5.82%; m/z (Found: M 242.09537; 
C 15H1403 requires 242.09429); u,, (CliBr3)/cm 1 3600-3300 (br. OH), 3020 
(ArCH), 1712 (CO2H), 1512 (aromatic C=C); X (MeOH)/nm 284 (/dm 3mo1-lcm- I 
151), 276 (303); oH (200 MHz, CDC1 3) 3.59 (2H, s, CH2CO), 5.05 (2H, s, 0C112 ), 
6.93-7.45 (9H, in, aromatics), 12.5 (111, br., OH); OC (200 MHz, CDC1 3), 40.02 
(CH2CO), 69.90 (CH20), 114.89, 127.34, 127.86, 128.47, 130.33 (aromatic CH), 
125.47 & 136.81 (quat. aromatic, c-CH2), 157.98 (quat. aromatic, C-O) 177.98 
(CO2H); m/z (FAB) 242 (Mt, 100%). 
4-Benzyloxyphenylacetyl chloride (75) 
4-Benzyloxyphenylacetic acid (70) (4.7g, 19.4mmol) was stirred in sodium dried 
benzene (50m1) under an atmosphere of dry nitrogen. Freshly distilled oxalyl chloride 
(2.6g, 20.6mmol) was added followed by DMF (0. lml). The reaction flask was fitted 
with a drying tube and the mixture stirred for 1 hour, until all the gas had evolved. 
The benzene was removed in vacuo to yield the acid chloride as a white solid which 
was not purified further. u (CHIBr3)/cm 1 3056 (ArCH), 1800 (COC1), 1611 & 
1512 (aromatic C=C); OH (60 MHz, CDC1 3) 4.22 (2H, s, CH2COC1), 5.22 (211, s, 
OCH2 ), 7.65-7.20 (911, in, aromatics). 
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Copper[NE4_benzyloxyphenylacetyl Iysine] 2 (77) 
Copper[lysine] 2 (76) (3.4g, 9.6mmol) was dissolved in water (50m1) and the pH 
adjusted to 10.0 using 10% sodium carbonate. 4-Benzyloxyphenylacetyl chloride (75) 
(5.0g, 19mmol) in 1,4-dioxan (lOmi) was added dropwise over 0.5 hour keeping the 
pH constant at 10.0. The product precipitated from solution as the reaction 
progressed, after 1 hour the blue precipitate was removed by filtration, washed 
copiously with water and dried in vacuo to give the title compound as a blue solid 
(5.2g. 67%). 
NL4Benzyloxyphenylacetyl lysine 
Dry, finely powdered, copper[NC4benzy1oxyphenylacetyl lysine] 2 (77) (4.0g, 
5. Ommol) was suspended in a stirred solution of ethylenediaminetetraacetic acid 
disodiuni salt (6.5g, 17.5mmol) in water (lOOm!). The mixture was stirred for 2 days; 
after which time the precipitate was still a blue colour indicating that all the copper 
had not been removed. The mixture was then sonicated for a further 2 days. Then 
the white precipitate of NC4benzyloxyphenylacetyl lysine was filtered from the blue, 
copper containing, solution. The precipitate was washed copiously with water and 
dried in vacuo to give the title compound as a very pale blue solid (3.6g, 97%). 
lysine (71) 
N6 4Benzyloxyphenylacety1 lysine (3.3g, 8.9nimol ) was stirred in water (SOml) and 
triethylamine (0.95g. 9. lmmol) in 1,4-dioxan (50ml) was added. To this suspension 
was added 9-fluorenylmethylsuccinimidyl carbonate (2.8g, 8.4mmol) and the mixture 
stirred overnight. The reaction mixture was filtered and the filtrate diluted with water 
(100m!), then acidified to pH 2.0 using 2M HC1. The resulting precipitate was 
extracted into ethyl acetate, washed with water then brine, dried (MgSO 4) and the 
solvent removed in vacuo to give a pale yellow solid. Recrystaffisation from ethyl 
acetate/diethyl ether gave the title compound as a white powder (3.9g, 74%); nIp. 
152°C;t.1.c. (DCMJMeOH, 80:20) R f 0.38, (DCMfMeOH, 90:10) Rf 0.25; Found: C, 
72.69; H, 6.40; N, 4.77; C 361-136N206 requires C, 72.97; H, 6.12; N, 4.73%; m/z 
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(Found: MIf 593.265 17; C36H37N206 requires 593.265 14); Unm (CHBr3)/cm' 3362, 
3325 (NH), 3020 (ArCH), 1736 (urethane CO), 1669 (CO 2H), 1648 (CO amide I), 
1552 (CO amide H), 1511 (aromatic C=C); X (MeOH)/nm 302 (c/dm 3moF'cm-
1 8876), 290 (7692), 266 (29586); SH (200 MHz, d 6-DMSO) 1.36 (411, m, CI-12 x 2, 
Lys), 1.63-1.69 (2H, in, CICH,  Lys), 3.01-3.03 (211, m, CH2-NH, Lys), 3.30 (21-L s, 
COCH-Ar), 3.89-3.92 (111, m, cxCH, Lys), 4.21-4.30 (3H, in, OCH & Cl-I, 
fluorenyl), 5.05 (211., s, OCH-Ar), 6.90-8.00 (1911, m, aromatics & NH x 2), 12.6 
(111, br., OH); 5C (200 MHz, d6-DMSO ) 23.23, 28.79, 30.53, 30.82 (CH2 x 4, Lys), 
41.66 (cH2CO)  46.77 (cxCH, Lys), 53.88 (CH, fluorenyl), 65.72 (CH, fluorenyl), 
69.22 (CH0), 114.62, 120.24, 125.41, 127.19, 127.71, 127.87, 128.52, 130.03 
(aromatic CH), 128.85 & 137.31 (quat. aromatic, c-CH2), 140.83, 143.92 (quat. 
fluorenyl, C's), 156.30, 157.02 (çO20H & quat. aromatic, C-OCH2), 170.34 (amide 
CO), 174.14 (urethane CO); m/z (FAB) 593 (MH, 100%); [CC]D=+60 , c=0.1 in 
MeOH. 
4-Methoxybenzyl bromide 
A mixture of 4-methoxybenzyl alcohol (10.0g, 72.4mmol) and concentrated 
hydrobromic acid (33.2g, 405mmol) was vigorously stirred for 15 minutes. The 
reaction mixture was then extracted with diethyl ether. The combined etheral extracts 
were washed with saturated sodium hydrogen carbonate then water, dried (CaCl 2) 
and the diethyl ether removed in vacuo. The title compound was obtained as a clear 
liquid which was used for the next reaction without further purification (13g, 89%). 
Methyl 4-(4'-methoxybenzyloxy)phenylacetate 
To a solution of methyl 4-hydroxyphenylacetate (7.2g, 43mmol) and 4-methoxybenzyl 
bromide (13g, 64.7mmol) in DMF (150m1) was added potassium carbonate (11.9g, 
86.2mmol) and the resulting mixture was heated at 60°C for 7 hours and at room 
temperature overnight. The reaction mixture was filtered and diethyl ether (1 OOml) 
added to the filtrate. This organic solution was washed with IM HC1 then brine, dried 
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(MgSO4) and the solvent removed in vacuo. The resulting orange residue was 
recrystallised from n-hexane to yield the title compound as a white solid (10.5g. 
85%); t1c. (DCM) Rf 0.70; u (CHBr3)/cnr' 3040 (ArCH), 1730 (CO 2Me), 1610 
& 1511 (aromatic CC); X. (MeOH)/nm 283 (E/dm 3moF'cm' 1987), 279 (2340); 
6H (200 MHz, CDC13) 3.57 (211, s, CHCO), 3.66 (311., S. CO2CH3), 5.00 (211, s, 
OCH2 ), 6.82-7.42 (811, m, aromatics); 8C (200 MIFIz, CDC1 3) 40.17 (CH2CO), 51.92 
(CO2CH3), 55.10 (Ar-OCH 3), 69.70 (CH20), 113.89, 114.9, 129.09, 130.21 
(aromatic CH), 125.84 & 128.85 (quat. aromatic, c-CH 2), 157.85 & 158.03 (quat. 
aromatic, C-OMe &. C-O), 172.24 (CO2Me). 
4-(4'-Methoxybenzyloxy)phenylacetic acid (82) 
To a suspension of methyl 4-(4'-methoxybenzyloxy)phenylacetate (10.0g, 35mmol) in 
acetone:water (50m1, 4:1) was added lithium hydroxide (2.2g, 52.5mmol) in water 
(30m1) and the mixture stirred for 1 hour. The white precipitate which formed was 
filtered ol1,  washed with ethyl acetate, suspended in water (lOOmI) and slowly 
acidified to pH 3 using 2M HCI. The resulting precipitate was extracted into ethyl 
acetate, washed with water and brine, dried (MgSO 4) and the solvent removed in 
vacuo to give a white solid. The title compound was recrystallised from ethyl acetate 
(6.1g, 64%), nip. 165°C; t.l.c. (DCMIMeOH, 80:20) R f 0.60; Found C, 70.86; H, 
6.15; C 16H1604 requires C, 70.58; H, 5.92%; 	(CHBr3)/cm 1 3600-3300 (br. OH), 
3020 (ArCH), 1710 (CO2H), 1611 & 1512 (aromatic C=C); X (MeOH)/nm 283 
(c/dm3moF1 cm' 1224), 274 (1496); 6H (200 MIHz, CDC13) 3.58 (211, s, CH2CO), 
3.81 (311, s, Ar-CH3), 4.96 (211, s,OCH), 6.89-7.36 (811, m, aromatics), 12.5 (1H, 
br., OH); 6C (200 MHz, CDC1 3) 39.92 (CH2CO), 55.20 (ArOCH3), 69.71 (0H20), 
113.90, 114.90, 129.11, 130.30 (aromatic CH), 125.43 & 128.84 (quat. aromatic, C- 
CH2 ), 158.03 & 159.35(quat. aromatic, C-O & C-OMe) 177.98 (CO 211); ni/z (FAB) 
272 (Mt, 60%). 
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4-(4'-Methoxybenzyloxy)phenylacetyl chloride (84) 
4-(4'-Methoxybenzyloxy)phenylacetic acid (82) (ig, 3.7mmol) was stirred in sodium 
dried benzene (50m1) under an atmosphere of dry nitrogen. Freshly distilled oxalyl 
chloride (0.56g. 4.4mmol) was added followed by DMF (0.lml). The reaction flask 
was fitted with a drying tube and the mixture stirred for 1 hour, until all the gas had 
evolved. The yellow solution was reduced in vacuo to approximately 25m1 and then 
used in the next reaction undiluted. U (C6H6)/cm' 3050 (ArCH), 1799 (COd), 
1612 & 1511 (aromatic C=C). 
Copper[NE4(4'methoxybenzyIoxy)phenylacetyl lysine] 2 (85) 
Copper[lysine]2 (76) (0.67g. 1.9mmol) was dissolved in water (25M1) and the pH 
adjusted to 10.0 using 10% sodium carbonate. 4-(4'-Methoxybenzyloxy)phenylacetyl 
chloride (84) (1. ig, 3.7mmol), in benzene, was added dropwise over 0.5 hour keeping 
the pH constant at 10.0. The product precipitated from solution as the reaction 
progressed, after 1 hour the blue precipitate was removed by filtration, washed 
copiously with water and dried in vacuo to give the title compound as a blue solid 
(0.7g. 47%). 
NC4_(4'Methoxybenzyloxy)pheny1acetyl lysine 
Dry, finely powdered, copper[NC4(4'methoxybenzy1oxy)phenylacetyl lysine] 2 (85) 
(0.5g. 0.6mmol) was suspended in a saturated ethylenediaminetetraacetic acid 
disodium salt (2.2g, 6.Ommol) solution (water 25m1). The reaction mixture was then 
sonicated for 3 days; after which time the white precipitate of NC4(4' 
methoxybenzyloxy)phenylacetyl lysine was filtered from the blue, copper containing, 
solution, washed copiously with water and dried in vacuo to give the title compound 




N-4-(4'-Methoxybenzy1oxy)phenylacety1 lysine (0.3g. 8.9mmol ) was stirred in water 
(20m1) and tnethylamine (0.08g, 0.75mmol) in 1,4-dioxan (20m1) was added. To this 
suspension was added 9-fluorenylmethylsuccinimidyl carbonate (0.24g. 0.71mmol) 
and the mixture stirred overnight. The reaction mixture was filtered and the filtrate 
diluted with water (50m1), then slowly acidified to pH 2.0 using 2M HC1. The 
resulting precipitate was extracted into ethyl acetate, washed with water then brine, 
dried (MgSO4) and the solvent removed in vacuo. The pale yellow oil obtained was 
triturated with diethyl ether to yield an off white solid. The title compound was 
obtained, after recrystallisation from ethyl acetate, as a white solid (0.2g. 46%); nip. 
108-110°C; t.Lc. (DCMIMeOH. 90:10) Rf 0.37; Found C, 72.76; H, 6.39; N, 4.82; 
C37H38N207 requires C, 72.48; H, 5.17; N, 4.51%; m/z (Found: yffl  623.27583; 
C37H39N207 requires 623.27573); u (CHBr3)/cm' 3365, 3320 (NH), 3020 
(ArCH), 1735 (urethane CO), 1668 (CO 2H), 1648 (CO amide I), 1550 (CO amide II), 
1511 (aromatic C=C); X (MeOH)/nm 302 (c/dm 3moi'cm-1 7273), 290 (8485), 266 
(23939); oH (200 MHz, d6-DMSO) 1.34-2.75 (611, m, CH2 x 3, Lys), 3.01 (2H m, 
CH2-NH, Lys), 3.29 (2H, s, COCII2-Ar),  3.74 (3H, s, OCH3), 3.89-3.94 (1H, in, 
ctCH, Lys), 4.22-4.26 (3H, iii, OCH2 & CII,, fluorenyl), 4.96 (2H, s, OCH2-Ar), 6.88-
7.90 (1811, m, aromatics & NH x 2), 12.6 (1H. br ., OH); OC (200 MHz, d 6-DMSO) 
23.02, 28.82, 35.44, 38.59 (CH x 4, Lys), 40.60 (CHCO) 46.79 (ctCH, Lys), 55.01 
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(CH, fluorenyl), 55.17 (OCH3), 65.60 (CH2, fluorenyl), 68.98 (CHO), 113.88, 
114.63, 120.26, 129.49, 129.97 (aromatic CH), 125.27 & 128.69 (quat. aromatic, ç- 
CH2), 140.80, 143.94, 143.99 (quat. fluorenyl, C's & quat. aromatic C-OMe), 157.05, 
159.02 (cO20H & quat. aromatic, C-OCH2), 170.35 (amide CO), 173.90 (urethane 
CO); m/z (FAB) 623 (MH, 30%); [a] D=+1O°, c0.1 in MeOH. 
4-Methylbenzyl bromide 
A mixture of 4-methylbenzyl alcohol (10.0g, 82mmol) and concentrated hydrobromic 
acid (33.2g, 405mmol) was vigorously stirred for 2 hours. The reaction mixture was 
then extracted with diethyl ether. The combined etheral extracts were washed with 
saturated sodium hydrogen carbonate then water, dried (CaCl 2) and the diethyl ether 
removed in vacuo. The title compound was obtained as a clear liquid which was used 
for the next reaction without further purification (12g. 79%). 
Methyl 4-(4'-methylbenzyloxy)phenylacetate 
To a solution of methyl 4-hydroxyphenylacetate (7.2g. 43mmól) and 4-methylbenzyl 
bromide (12g, 65mmol) in DMF (lSOnil) was added potassium carbonate (11.8g, 
86. lmmol) and the resulting mixture was heated at 60°C overnight. The reaction 
mixture was then filtered and diethyl ether (1 OOml) added to the filtrate. This organic 
solution was washed with 1M HC1 then brine, dried (MgSO4) and the solvent 
removed in vacuo. The resulting orange residue was recrystallised from n-hexane to 
yield the title compound as a white solid (9.3g, 80%); t.1.c. (DCMIMeOH, 80:20) R.f 
0.80; u < (CHBr3)1cm 1 3019 (ArCH), 1730 (CO 2Me), 1612 & 1510 (aromatic 
C=C); 6H (200 MHz, CDC1 3) 2.36 (3H, s, ArCH3), 3.56 (2H, s, CH2 CO), 3.68 (31-1, 
S, CO2CH3), 5.00 (2H, s, OCH2 ), 6.91-7.30 (8H, in, aromatics); öC (200 MIHz, 
CDC13 ) 21.07 (ArCH3), 40.17 (cH2CO), 51.88 (CO2CH3), 69.79 (CH2 0), 114.80, 
127.46, 129.13, 130.14 (aromatic CH), 126.06, 137.60 (quat. aromatic, C-Cl 2 ), 
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133.78 (quat. aromatic, C-CI 3), 157.85 (quat. aromatic, C-O), 172.24 (CO 2Me); m/z 
(FAB) 271 (l4fl 70%). 
4-(4'-Methylbenzyloxy)phenylacetic acid (83) 
To a suspension of methyl 4-(4'-methylbenzyloxy)phenylacetate (8.8g, 33mmol) in 
acetone:water (40m1, 4:1) was added lithium hydroxide (2.0g. 49mmol) in water 
(24m1) and the mixture stirred for 1 hour. The white precipitate which formed was 
filtered off washed with ethyl acetate, suspended in water (lOOmi) and slowly 
acidified to pH 3 using 2M HC1. The acidic mixture was extracted into ethyl acetate, 
washed with water and brine, dried (MgSO4) and the solvent removed in vacuo to 
give a white solid. The title compound was recrystallised from ethyl acetate (6.0g, 
71%), nip. 155°C; t.l.c. (DCMIMeOH,80:20) Rf 0.60; Found C, 75.21; H, 6.13; 
C 16H1603 requires C, 74.98; H, 6.29%; u (CHBr3)/cm' 3600-3300 (br. OH), 3020 
(ArCH), 1702 (CO2H), 1600 & 1512 (aromatic C=C); X. (MeOH)/nm 283 
(e/dm3mol'cm' 1446), 274 (1486); 5H (200 MHz, CDC13) 2.48 (31, s, CH3), 3.68 
(2H, s, C112CO), 5.22 (214, s, OCH), 7.04-7.61 (8H, m, aromatics), 12.5 (1H, br., 
OH); 6C (200 MHz, CDC13) 20.93 (Ar-CH3), 40.09 (CH2CO), 69.71 (0120), 
114.94, 127.56, 129.23, 130.24 (aromatic CH), 126.26, 137.80 (quat. aromatics), 
133.88 (quat. aromatic c-CH3), 158.03, (quat. aromatic, C-O), 177.96 (CO 2H); m/z 
(FAB) 257 (MIH, 100%). 
4-(4'-Methylbenzyloxy)phenylacetyl chloride (87) 
4-(4'-Methylbenzyloxy)phenylacetic acid (83) (6.0g, 23mmol) was stirred in sodium 
dried benzene (50m1) under an atmosphere of dry nitrogen. Freshly distilled oxalyl 
chloride (2.9g, 23mmol) was added followed by DMIF (0. imi). The reaction flask 
was fitted with a drying tube and the mixture stirred for 1 hour, until all the gas had 
evolved. The benzene was removed in vacuo to yield the acid chloride as a white 
solid which was not isolated (5.5g, 87%); U. (CHBr 3 )/cm 1 3042 (ArCH), 1798 
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(COd), 1611 & 1510 (aromatic C=C); 5H (200 MiHz, CDC1 3) 2.34 (3H, s, C143), 
4.34 (2H., s, CH2 COC1), 4.98 (2H, s, OCH 2 ), 6.88-7.27 (9H, in, aromatics). 
Copper [NE4_(4'Methy1benzyloxy)pheny1acety1 lysine]2 
Copper[lysine] 2  (76) (4.2g, 12mmol) was dissolved in water (75m1) and the pH 
adjusted to 10.0 using 10% sodium carbonate. 4-(4'-Methylbenzyloxy)phenylacetyl 
chloride (87) (5.5g, 20mmol) in 1,4-dioxan (20m1) was added dropwise over 0.5 hour 
keeping the pH constant at 10.0. The product precipitated from solution as the 
reaction progressed, after 1 hour the blue precipitate was removed by filtration, 
washed copiously with water and dried in vacuo to give the title compound as a blue 
solid (6. ig, 76%). 
(4'-Methylbenzyloxy)phenylacetyl lysine 
Dry, finely powdered, copper[NE4(4'methylbenzy1oxy)pheny1acetyl lysine1 2 (5.5g, 
6.8mmol) was added to a saturated ethylenediaminetetraacetic acid disodiuin salt 
(12.5g, 34mmol) solution (water lOOmi). The reaction mixture was then sonicated 
for 7 days; after which time the white precipitate of N 6-4-(4'-
methylbenzyloxy)phenylacetyl lysine was filtered from the blue, copper containing, 
solution, washed copiously with water and dried in vacuo to give the title compound 
as a white solid (4.5g, 87%); [CC]D=+9 0, c=0. 1 in MeOH. 
lysine 
(88) 
NF4-(4'-Methylbenzyloxy)phenylacetyllysine (4.2g, 10.9mmol ) was stirred in water 
(75m1) and triethylamine (l.lg, 10.9mmol) in 1,4-dioxan (75ml) was added. To this 
suspension was added 9-fluorenylmethylsuccmimidyl carbonate (3.5g, 10.4mmol) and 
the mixture stirred overnight. The reaction mixture was filtered and the filtrate 
diluted with water (lOOml), then slowly acidified to pH 2.0 using 2M HC1. The 
resulting precipitate was extracted into ethyl acetate, washed with water then brine, 
dried (MgSO4) and the solvent removed in vacuo to give a pale yellow oil which was 
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triturated with diethyl ether to yield an off white solid. Recrystallisation from ethyl 
acetate gave the title compound as a white solid (3.2g, 49%); m.p. 125°C; t.1.c. 
(DCMIMeOH, 80:20) R 0.50; Found: C, 73.04; H, 6.45; N, 4.72; C 37H38N206 
requires C, 73.25; H, 6.31; N, 4.62%; mlz (Found 607.28356; C 371138N206 requires 
60728281; u1 (CHBr3 )Icn7l 3412, 3309 (NH), 3018 (ArCH), 1720 (urethane CO), 
1695 (CO214), 1645 (CO amide I), 1544 (CO amide H), 1510 (aromatic C=C); X. 
(MeOH)/nm 302 (/dm 3moF 1 cm 1 7273), 290 (8485), 266 (23939); 6H (200 MHz, d 6-
DMSO) 1.38 (4H, m, CH x 2, Lys), 1.63-1.69 (2H, m, CH2CH, Lys), 2.28 (3H, s, 
ArCH3), 3.03-3.05 (2H, in, C112-NH, Lys), 3.31 (2H, s, COCH2-Ar), 3.91-3.98 (1H, 
m, aCH, Lys), 4.23-4.31 (3H, m, OCH & CH, fluorenyl), 5.00 (21L s, OCH 2-Ar), 
6.89-8.01 (181L in, aromatics & NH x 2), 12.6 (1H, br., OH); 6C (200 MHz, d 6-
DMSO ) 20.90 (ArCH3), 23.27, 28.82, 30.59, 38.59 (CH2 x 4, Lys), 41.72 (çH2CO), 
46.82 (aCH, Lys), 53.95 (CH, fluorenyl), 65.78 (CH, fluorenyl), 69.16 (CH2O), 
114.69, 120.26, 125.45, 127.23, 127.83, 129.09, 130.05 (aromatic CH), 128.80, 
134.28, 137.12 (quat. aromatic), 140.87 & 143.95 (quat. fluorenyl, C's), 156.36 & 
157.09 (cO20H & quat. aromatic, C-OCH2), 170.45 (amide CO), 174.19 (urethane 
CO); m/z (FAB) 607 (MH, 100%); [a]D=+12 0, c=0. 1 in MeOH. 
4.3.2: Synthesis of peptides incorporating enzyme cleavable lysine protecting 
groups 
B-Phe-Gly-Lys(Mepa)-Ala-Gly-OH (69) 
The initial resin was Fmoc-Gly-Wang resin (0.46g, 0.55mmoIIg, 0.25mmol). The 
amino acids were coupled using the HOBt method and lysine was incorporated as the 
4-methoxyphenylacetyl (Mepa) derivative. The peptide-resin was cleaved using a 
solution of TFA (9.5m1), water (0.5m1) for 1 hour and the resin was removed by 
filtration. The resin was washed with TFA (2m1), DCM (5m1) and the filtrate 
concentrated in vacuo to an oil. The peptide was precipitated from diethyl ether, 
filtered, dissolved in 20% aqueous acetic acid and lyophilised to yield the title 
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compound as a white fluffy solid (135mg, 86%); HPLC (vydac C 18, 250x4.6mni,, 
5.tm, A=H20, B=CH3CN, 0.1% TFA; mu/mm., 10-90% over 30 minutes, X=214nm) 
Rt 17 mins., %B 49; m/z (FAB) 627 (MI-I+); AAA (12 hours) G1y2 2. 1, Ala, 1.0, Phe 1 
1.1,Lysj 1.2. 
H-Phe-Gly-Lys(Phenac)-Ala-Gly-OH (68) 
The initial resin was Fmoc-Gly-Wang resin (0.46g. 0.55mmolJg, 0.25mmol). The 
amino acids were coupled using the HOBt method and lysine was incorporated as the 
phenylacetyl (Phenac) derivative. The peptide-resin was cleaved using a solution of 
TFA (9.5m1), water (0.5m1) for 1 hour and the resin was removed by filtration. The 
resin was washed with TFA (2m1), DCM (5m1) and the filtrate concentrated in vacuo 
to an oil. The peptide was precipitated from diethyl ether, filtered, dissolved in 20% 
aqueous acetic acid and lyophilised to yield the title compound as a white fluffy solid 
(130mg, 87%); HPLC (vydac C 18, 250x4.6mm, 5gm, A=H20, B=CH3CN, 0.1% TFA; 
imI/min., 10-90% over 30 minutes, X=214mn) Rt  17 mins., %B 49; m/z (FAB) 597 
(MIH); AAA (12 hours) Gly2 2.2,A1a 1 1.0,Phe 1 1.1,Lys, 1.1., 
H-Phe-GIy-Lys(flopa)-Ala-Gly-OH (64) 
Route A: from H-Phe-Gly-Lys(Bepa)-Ala-Gly-OH (72) 
Route B: from H-Phe-Gly-Lys(MeBepa)-Ala-Gly-OH (89) 
Route A 
The initial resin was Fmoc-Gly-Wang resin (0.42g. 0.59mmoI/g, 0.25mmol). The 
amino acids were coupled using the HOBt method and lysine was incorporated as the 
4-benzyloxyphenylacetyl (Bepa) derivative. The peptide-resin was cleaved using the 
following cleavage mixture for 3 hours: crystalline phenol (0.75g); 1, 2-ethanedithiol 
(EDT) (0.5m1), thioamsole (0.5mi); water (0.5ml) and TFA (lOmi). The resin was 
washed with TFA (2mi), DCM (5mi) and the filtrate concentrated in vacuo to an oil. 
The peptide was precipitated from diethyl ether, filtered, dissolved in 20% aqueous 
acetic acid and lyophilised. HPLC (vydac C 18, 250x4.6mm, 5pm, A=1120, BCH3CN, 
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0.1% TFA; imI/min., 10-90% over 30 minutes, A=214nm) 3 peaks (a, b & c 
(25:1:5)): (a) R 12 mins., %B 38; mlz (LDTOF) 611.7 (Mt, Phe-Gly-Lys(Hopa)- 
Ala-Gly-OH, requires 611.4); (b) R 18 mins., %B 52, m/z (LDTOF) 703 (M t, Phe- 
Gly-Lys(Bepa)-Ala-Gly-OH, requires 702.5); (c) R 20 mins., %B 56, mlz (LDTOF) 
700 (Mt, Phe-Gly-Lys(Bepa)-Ala-Gly-OH, requires 702.5). The peptides 
corresponding to peaks (b) & (c) must be isomers. 
Route B 
The initial resin was Fmoc-Gly-Wang resin (0.30g, 0.83mmoIIg, 0.25mmol). The 
amino acids were coupled using the HOBt method and lysine was incorporated as the 
4-(4'-methylbenzyloxy)phenylacetyl (MeBepa) derivative. The peptide-resin was 
cleaved using the following cleavage mixture for 3 hours: crystalline phenol (0.75g); 
EDT (0.5m1), thioanisole (0.5m1); water (0.5m1) and TFA (lOml). The resin was 
washed with TFA (2m1), DCM (5m1) and the filtrate concentrated in vacuo to an oil. 
The peptide was precipitated from diethyl ether, filtered, dissolved in 20% aqueous 
acetic acid and lyophilised. HPLC (vydac C 18, 250x4.6mm, 5.tm, A=H20, B=CH3CN, 
0.1% TFA; lml/min., 10-90% over 30 minutes, ?214mñ) 3 peaks (a, d & e 
(25:1:5)): (a) K 12 mins., %B 38, m/z (LDTOF) 612.3 (MI-I+, Phe-Gly-Lys(Hopa)- 
Ala-Gly-OH, requires 612.4); (d) K 17 mins., %B 52, m/z (LDTOF) 717.9 (Ma-l+, H- 
Phe-Gly-Lys(MeBepa)-Ala-Gly-OH, requires 717.6); (e) K 19 mins., %B 55, m/z 
(LDTOF) 718.9 (M}P, H-Phe-Gly-Lys(MeBepa)-Ala-Gly-OH, requires 717.6). The 
peptides corresponding to peaks (d) and (e) must be isomers. Phe-Gly-Lys(Hopa)- 
Ala-Gly-OH: m/z (Found 613.29859; C 30H41N608 requires 613.29856); AAA (12 
hours) G1y2 2.0, Ala 1 1.2, Phe 1 1.0, Lys 1 1.0. 
H-Phe-Gly-Lys-Ala-Gly-OH 
Route A: from H-Phe-Gly-Lys(Mepa)-Ala-Gly-OH (69) 
Route B: from H-Phe-Gly-Lys(Phenac)-Ala-Gly-OH (68) 
Route C: from H-Phe-Gly-Lys(Hopa)-Ala-Gly-OH (64) 
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As a general method, a 13mg (0.2mmol) portion of each peptide was added to 
Tris.HC1 buffer (50mM, 6m1, pH 8.1). Resin bound penicillin acylase (60mg, 
E.C.3.5. 1.11, 1325M.units/Kg, supplied by SmithKline Beecham Pharmaceuticals 
Ltd.) was added and the mixture was allowed to mix gently whilst incubating at 37 
°C. The progress of each reaction was monitored by HPLC (vydac C 18, 250x4.6mm, 
5j.tm, A=H20, B=CH3CN, 0.1% TFA; imI/min., 10-50% over 30 minutes, ?.=214nm). 
The half lives for each deprotection reaction were estimated as follows: Route A: 
Mepa, 22 hours; Route B: Phenac, 6.5 hours and Route C: Hopa, 4 hours. On 
completion of the reactions the resin bound enzyme was removed by filtration and the 
peptides purified by semi-preparative HPLC (ABI C 18 Aquapore, 250x25mm, 20tm, 
A=H20, B=CH3CN, 0.1% TFA; 5m1/min., 10-50% over 30 minutes, A.=214nm) 
lyophilised to yield the title compound as a white fluffy solid (5mg, 52%); HPLC 
(vydac C 18, 250x4.6mm, 5pM, A=H20, B=CH3CN, 0.1% TFA; lmllmin., 10-40% 
over 30 minutes, ?214nm) Rt  8 mins., %B 10; m/z (FAB) 479 (M1H); mlz (Found: 
479.26184; C22H35N606 requires 479.26179); AAA (12 hours) G1y2 2.1, Ala 1 
1.1,Phe 1 1.0,Lysi 1.2. 
4.3.3: Synthesis of ubiquitin incorporating Lys(Bepa) 
Chemical synthesis of 16,11,27,29,33&63-Lys(Bepa)1 ubiquitin (95) 
The synthesis was performed on a 0.2mmol scale using the Fmoc-Gly functionalised 
Wang resin (0.49g, 0.41mmoIIg). The side chain protecting groups used were as 
follows: tert-butyl (But)  ethers for serine, threonine and tyrosine; But  esters for 
aspartic and glutamic acid; t-triphenylmethyl (Trt) for histidine; 2,2,5,7,8-
pentamethylchroman-6-sulphonyl (Pmc) for arginine. The carboxamide side chains of 
asparagine and glutamine were incorporated as the 4,4'-dimethoxybenzhydryl (MBH) 
derivative. Lysine(48) was incorporated as the tert-butyloxycarbonyl (Boc) derivative 
and the other six lysine residues were protected as the 4-benzyloxyphenylacetyl 
(Bepa) (70) derivative. All amino acids were double coupled using the HOBt method 
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(0.5mmol DIC/immol HOBt) with the exception of glycine which was single coupled 
and asparagine, glutamine and lysine which were double coupled as the HOBt ester 
(0.5mmol HOBt/lmmol HOBt). Following completion of the synthesis the N-
terminal Fmoc was left on and the resin bound product was capped by sonication for 
30 minutes in acetic anhydride (0.5M), DLEA (0.125M) and HOBt (0.2% w/v) in 
DCM (20m1). The Fmoc-[6,11,27,29,33&63-Lys(Bepa)] ubiquitin-resin (95) was 
separated by filtration, washed with DMF and 1,4-dioxan and divided into four equal 
portions which were stored in 1,4-dioxan at 4 °C until required. 
Tbfmoc loading 
A 240mg portion of the Fmoc-[6, 1 l,27,29,33&63-Lys(Bepa)] ubiquitin-resin (95) 
was sonicated in 20% v/v piperidinefDMF for 20 minutes to remove the Fmoc group 
and subsequently washed with DMF, DCM and diethyl ether and dried in vacuo for 
30 minutes. Thfmoc chloroformate (38) (12.4mg, 0.027mmol) was dissolved in DCM 
(lOmI) and the solution added to the dry resin (240mg, 0.009mmol) followed by 
DIEA (4.7j.iJ, 0.027mmol). The mixture was sealed and sonicated in the dark for 3 
hours with occasional mixing. The Thfmoc-[6, 1 l,27,29,33&63-Lys(Bepa)] ubiquitin-
resin (96) was filtered, washed copiously with DCM then diethyl ether and dried in 
vacuo. AAA (40hours) Asx7 7.74, Thr7 6.13, Ser3 2.39, G1x 12 13.12, Pr03 3.02, G1y6 
5.77, Ala2 2.23, VaL 3.54, Met 1 0.57, 11e7 6.84, Leu9 8.20, Tyr i 0.71, Phe2 2.0, His, 
0.86, Lys7 6.23, Arg4 3.17. 
Cleavage of Tbfmoc- 16,11 ,27,29,33&63-Lys(Bepa)] ubiquitin-resin (96) 
The next step was cleavage of the peptide from the resin and the simultaneous 
deprotection of all side chain protecting groups, with the exception of the six 
Lys(Bepa) residues which were only partially cleaved to give 4-hydroxyphenylacetyl 
lysine, Lys(Hopa). This was accomplished by firstly swelling the Thfmoc-peptide-
resin (96) in phenol (0.85g), EDT (0.5m1) and thioanisole (0.5m1) for 30 minutes 
under an atmosphere of thy nitrogen whilst protected from the light. Then water 
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(0.5ml) and TFA (lOmi) were added and the cleavage mixture stirred for a further 4.5 
hours. The resin was separated by filtration, washed with TFA (2ml) and DCM (5m1) 
and the filtrate concentrated in vacuo to a yellow oil. The crude Thfmoc-peptide was 
precipitated from the oil by the addition of 2% v/v -mercaptoethanol in diethyl ether 
(lOOmI) at 0°C. The solid Thflnoc-peptide was filtered, washed with diethyl ether, 
dissolved in 20% aqueous acetic acid and lyophilised to yield a white fluffy solid of 
Thfmoc- [6,11,27,29,33 &63-Lys(Hopa)] ubiquitin (Thfmoc-Ub(Hopa) 6) (97) 
(125mg). AAA (40hours) Asx7 7.64, Thr7 6.34, Ser3 2.22, G1x 12 13.3 6, Pr03 2.78, 
G1y6 5.69, Ala2 2.23, VaL1 3.68, Met 1 0.55, 11e7 6.83, Leu9 8.48, Tyr 1 0.72, Phe2 2.24, 
His, 0.75, Lys7 6.36, Arg4 3.47. 
TbfmocIPGC and gel filtration of Tbfmoc -16,1 1 ,27,29,33&63-Lys(Hopa)] 
ubiquitin (97) 
The crude Thfinoc-[6,1 l,27,29,33&63-Lys(Hopa)] ubiquitin (97) (120mg) was 
solubilised in 6M GdniCl (lOmi) and diluted with isopropanol (lOmi) and centrifuged 
to remove a small amount of insoluble material PGC (HPLC grade, 7.tm, 600mg) 
was added and mixture vortexed for 10 minutes and centrifuged (15 minutes, 
4000rpm) to a pellet. The supernatant was decanted and the adsorption of the 
Thfmoc-Ub(Hopa)6 (97) monitored by analytical }IPLC (vydac C 8, 250x4.6mm, 54m, 
A=H20, B=CH3CN, 0.1% TFA; mu/mm., 10-90% over 30 minutes, X 1 =214um, 
A2=364nm). No absorbance was visible at 364mn; thus it was assumed that all the 
Thfinoc material had been adsorbed onto the PGC. The PGC was then washed to 
remove truncated peptides by vortexing with 6M GdmCl/isopropanol (1:1, 20m1) 
followed by centrifuging the PGC to a pellet. The wash protocol was repeated until 
no absorbance at 214nm was visible by HPLC. The protein was cleaved from the 
Thfmoc by vortexing the PGC with 10% piperidine in 6M GdmCllisopropanol (1:1, 
20m1 x 2) for 10 minutes after which the mixture was centrifuged to a pellet. The 
combined deprotection supernatants were neutralised to pH 4.5 with acetic acid and 
the isopropanol removed in vacuo prior to being loaded onto a Sephadex G50 (fine) 
column (660x30mm) which had been equilibrated with 30% aqueous acetic acid. The 
column was eluted at 30mJIh with monitoring at 226 and 277uim and collecting 20 
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minute fractions. The protein containing fractions were pooled and lyophilised. Pure 
4-hydroxyphenylacetyl lysine protected ubiquitin Ub(Hopa) 6 (98) was obtained by 
semi-preparative HPLC (ABI aquapore RP300 C 8, 250x9.2mm, 7pni, A=H20, 
B=CH3CN, 0.1% TFA; 5m1/min., 10-60% over 30 minutes, X=214nm) and lyophilised 
to yield a white fluffy solid of Ub(Hopa) (40mg); IIPLC (ABI aquapore RP300 C 8 , 
220x4.6mni, 7pm, A=H20, B=:CH3CN, 0.1% TFA; lmllmin., 10-90% over 30 
minutes, ?214nm) Rt  16.4mins., 49%B; m/z (LDTOF) 9393.7 (Na adduct), 
C426H 66N 10501 32S1 requires 9370.7; AAA (40hours) Asx 7 7.54, Thr7 6.55, Ser3 2.60, 
G1x 12 12.87, Pr03 2.5 6, G1y6 5.77, Ala2 219, VaL 3.65, Met, 0.68, 11e7 6.5 9, Leu9 
8.36, Tyr 1 0.64, Phe2 2.25, His, 0.77, Lysi 6.44, Arg4 3.83. Sequencing analysis from 
N-terminus repetitive yield = 93% (Table 5). 
Residue No. 1 2 3 4 5 6 7 8 9 10 11 12 13 
Amino acid Met Gin lie Phe Val Lys Thr Leu Thr Gly Lys Thr lie 
Pmol 147 118 143 133 133 151 61 114 50 67 74 47 65 
Table S N-Terminal sequencing results for Ub(Hopa) 6 (98) 
Chemical synthesis of 163-Lys(Bopa)Jubiquitin-(36-76) (100) 
The [63-Lys(Hopa)]ubiquitin-(36-76) peptide was obtained by the removal of 
approximately one third of the resin after the coupling of Ile 36 from the synthesis of 
[6,11,27,29,3 3&63-Lys(Bepa)] ubiquitin. The [63-Lys(Hopa)]ubiquitin-(36-76) 
(100) was purified by the same procedure as for [6,11,27,29,33&63-Lys(Hopa)] 
ubiquitin. HPLC (vydac C 18, 250x4.6mm., 5pm, A=H20, B=CH3CN, 0.1% TFA; 
imI/min., 10-90% over 30 minutes, X=214nm) Rt  20.8mins., 62%B; mlz (LDTOF) 
4812.0, C42 H666N 1050132 S 1 requires 4812.4; AAA (40hours) Asp 4 3.83, Thr2 1.78, 
Ser2 1.83, G1u6 5.89, Pr02 2.34, G1y4 4.12, Ala, 0.95, Va! 1 0.89, 11e3 2.37, Leu7 7.32, 
Tyr 1 0.60, Phe 1 0.86, His, 0.88, Lys2 2. 11, Arg4 3.66. 
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Enzyme deprotection studies on 4-hydroxyphenylacetyl (Hopa) protected lysine 
peptides 
Three Hopa protected lysine peptides: [6,1 l,27,29,33&63-Lys(Hopa)] ubiquitin (98), 
[63-Lys(Hopa)]ubiquitin-(3 6-76) (100) and H-Phe-Gly-Lys(Hopa)-Ala-Gly-OH (64) 
were individually incubated with penicillin acylase under the different conditions 
stated in table 4 and the reactions monitored by analytical HPLC. Three types of 
enzyme were employed in the deprotection experiments: (A) resin bound penicillin 
acylase (supplied by SmithKline Beecham Pharmaceuticals Ltd.), (B) resin bound 
penicillin acylase (supplied by Sigma) and (C) soluble penicillin acylase (supplied by 
Sigma). As a general method, 1mg portions of each peptide (64), (98) & (100) were 
dissolved in either 2m1 of Tris.HC1 buffer (50mM, pH 8.1) or ammonium acetate 
buffer (0. 1M, pH 8.5). Penicillin acylase was added along with various reagents and 
the mixtures incubated at 37 °C. The progress of each reaction was monitored by 
HPLC (ABI aquapore RP300 C 8, 220x4.6mm, 7pm, A=H20, B=CH3CN, 0.1% TFA; 
lml/min., 10-90% over 30 minutes, X=214nm) for [6,11,27,29,33&63-Lys(Hopa)] 
ubiquitin (98) or (vydac C 18, 250x4.6mm, 5pm, A=H20, B=CH3CN, 0.1% TFA; 
imI/min., 10-30% over 30 minutes, X214nm) for [63-Lys(Hopa)]ubiquitin-(36-76) 
(100) and the pentapeptide (64). Table 6 shows the enzyme deprotection experiments 
carried out on H-Phe-Gly-Lys(Hopa)-Ala-Gly-OH (64). Experiments 1-11 (Table 6) 
were repeated for [6,1 l,27,29,33&63-Lys(Hopa)] ubiquitin (98) and [63-
Lys(Hopa)]ubiquitin-(36-76) (100) however no deprotection was observed for either 
protein in any of the reaction conditions listed. 
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substrate/ penicillin acylase buffer temp variables deprotection 
expt. no. after 24hrs * 
(64) A, B, C Tris.HC1 37°C 7 
expt. 1  
(64) A, B, C Tris.HCJ 37°C 50mM Lys.HC1 i * 
expt. 2 
(64) A Tris.HC1 37°C 4M GdniHCl no 
expt. 3  deprotection 
(64) A Iris. HC1 37°C 4M urea no 
expt. 4  deprotection 
(64) A, B, C Iris.HC1 37°C 10%MeOH 6 
expt. 5  
(64) A, B, C NH4OAc 370C 50mM Lys.HC1 2 
expt. 6  
(64) A, B, C Tris.HC1 500C 50mM Lys.HC1 3 
expt. 7  
(64) A, B, C Tris.HCI 37°C 50mM Lys.HC1 5 
expt. 8  0. 1M LiC1  
(64) A, B, C Ins.HC1 37°C 50mM Lys.HC1 4 
expt. 9 0. 1M NaC1 
(64) A Tris.HC1 37°C 50mM Lys.HCI no 
expt. 10  50-80% DMSO deprotection 
(64) A, B, C Tris.HCI 37°C 50mM Lys.HC1 8 
expt. 11  50% glycerol  
* (64) in expt. 2 was deprotected fastest and was given a relative deprotection rate of 
1 the other experiments were given rates with respect to expt. 1. (64) in expt. 11 was 
deprotected slowest. 
Table 6 Summary of enzyme deprotection experiments on H-Ph e-Gly-Lys(Hopa)-
Ala-Gly-OH (64) 
4.3.4: Synthesis of chemically cleaved lysine protecting group 
3-Hydroxymethyl-3-nitro-1 ,5-dioxaspiro-5: 5-undecane' 36 (107) 
Cyclohexanone (40m1, 0.3 9mol) and tris(hydroxymethyl)nitromethane (58.9g, 
0.39mo1), plus a catalytic amount of toluene-4-sulphonic acid were refluxed in sodium 
dried toluene using a Dean Stark apparatus. After 24 hours, the solution was cooled 
to room temperature, washed with water (2xlOOml), and the organic layer dried over 
MgSO4. Concentration in vacuo gave a cream coloured solid which after 
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recrystallisation from hexane/ether gave the title compound as a white solid (37g, 
41 %);  m.p. 99°C (lit., 136 97-98); t.l.c. (ethyl acetate/hexane, 30:70) R f 0.57; Found: C, 
52.19; H, 7.54; N, 5.65; calculated for C 10H 17N05 C, 51.96; H, 7.36; N, 6.06%; umax  
(nujol)/cm- ' 3415 (OH), 1545 (NO2); 8H (200 MHz, CDC1 3) 1.40-1.79 (10H, m, 
aliphatic ring CH2), 2.09 (1H, t, J 6.3 8Hz, OH), 4.07 (2H, d, J 12.57Hz, axial dioxan 
ring CH2) 4.09 (2H, d, J 6.33Hz, CH 20H) 4.36 (2H, d, J 12.56Hz, equatorial dioxan 
ring CH2), 8C  (200 MHz, CDC13) 21.93-32.44 (CH 2 x 5, aliphatic ring), 60.19 
(2xdioxan ring CH2), 63.10 (CH20H), 86.28 (quat. C), 99.19 (ring junction quat. C); 
mlz (FAB) 232 (MH). 
The pentafluorophenyl carbonate of 3-hydroxymethyl-3-nitro-1,5-dioxaspiro-
5:5-undecane (108) 
3-Hydroxymethyl-3 -nitro- 1 ,5-dioxaspiro-5 : 5-undecane 	(107) 	(1 g, 	Smmol), 
triphosgene (0.5g, 1 .66mmol) and N-N'-diisopropylethylamine (DIEA) (0.9ml, 
5mmol) were stirred in sodium dried toluene under an inert atmosphere of dry 
nitrogen. After 15 minutes a white precipitate had formed (DIEA.HC1), the first step 
of the reaction, formation of the chloroformate, was judged to have been completed 
(confirmed by IR: COC1 1 779cm' in toluene). The chloroformate was reacted 
immediately in situ by the addition of a mixture of pentafluorophenol (1.01g, 
5.5mmol) and DIEA (0.9m1, 5mmol), dissolved in the minimum amount of toluene. 
The reaction was then stirred for a further 15 minutes, (comparative IR indicated 
peak at 1779cm' replaced by COPFP 1787cm'). The reaction mixture was then 
rapidly washed twice with iced water, followed by brine solution, dried (MgSO 4), 
filtered and the solvent removed in vacuo. The title compound was obtained, after 
recrystallisation from hexane/ethyl acetate as a white solid (2.04g, 93%); m.p. 121-
123°C; t.l.c. (ethyl acetate/hexane, 30:70) R f 0.65; Found: C, 46.26; H, 3.62; N, 3.17; 
C 17H 16N07 requires C, 46.56; H, 3.72; N, 3.33%; mlz (Found: MH 442.09070; 
C 17H 16N07 requires 442.09252); Umax  (nujol)/cm - ' 1787 (CO), 1529 (NO2); 8H (250 
MHz, CDC13) 1.42-1.85 (10H, m, aliphatic ring CH 2), 4.12 (2H, d, J 12.66Hz, axial 
ring pair 2xCH), 4.45 (2H, d, J 12.63Hz, equatorial ring pair 2xCH), 4.85 (2H, s, 
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CH20-); 6C (50 M}Iz, CDC13) 22.24-33.96 (CH2x5, aliphatic ring), 60.42 (2xCH 2, 
dioxan ring), 68.24 (CH20-), 83.15 (quat. aliphatic C), 100.01 (ring junction quat. C), 
150.45 (CO); m/z (FAB) 442 (MH). 
,5-dioxaspiro-5:5-undecane-3-nitro-3- 
methoxycarbonyl-lysine (104) 
Fmoc-lysine (1.4g, 3.8mmol) was suspended in 1,4 dioxanlwater (2:1, 60m1) and 
triethylamine (1. imi, 7.6mmol) added. The solution was then cooled to 0°C and the 
pentafluorophenyl carbonate of 3 -hydroxymethyl- 3 -nitro- 1 ,5-dioxaspiro- 5: 5-undecane 
(108) (1.7g, 3.85mmol) added. The reaction mixture was allowed to warm to room 
temperature and stirred overnight. The reaction mixture was then concentrated in 
vacuo and the resulting residue was dissolved in ethyl acetate, washed with brine 
solution, water, dried (MgSO 4) and evaporated in vacuo to yield a white foam- This 
foam was redissolved in the minimum amount of DCM and purified by wet flash 
chromatography using DCMIMeOH as eluent. Fractions of R f 0.3 (DCMIMeOH, 
90:10) were combined and evaporated in vacuo to yield the title compound as a 
white solid (1.9g. 80%); nip. 172°C; t.Lc. (DCMIMeOH, 90:10) R f 0.30; Found: C, 
61.10; H, 6.63; N, 6.41; C 32H39N3010 requires C, 61.40; H, 3.726.30; N, 6.71%; m/z 
(Found: MH 626.27105; C32H39N3010 requires 626.27137); u,M (KBr)/cm' 3408 
(NH), 2937 (CH), 1708 (CO), 1552 (NO2); Amax (MeOH)/nm 265 (s/dm3mor 1 cm' 
19000), 290 (4800), 300(5700); 6H (250MIHz, d6-DMSO) 1.23-1.84 (161, in, CH2), 
2.91 (211, s, NHCII2) 4.12- 4.23 (4H, in, axial ring pair 2xCH., aCH, Fmoc CH), 
4.39-4.33 (611, in, equatorial ring pair 2xCH, carbamate CH 2, Fmoc CH2) 7.30-7.90 
(811, in, aromatic CH); (50 MHz, d6-DMSO) 22.20, 25.03, 28.23, 38.60 (J3CH2 & 
ringCH2), 30.82(aCH), 46.89(Fmoc CH), 60.50 (dioxan ring CH2), 63.24 (ester 
CH2), 65.45 (FmocCH) (8H, m, aromatic CH); 68.24 (CH20-), 83.15 (quat. aliphatic 
C), 100.01 (ring junction quat. C), 150.45 (CO); m/z (FAB) 626 (MH); [a]D=+4 0 , 
c=0. 1 in MeOH. 
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4.3.5: Synthesis of ubiquitin incorporating Lys(Tnm) 
Chemical synthesis of 16,11 ,27,29,33&63-Lys(Tnm)J ubiquitin 
The synthesis was performed on a 0. 13mmol scale using the Fmoc-Gly fünctionalised 
Wang resin (0.49g, 0.264mmoIIg). The side chain protecting groups used were as 
follows: tert-butyl (But)  ethers for serine, threonine and tyrosine; But  esters for 
aspartic and glutamic acid; t-triphenylmethyl (Trt) for histidine; 2,2,5,7,8-
pentamethylchroman-6-sulphonyl (Pmc) for arginine. The carboxamide side chains of 
asparagine and glutamine were incorporated as the 'r-triphenylmethyl (Trt) derivative. 
Lysine(48) was incorporated as the tert-butyloxycarbonyl (Boc) derivative and the 
other six lysine residues were protected as the NE_1,5dioxaspiro_5:5_undecane3 
nitro-3-methoxycarbonyl (Turn) derivative (104). The amino acids were single 
coupled using the HOCt method (immol) with the exception of histidine which was 
double coupled as the HOBt ester (lmmol each). The last 9 residues, Thr(9)-Met(l) 
and GIn(4 1 )&(40) were double coupled as their HOCt active esters. Following 
completion of the synthesis the N-terminal Fmoc was left on and the resin bound 
product was capped by sonication for 30 minutes in acetic anhydride (0.5M), DIEA 
(0.125M) and HOBt (0.2% w/v) in DCM (20m1). The Fmoc-[6,11,27,29,33&63-
Lys(Tnm)]ubiquitin-resin (109) was separated by filtration, washed with DMF and 
1,4-dioxan and divided into four equal portions which were stored in 1,4-dioxan at 
4°C until required. 
Tbfmoc loading 
A 640mg portion of the Fmoc-[6, 1 l,27,29,33&63-Lys(Tnm)]ubiquitin-resin (109) 
was sonicated in 20% v/v piperidine/DMF for 20 minutes to remove the Fmoc group 
and subsequently washed with DMF, DCM and diethyl ether and dried in vacuo for 
30 minutes. Thfrnoc chloroformate (38) (37.1mg, 0.08 immol) was dissolved in DCM 
(tOrn!) and the solution added to the thy resin (600mg, 0.027mmol) followed by 
DIEA (14. ltl, 0.08 immol). The mixture was sealed and sonicated in the dark for 3 
hours with occasional mixing. The Thfinoc-[6,11,27,29,33&63-Lys(Tnm)]ubiquitin- 
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resin (110) was filtered, washed copiously with DCM then diethyl ether and dried in 
vacuo. AAA (40hours) Asx7 8.5 8, Thr7 6.4 1, Ser3 2.29, G1x12 13.41, Pr03 3.4 5, G1y6 
5.65, Ala2 2.54, Va11 3.62, Met 1 0.53, llei 7.67, Leu9 6.75, Tyri 0.68, Phe2 2.45, His, 
0.73, Lys7 7.35, Arg4 2.95. 
Cleavage of Tbfmoc- 16,11 ,27,29,33&63-Lys(Tnm)J ubiquitin-resin (110) 
The next step was cleavage of the peptide from the resin and the simultaneous 
deprotection of all side chain protecting groups, with the exception of the six 
Lys(Tnm) residues which were only partially cleaved. This was accomplished by 
firstly swelling the Thflnoc-peptide-resin in phenol (0.75g), EDT (2m1), thioarnsole 
(0.5ml) and triisopropylsilane (TIS) (200d) for 30 minutes under an atmosphere of 
dry nitrogen whilst protected from the light. Water (0.5m1) and TFA (lOmI) were 
then added and the cleavage mixture stirred for a further 4 hours. The resin was 
separated by filtration, washed with TFA (5m!) and DCM (5m!) and the filtrate 
concentrated in vacuo to a yellow oil. The crude Thflnoc-peptide was precipitated 
from the oil by the addition of 2% v/v -mercaptoethanol in diethyl ether (lOOmI) at 
0°C. The diethyl ether was decanted off and the crude Thfmoc-peptide dissolved in 
20% aqueous acetic acid and lyophilised to yield a white fluffy solid of Thfmoc-
Ub(Tnm)6 (111) (350mg). AAA (40hours) Asx 7 7.6 8, Thr7 6.52, Ser3 2.37, G1x 12 
12.89, P1703  2.78, G1y6 5.45, Ala2 2.42, Va11 3.65, Met, 0.62, 11e7 7.54, Leu9 6.98, 
Tyri 0.59, Phe2 2.37, His 1 0.73, Lysi 7.42, Arg4 3.50. 
One portion of Thfmoc-Ub(Tnm) 6 (111) was purified using the Thfmoc/charcoal 
protocol while the second was purified without affinity purification onto charcoal. 
Affinity purification on charcoal of Tbfmoc-16,11,27,29,33&63-Lys(Tnm)] 
ubiquitin (i'll) 
The crude Thflnoc-[6,11,27,29,33&63-Lys(Tnm)] ubiquitin (111) (150mg) was 
solubilised in 6M GdmCl (1 Sm!), diluted with isopropanol (1 5m1) and centrifuged to 
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remove a small amount of insoluble material. To the supernatant was added charcoal 
(1.5g) which had been prewashed with 10% piperidine in 6M GdmCllisopropanol 
(1:1, lOOm!) followed by 6M GdmCllisopropanol (1:1, 5xl00ml). The mixture was 
vortexed for 10 minutes and centrifuged (15 minutes, 4000rpm) to a pellet. The 
supernatant was decanted and the adsorption of the Thfmoc-protein monitored by 
HPLC (ABI aquapore RP300 C 8, 220x4.6mni, 7jim, A=H20,  B=CH3CN, 0.1% TFA; 
imI/min., 10-90% over 30 minutes, X 1 =214n.m, X2=364mn). No absorbance was 
visible at 364nm; thus it was assumed that all the Thfmoc material had been adsorbed 
onto the charcoal. The charcoal was then washed to remove truncated peptides by 
vortexing with 6M GdmCllisopropanol (1:1, 20m1) followed by centrifuging the 
charcoal to a pellet. The wash protocol was repeated until no absorbance at 2 l4nm 
was visible by HPLC. 
The protein was cleaved from the Thfmoc by vortexing the charcoal with 10% 
piperidine in 6M GdmCllisopropanol (1:1, 20m1 x 3) for 10 minutes after which the 
mixture was centrifuged to a pellet. The combined deprotection supernatants were 
neutralised to pH 4.5 with acetic acid and the isopropanol removed in vacuo prior to 
being loaded onto a Sephadex G50 (fine) column (66000mm) which had been 
equilibrated with 25% aqueous acetic acid. The column was eluted at 35m1/h with 
monitoring at 226 and 277nm and collecting 20 minute fractions. The protein 
containing fractions were pooled and lyophilised to yield fully deprotected Ub 
sulphoxide and Ub (labelled Ub(112)) as a white fluffy solid (80mg). AAA (40hours) 
Asx7 7.80, Thr7 6.3 1, Ser3 2.69, G1x12 13.52, Pr03 3.2 5, Gly6 5.34, Ala2 2.66, VaL1 
3.62, Met, 0.53, 11e7 7.29, Leu9 6.82, Tyr i 0.68, Phe2 1.95, His1 0.83, Lys7 7.15, Ar94 
2.87. 
HPLC (ABI aquapore RP300 C 8, 220x4.6mm, 7pm, A=H20, B=CH3CN, 0.1% TFA; 
[ml/mm., 10-90% over 30 minutes, X=214nm) HPLC analysis showed two main 




mlz (LDTOF) (1) 8581.8 ([MetS-oxide]Ub), C 378171630N 1050119S 1 requires 8581.8, (2) 
8588.47 (Na adduct), C 378H630N 1050118 S 1 requires 8565.9; 
m/z (Electrospray) (2) 8557.0 (bovine Ub (Sigma) Found, 8558.0, C378H630N 1050 118 S 1 
requires 8565.9). 
MMA reduction and cation exchange/CM-Sepharose CL6B of deprotected 
Ub(1 12) 
Ub(112) (33mg) was dissolved in 10% aqueous acetic acid (lOmi) and MMA 
(850.5t1, 9.6mmol) added giving a 10% w/v solution, which was purged with 
nitrogen and incubated at 37 °C for 24 hours. The reduction reaction was monitored 
by analytical RP HPLC at 214mii The protein solution was diluted to 60m1 with 
50mM NthOAc, the pH adjusted to pH 4.5, and then loaded onto a CM-Sepharose 
CL613 column (280x16mm) which had been equilibrated with 50mM NIH4OAc pH 
4.5. The column was then eluted with 50mM NH 4OAc pH 4.5 (90m1) at 30mlIh for 3 
hours with monitoring at 226/277nm. A pH gradient of 50mM NH4OAc at pH 4.5 to 
50mM NH4OAc pH 5.5 (500m1) was then run overnight. After which the column was 
run isocratically at 50mM NH 4OAc pH 5.5 (120m1) for 4 hours followed by a salt 
gradient of 50mM N}LOAc pH 5.5 to 0.3M NH4OAc at pH 5.5 (500m1) to elute the 
protein from the column. The protein containing fractions were pooled and 
lyophilised to give (8mg) of folded [lb. This material was further purified by semi-
preparative HPLC (ABI aquapore RP300 C 8, 250x9.2mni, 7pm, A=H20, B=CH3CN, 
0.1% TFA; 5m1/min., 10-60% over 30 minutes, X=214nm) and lyophilised to yield a 
white fluffy solid of pure folded Ub(116) (5mg); HPLC (vydac C 8, 250x4.6mm, 54m, 
A=H20, B=CH3CN, 0.1% TFA; lmllmin., 10-90% over 30 minutes, X 1 =214um, 
?.2-364nm), R=17.4 mins., 53%B; m/z (LDTOF) 8566.95, C378H 30N 1050 118S 1 
requires 8565.85; AAA (40hours) Asx7 7.3 7, Thri 7.03, Ser3 3.09, G1x12 12.4 9, Pr03 
3.5 2, G1y6 5.93, Ala2 2.07, VaL 4.01, Met 1 0.63, lie7 6.66, Leu9 8.57, Phe2 1.99, His 1 
0.91, Lys7 6.60, Arg4 3.60. UV circular dichroism: Ub(116) 0.5mgmr' in 50mM 
sodium borate buffer, pH 7, a-helice 11% ± 1.5% and f3-sheet of 60% ± 2.8%. 
121 
Experimental 
Gel filtration/Sephadex G50 of Tbfmoc-(6,1 1 ,27,29,33&63-Lys(Tnm)J ubiquitin 
(111) 
A portion of the crude Thfmoc-[6,11,27,29,33&63-Lys(Tnm)] ubiquitm (111) 
(200mg) was dissolved in 25% aqueous acetic acid (20m1) prior to being loaded onto 
a Sephadex G50 (fine) column (66000mm) which had been equilibrated with 25% 
aqueous acetic acid. The column was eluted at 35m1/h with monitoring at 226 and 
364nm and collecting 20 minute fractions. The Thflnoc-Ub(Tnm) 6 (113) containing 
fractions were pooled and lyophilised (100mg); HPLC (ABI aquapore RP300 C 8 , 
220x4.6mm, 74m, A=H20, B=CH3CN,  0.1% TFA; lmllmin., 10-90% over 30 
minutes, X 1 =214nm,, X2=364nm); R26 mins., 76.6%B; AAA (44 hours) Asx 7 7.64, 
Thr7 5.95, Ser3 2.40, G1x12 12.59, Pr0 3 3.94, G1y6 5.57, Ala2  2.43, VaL1 3.74, Be7 
7.07, Leu9 8.05, Tyri 0.65, Phe2 1.87, His1 0.92, Lysi 6.81, Ar94 3.14. 
Non-Thfmoc material (114) (truncations) which eluted from the column were also 
pooled and lyophilised; HPLC (ABI aquapore RP300 C 8, 220x4.6mni, 7pm, A=H20, 
B=CH3CN, 0.1% TFA; lmllmin., 10-90% over 30 minutes, ? 1 =214nm, X2=364nm); 
L=19.4 mins., 57%B; m/z (LDTOF) 8079.85 (acetyl Thr(12)-Gly(76) requires 
8068.8), 5083.6 (acetyl Glu(34)-Gly(76) requires 5083.6), 4064.7 (acetyl Leu(43)-
Gly(76) requires 4062.6). 
Deprotection of Tnm group in Tbfmoc-16,11,27,29,33&63-Lys(Tnm)] ubiquitin 
(113) 
Thfmoc-[6,1 l,27,29,33&63-Lys(Tnm)] ubiquitin (113) (5mg) was dissolved in 6M 
GdmClltns base pH 8.8 (5m1) and the solution somcated at room temperature for 1.5 
hours. The deprotection reaction was followed by analytical RP HPLC (ABI 
aquapore RP300 C 8, 220x4.6mni, 7nn, A=H20, BCH3CN, 0.1% TFA; imi/min., 
10-90% over 30 minutes, X 1 =214nm, X2=364nm). The reaction mixture was then 
loaded onto a Sephadex G50 (fine) column (66000mm) which had been equilibrated 
with 25% aqueous acetic acid. The column was eluted at 35m1/h with monitoring at 
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226 and 364nm and collecting 20 minute fractions. The protein containing fractions 
were pooled and lyophilised to yield fully deprotected Ub(115) as a white fluffy solid 
(3mg); HPLC (ABI aquapore RP300 C8, 220x4.6mm, 7pm, A=H 20, B=CH3CN, 
0.1% TFA; lmllmin., 10-90% over 30 minutes, ?214nm) Rt=16.8 mins., 5 1%B; 
(bovine Ub, Rt=16.8mins.,  51%B); m/z (LDTOF) 8601.61 (C378H 30N 1050118 S 1 
requires 8565.9); AAA (40hours) Asx7 7.03, Thr7 6.03, Ser3 2.72, G1x12 12.82, Pr03 
4.47, G1y6 5.39, Ala2 2.61, VaL1 3.44, Met, 0.34, 11e7 6.66, Leu9 7.58, Tyr 1 0.42, Phe2 
1.83, His, 0.68, Lysi 6.49, Ar94 3.27. 
Non-Tbfmoc purification of 16,11 ,27,29,33&63-Lys(Tnm)J ubiquitin 
A 225mg portion of the peptide-resin (109) was somcated in 20% v/v piperidine/DMF 
for 20 minutes and subsequently washed with DMF, DCM and diethyl ether and dried 
in vacuo for 30 minutes. Cleavage of the peptide from the resin was accomplished by 
firstly swelling the peptide-resin in phenol (0.75g), EDT (2m1), thioanisole (0.5m1) 
and trüsopropylsilane (TIS) (200tl) for 30 minutes under an atmosphere of dry 
nitrogen. Water (0.5m1) and TFA (lOmi) were then added and the cleavage mixture 
stirred for a further 4 hours. The resin was separated by filtration, washed with TFA 
(5m1) and DCM (5m1) and the filtrate concentrated in vacuo to an oil. The crude 
peptide was precipitated from 2% v/v -mercaptoethano1 in diethyl ether (lOOmI). 
The diethyl ether was decanted off and the crude peptide dissolved in 20% aqueous 
acetic acid and lyophilised to yield a white fluffy solid of Ub(Tnm) 6 (117) (110mg). 
Gel filtration/Sephadex G50 of 16,11,27,29,33&63-Lys(Tnm)I ubiquitin (117) 
A portion of the crude Ub(Tnm) 6 (117)(100mg) was dissolved in 25% aqueous acetic 
acid (20ml) prior to being loaded onto a Sephadex G50 (fine) column (660x30mm) 
which had been equilibrated with 25% aqueous acetic acid. The column was eluted at 
35m1/h with monitoring at 226 and 277nm and collecting 20 minute fractions. The 
protein containing fractions were pooled and lyophilised to yield Ub(Tnm) 6 (118) as a 
123 
Experimental 
white fluffy solid (90mg); HPLC (ABI aquapore RP300 C8, 220x4.6mm, 74m, 
A=H20, B=CH3CN, 0.1% TFA; lmllmin., 10-90% over 30 minutes, X=214nm) broad 
peak Re=24mins.,  71%B; m/z (LDTOF) 9491.22, (C408H6 72N111 0154S 1 requires 
9628.56); AAA (40hours) Asx 7 7.80, Thr7 6.31, Ser3 2.69, G1x 12 13.52, Pr03 3.25, 
G1y6 5.34, Ala2 2.66, VaL1 3.62, Met 1 0.53, 11e7 7.29, Leu9 6.82, Tyr 1 0.68, Phe2 1.95, 
His1 0.83, Lysi 7.15, Ar94 2.87. 
FPLC/SuperdexTM 75 of 16,11,27,29,33&63-Lys(Tnm)J ubiquitin (117) 
Ub(Tnm)6 (117) (90mg) was somcated in 6M GdmCl (6m1), centrifuged (15 mins., 
4000rpm) and the supernatant loaded onto a SuperdexTM 75 HR 10/30 column which 
had been equilibrated with 6M GdmCL The column was eluted at 0.5mllmin with 
monitoring at 280nm and collecting 0. 5m1 fractions. Fractions 40-48 and fractions 
75-80 absorbed at 280nm and after isolation by HPLC, gave identical mass spectra 
corresponding to [6,1 l,27,29,33&63-Lys(Tnm)] ubiquitin. All fractions containing 
protein were combined and extensively dialysed (MWCO 500, Spectra/Por® CE) 
against water and lyophilised to give Ub(Tnm) 6 (120) (80mg) HPLC (ABI aquapore 
RP300 C 8, 220x4.6mm, 7p.m, A=1120,  B=CH3CN, 0.1% TFA; imI/min., 10-90% 
over 30 minutes, A=214nm) broad peak R24niins., 71%B; m/z (LDTOF) 9448.44 
(C408H 72N1110154S 1 requires 9628.56); AAA (40hours) Asx7 7.80, Thr7 6.3 1, Ser3 
2.69, G1x 12 13.52, Pr03 3.25, G1y6 5.34, Ala2 2.66, VaL1 3.62, Met 1 0.53, 11e7 7.29, 
Len9 6.82, Tyr i 0.68, Phe2 1.95, His 1 0.83, Lys7 7.15, Arg4 2.87. 
Deprotection of Tnm group in 16,11,27,29,33&63-Lys(Tnm)1 ubiquitin (118) 
[6,11,27,29,33&63-Lys(Tnm)] ubiquitin (118) (13mg) was dissolved in 6M 
GdmClltris base pH 8.8 (1 Oml) and the solution sonicated at room temperature for 
1.5 hours. The deprotection reaction was followed by analytical HPLC (vydac C8, 
250x4.6mm, 5pni, AH20, B=CH3CN, 0.1% TFA; lml/min., 10-90% over 30 
minutes, X 1 =214nm). The reaction mixture was then loaded onto a Sephadex G50 
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(fine) column (660x30mm) which had been equilibrated with 25% aqueous acetic 
acid. The column was eluted at 35m1/h with monitoring at 226 and 377nm and 
collecting 20 minute fractions. The protein containing fractions were pooled and 
lyophilised to yield fully deprotected Ub(119) as a white fluffy solid (9mg); HPLC 
(vydac C 8, 250x4.6mm, 5.tm, A=H20, B=CH3CN,  0.1% TFA; lm]/min., 10-90% 
over 30 minutes, X=214nm) Rt=23.5  mins., 68%B; (bovine Ub, R23.5mins., 68%B) 
m/z (LDTOF) 8582.4 ([MetS-oxide]Ub C 37811630N 1050119 S 1 requires 8581.8). AAA 
(40 hours) Asx7, Thr7, Ser3, G1x 12, Pr03, G1y6, Ala2, Va11, Met 1 , Be7, Leu9, Tyri 
,Phe2, His 1 , Lys7 , Arg4 . 
MMA reduction and gel filtrationlG50 Sephadex of Ub(119) 
Ub(119) (9mg) was dissolved in 10% aqueous acetic acid (5m1) and MMA (464p1, 
5.25mmol) added giving a 10% w/v solution, which was purged with nitrogen and 
incubated at 37°C for 72 hours. The reduction reaction was monitored by analytical 
RP HPLC at 2 l4nm. The protein solution was diluted with water and lyophilised 
three times. MMA was still present thus the reaction mixture was diluted with water 
and applied to a Sephadex G50 (fine) column (66000mm) which had been 
equilibrated with 25% aqueous acetic acid. The column was eluted at 35m1/h with 
monitoring at 226 and 277nm and collecting 20 minute fractions. The protein 
containing fractions were pooled and lyophilised to yield Ub as a white fluffy solid 
(6mg); HPLC (vydac C 8, 250x4.6nim, 5gm, AH20, BCH3CN, 0.1% TFA; 
ImI/min., 10-90% over 30 minutes, A=214nm) R 1 23.5 mins., 68%B; (bovine Ub, 
R=23.5mins., 68%B) m/z (LDTOF) 8567.65, C 378H630N 1050 118 S 1 requires 8565.85; 
AAA (40hours) Asx7 7.45, Thr7 7.04, Ser3 3.07, G1x 12 12.54, Pr03 3.9, G1y6 5.95, 




4.3.6: Chemical synthesis and purification of dhIFN-y 
Chemical synthesis of dhlFN-y 
The synthesis was performed on a 0. immol scale using the Fmoc-GIn(Trt) Wang resin 
(0. 72g, 0. 14mmoIIg). The side chain protecting groups used were as follows: tert-
butyl (But)  ethers for serine, threonine and tyrosine; But  esters for aspartic and 
glutamic acid; 'r-triphenylmethyl (Trt) for histidine; 2,2,5,7, 8-pentamethylchroman-6-
sulphonyl (Pmc) for arginine. The carboxamide side chains of asparagine and 
glutamine were incorporated as the 'r-triphenylmethyl (Trt) derivatives. Lysine and 
tryptophan were protected as the tert-butyloxycarbonyl (Boc) derivatives. The amino 
acids were single coupled using the HOCt method (lmmol) with the exception of 
histidine which was coupled as the active HOBt ester. The last 44 residues, GIn( 1)-
lle(44) were double coupled as their HOCt active esters. Approximately one third of 
the resin was removed after Asp(76) and the remaining resin used to continue the 
synthesis. On completion of assembly the N-terminal Fmoc group was left on and the 
resin bound product was capped by sonication for 30 minutes in acetic anhydride 
(0.5M), DIEA (0.125M) and HOBt (0.2% w/v) in DCM (20m1). The Fmoc-cthIFN-y-
resin (125) was separated by filtration, washed with DMIF and 1,4-dioxan and divided 
into four equal portions which were stored in 1,4-dioxan at 4 °C until required. 
Tbfmoc loading 
A 640mg portion of the Fmoc-dhlFN-y-resin (125) was sonicated in 20% v/v 
piperidine/DMF for 20 minutes to remove the Fmoc group and subsequently washed 
with DMF, DCM and diethyl ether and dried in vacuo for 30 minutes. Thfmoc 
chioroformate (38) (29mg, 0.063mmol) was dissolved in DCM (lOml) and the 
solution added to the dry resin (540mg) followed by DIEA (1 ipi, 0.063mmol). The 
mixture was sealed and sonicated in the dark for 3 hours with occasional mixing. The 
Thfmoc-dh]FN-y-resin (126) was filtered, washed copiously with DCM then diethyl 
ether and dried in vacuo. AAA (40 hours) Asx 20 22.43, Thr5 5.43, Ser 11 10.02, G1x 18 
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21.05, Pr02 3.73, G1y5 5.30, Ala8 7.70, Va18 9.31, Met4 2.31, 11e7 7.91, Leu 10 11.19, 
Tyr4 3.91, Phe 10 12.04, His2 2.77, Lys20 20.43, Arg8 6.30. 
Cleavage of Tbfmoc-dhIFN-y-resin (126) 
To the resin bound Thfmoc-protein (126) (540mg) were added phenol (0.75g), EDT 
(2m1), thioanisole (0.5ml) and allowed to remain for 30 minutes under an atmosphere 
of dry nitrogen whilst protected from the light. Water (0. 5m1) and TFA (1 OmI) were 
then added and the cleavage mixture stirred for a further 4 hours. The resin was 
separated by filtration, washed with TFA (2m1) and the Thfmoc-protein was 
precipitated from the filtrate by the addition of 2% v/v 3-mercaptoethanol in diethyl 
ether (100m1) at 0 °C. The Thfmoc-proteinldiethyl ether mixture was centrifuged 
(lOmins., 4000rpm) to give a pellet of Thfmoc-protein which was dissolved in 20% 
acetonitrile in H20 and lyophilised to yield a white fluffy solid of crude Thfmoc-
dhJFNj' (127) (350mg), HPLC (ABI aquapore RP300 C 4, 100x4.6mm, 74m, 
A=1120, B=CH3CN, 0.1% TFA; imI/min., 10-90% over 30 minutes, X 1=214nni, 
A2=364nm), R=19.2mins., 53%B and Rt=20.6 mins., 58%B ;AAA (40 hours) Asx 20 
22.52, Thr5 5.42, Ser i  10.62, G1x 18 20.02, Pr02 1.89, G1y5 5.46, Ala8 7.54, Va18 9.5 1, 
Met4 3.38, 11e7 8.36, Leu 10 10.98, Tyr4 4.64, Phe 10 10.95, His2 2.49, Lys2o 21.61, Arg8 
6.55. 
Affinity purification on charcoal of Tbfmoc-dhJlFN-y-resin (127) 
The crude Thfmoc-dhWN-y (127) ((300mg) was solubilised in 6M GdmCl (15m1), 
diluted with isopropanol (1 5m1) and centrifuged to remove a small amount of 
insoluble material. To the supernatant was added charcoal (3g) which had been 
prewa shed with 10% pip eridine in 6M GdmCllisopropanol (1:1, 1 OOml) followed by 
6M GdmCllisopropanol (1:1, 5xlOOml). The mixture was vortexed for 10 minutes 
and centrifuged (15 minutes, 4000rpm) to a pellet. The supernatant was decanted and 
the adsorption of the Thfmoc-protein monitored by HPLC (ABI aquapore RP300 C 4 , 
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100x4.6mm, 74m, A=H20, B=CH3CN, 0.1% TFA; imI/min., 10-90% over 30 
minutes, X 1=2 l4nm, X2=364nm). No absorbance was visible at 364nm; thus it was 
assumed that all the Thfmoc material had been adsorbed onto the charcoal. The 
charcoal was then washed to remove truncated peptides by vortexing with 6M 
GdmCllisopropanol (1:1, 20m1) followed by centrifuging the charcoal to a pellet. The 
wash protocol was repeated until no absorbance at 214nm was visible by HPLC. The 
protein was cleaved from the Thfmoc by vortexing the charcoal with 10% piperidine 
in 6M GdmCllisopropanol (1:1, 20m1 x 3) for 10 minutes after which the mixture was 
centrifuged to a pellet. The combined deprotection supernatants were neutralised to 
pH 4.5 with acetic acid and reduced in vacuo to remove the isopropanol. The protein 
solution (50m1) was filtered through celite and a 2p.m filter, to remove residual 
charcoal, before being concentrated to a volume of lOmI (Amicon ultrafiltration, 
MWCO 5,000) of dhJFN-y/guariidine solution (128). HPLC (ABI aquapore RP300 
C4, 100x4.6mm, 7jtm, A=H20, B=CH3CN, 0.1% TFA; lmllmin., 10-90% over 30 
minutes, ? 2l4nm, 2 2=280nm), R17.2mins., 51%B; m/z (LDTOF) 16,909.1 
(C746H1188N2110221 S4 requires 16,777.2), 14,377.3, 13,256.3 and 10,693; SDS PAGE 
4 bands 16.8, 14.3, 13.2 and 10.5kDa; AAA (40 hours) Asx20 22.46, Thr5 5.60, 
Ser11 10.30, G1x18 19.74, Pr02 1.20, Gly5 5.64, Ala8 7.80, Va16 8.83, Met4 3.49, 11e7 
8.65, Leu 10 10.36, Tyr4 4.80, Phe 10 11.36, His2 2.57, Lys20 21.38, Ar98 7.41. 
Gel filtrationlSephadex G50 of dhIFN-y (128) 
A portion of the dhIFN-y/6M GdmCl solution (128) (5m1) was loaded onto a 
Sephadex G50 (line) column (66000mm) which had been equilibrated with 25% 
aqueous acetic acid. The column was eluted at 35m1/h with monitoring at 226 and 
277nm and collecting 20 minute fractions. The protein containing fractions were 
pooled and lyophilised to yield dhJFN-y as a white fluffy solid (60mg); HPLC (ABI 
aquapore RP300 C 4, 100x4.6mm, 7.tm, AH20, BCH3CN, 0.1% TFA; lml/min., 
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10-90% over 30 minutes, A 1 =214nm, X2=280nm). R=17.2mins., 51 0/613; m/z 
(LDTOF) 16,975.8 (C 746H 1188N2110221 S4 requires 16,777.2), 14,373.5, 13,292.1 and 
10,696.9; SDS PAGE 4 bands 16.8, 14.3, 13.2 and 10.5kDa; AAA (40 hours) Asx 20 
21.59, Thr5 4.61, Ser11 10.60, G1x 18 17.89, Pr0 2 1.25, G1y5 4.64, Ala 8 7.53, Va!8 8.09, 
Met4 3.42, 11e7 8.35, Leu 10 9.35, Tyr4  3.95, Phe 10 11.03, His2 2.12, Lys20  19.24, Ar98 
7.33. 
FPLC/SuperdexTM 75 of dhLFN-y (128) 
A portion of the dhlFN-y/6M GdmCl solution (128) (5m1) was loaded onto a 
SuperdexTM 75 HR 10/30 column which had been equilibrated with 6M GdmCl. The 
column was eluted at 0.5m1/min with monitoring at 280nm and collecting 0.5m1 
fractions. Fractions absorbing at 280nm were examined by analytical RP FIPLC (ABI 
aquapore RP300 C4, 100x4.6mm, 7pm, A=H20, B=CH3CN, 0.1% TFA; imI/min., 
10-90% over 30 minutes, X 1 =214am, ? 2=280nm). Fractions 8-15 eluted with the 
correct retention time (Rt=17.2mins., 5 1%B) however fractions 8-10 gave the 
sharpest HPLC profiles. Individual fractions were desalted examined by SDS PAGE 
PhastGel and mass spectra obtained; fraction 9: m/z (LDTOF) 16,884.9 
(C746H1188N2110221 S4 requires 16,777.2), 14,307.9 and 13,225.4; SDS PAGE 3 bands 
16.8, 14.3 and 13.2kDa; fraction 11: m/z (LDTOF) 16,909.1 (C 746H1188N2110221 S4 
requires 16,777.2), 14,294.2, 13,256.3 and 10,724.5; SDS gel 4 bands 16.8, 14.3, 
13.2 and 10.5kDa. 
Fractions 8 and 9 were combined to give dhlFN-y (129) for subsequent purification 
reactions. AAA (40 hours) Asx 20 22.56, Thr5 5.30, Ser 11 10.22, G1x 18 19.53, Pr0 2 
0.89, Gly5 5.67, Ala8 7.83, Va18 8.83, Met4 3.26, 11e7 8.21, Leu 10 10.72, Tyr4 4.68, 
Phe 10 11.02, His2 1.78, Lys20 20.96, Ar98 7.25. UV circular dichroism: 0.5mgmi' in 
50mM sodium borate buffer, pH 7, a-helice 44 ± 0.49% and 3-sheet of 25% ±.43%. 




Residue 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
No. 
Amino On Asp Pro Tyr Val Lys Glu Ala Giu Asn Leu Lys Lys Tyr Phe 
acid 
Pmol 310 152 350 288 426 352 171 315 178 251 355 381 519 252 364 
Table 7 N-Terminal sequencing results for dhIFN-y (129) 
Hydrophobic Interaction chromatography/ Phenyl Sepharose of dhIFN-y (128) 
A lml portion of the dhlFN-y/6M GdmCl solution (128) was slowly diluted to a 
volume of 6m1 with 0.7M ammonium sulfate in 10mM sodium borate buffer, pH8.0. 
The mixture was loaded onto a Phenyl Sepharose 6 Fast Flow (high sub) column 
(supplied by Pharmacia Biotech) which had been equilibrated with 0.7M ammonium 
sulfate in 10mM sodium borate buffer, pH8.0. The column was eluted with 0.7M 
ammonium sulfate in 10mM sodium borate buffer, pH8.0 (20m1) at 30mIIh with 
monitoring at 226/277nm. The column was then eluted with successively reduced 
concentrations of ammonium sulphate: 0.35M(20nil), 0. 175M(20m1) and finally only 
the 10mM sodium borate buffer. Fractions absorbing at 280nm were combined, 
concentrated and desalted (Aniicon ultrafiltration, MWCO 5,000) to give dliIFN-y 
(130). HPLC (ABI aquapore RP300 C 4, 100x4.6mni, 7tm, A=H20, B=CH3CN, 
0.1% TFA; imI/min., 10-90% over 30 minutes, ?=214nm, X 2=280nm) Rt=17.2mins., 
51%B; m/z (LDTOF) 16,975.8 (C7 46H1188N2110221 S4 requires 16,777.2), 14,373.5, 
13,292.1 and .10.696.9; SDS PAGE 4 bands 16.8, 14.3, 13.2 and 10.5kDa; AAA (40 
hours) Asx20 22.60, Thr5 4.61, Ser 11 10.50, G1x18 18.79, Pr02 1.25, G1y5 4.66, Ala8 
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6.76, Vals 8.09, Met4 3.41, 11e7 7.12, Leu 10 9.35, Tyr4 3.95, Phe 10 11.03, His2 2.12, 
Lys20  19.24, Arg8 7.33. 
Cation exchange FPLClResource S of dhIFN-y (129) 
As a general method the dhlFN-y/6M GdniCl (129) was slowly dialysed against 
native buffers (50mM IVIES buffer, pH 6.0 or 50mM phosphate buffer, pH 6.0) to fold 
the protein and desalt the solution to concentrations of :50. 1M 6M GdmCl. The 
protein/buffer solutions were loaded onto a cation exchange column (Resource S) 
which had been equilibrated with the appropriate buffer eluting at 4m]/min. The 
column was then eluted with a linear NaC1-gradient of 0- 1M NaC1 with monitoring at 
280iim. Fractions absorbing at 280nm were concentrated (centricon ultrafiltration, 
MWCO 1000) and both the filtrate and retentate were examined by analytical RP 
HPLC, SDS PAGE and MALDI TOF MS. No protein was recovered from any of the 
cation exchange experiments. 
Isoelecfric focusing (IEF) of dhIFN-y (129) 
An aliquot of dhlFN-'y/6M Gdm.Cl (129) was slowly dialysed against 1M urea 
solutions to obtain a dlilFN-y/lM urea solution (50m1). Ampholytes (pH3-10, 0.5nil) 
were added before the solution was loaded into the focusing chamber of the 
Rotofor® cell. The system was allowed to come to thermal equilibrium at the cooling 
temperature of 4 °C before connecting the power supply and running at 15W constant 
power. The run was monitored by observing the voltage increase over time and was 
judged to be completed after 4 hours when the voltage -stabilised. At this point the 
run was allowed to continue for 30 minutes before harvesting. The twenty fractions 
obtained were examined by HPLC and the protein containing fractions (fractions 1 & 
2, pH 4.5) were characterised by SDS-PAGE and MALDI MS and found to be 
indentical. dhlFN-y (131), HPLC (ABI aquapore RP300 C 4, 100x4.6mm., 7pm, 
A=H20, BCH3CN, 0.1% TFA; imI/min., 10-90% over 30 minutes, X 1 =214nm, 
X2=280nm) R1 17.2mins., 51%B; m/z (LDTOF) 16,908.5 (C746H 1188N211 0221 S4 
requires 16,777.2), 14,378.3, 13.257 and 10593; SDS PAGE 4 bands 16.8, 14.3, 
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13.2 and 10.5kDa; AAA (40 hours) Asx 20 22.52, Thr5 5.41, Ser 11 10.62, G1x 18 20.02, 
Pr02 1.89, G1y5 5.45, Ala8 7.45, Va!8 9.50, Met4 3.37, 11e7 8.36, Leu 10 10.98, Tyr4 
4.64, Phe 10 10.94, His2 2.49, Lys2o 21.61, Ar9 8 7.54. 
Tryptic digest of dhIFN-y (129) 
dhTFN-y (129) (0.5mg) was dissolved in 3M GdmCl buffered Tns.HCL (50mM, pH 
8, 370C). Trypsin (5% w/v) was added and the mixture incubated at 37 °C. After 2 
and 6 hours aliquots were removed and the digestion stopped by the addition of 
6MHC1 (5tl). m/z (LDTOF) 2379.5 (MLys(13)-Lys(34) requires 2380.2), 2160.8 
(MH* Asp(90)-Arg(107) requires 2158.1), 1822.4 (MW Ala(109)-Lys(125) requires 
1822.0), 1675.1 (MHlLeu(95)-Lys(108), Na adduct, requires 1674.9), 1642.2 (MW 
Lys(43)- Lys(55), Na adduct, requires 1642.8), 1496.6 (MW Glu(75)-Lys(86), Na 
adduct, requires 1496.7); HPLC (ABI aquapore RP300 C 4, 100x4.6mm, 7jim, 
A=H20, B=CH3CN, 0.1% TFA; lmllmin., 10-90% over 30 minutes, A 1=214nm, 
? 2-28Onm). 
Glycine-sodium dodecyl sulphate-polyacrylamide gel electrophoresis (glycine-
SDS-PAGE) 
Analytical experiments were carried out using BlO-RAD Mini-PROTEAW'' vertical 
gel electrophoresis apparatus. Proteins were analysed by electrophoresis at 50mA per 
gel, at 25 °C under denaturing conditions (in the presence of sodium dodecyl 
sulphonate (SDS) and -mercaptoethanol) using the Laemmli discontinuous buffer 
system. 131  Separating and stacking gels were made using Protogel (30% w/v 
acrylamide, 0.85 w/v N,N'-bis-methyleneacrylamide) and were polymerised by the 
addition of tetramethylethylenediamine (TEMED) and ammonium phosphate (APS). 
Separating gels (20% acrylamide) were prepared with 1.5M Tris.HC1, pH 8.8, 10% 
w/v SDS and stacking gels (4% acrylamide) were prepared with 125mM Tris.HC1, 
pH6.8, 10% w/v SDS. The gel running buffer contained 192mM glycine, 25mM 
Tris.HC1, pH 8.3 and 0.1% SDS. 
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Protein samples were prepared by heating the sample with the appropriate amount of 
5 x SDS reducing buffer (62.5mM Tris.HC1, pH 6.8, 10% v/v glycerol, 2% v/v SDS, 
5% v/v -mercaptoethano1, 0.05% w/v bromophenol blue) at 90°C for 5 minutes prior 
to electrophoresis. After electrophoresis, protein bands were visualised by staining 
with 10% v/v acetic acid, 40% v/v methanol, 0.1% w/v Coomassie Blue R-250 for 1 
hour, followed by destaining in 10% v/v acetic acid, 40% v/v methanol for 2 hours or 
until the band of interest could be identified. 
Western blot analysis of dhIFN-y (128) 
dhWN-y/6M GdmCl solution (128) was desalted, lyophilised and dhJFN-y (0.5mg) 
and Multimark multi-coloured standards were loaded onto a 15% acrylamide SDS-
gel. After electrophoresis the lane containing the molecular weight markers was cut 
out and kept for reference and the gel was allowed to equilibrate in transfer buffer 
(25mM Tris.HCI, pH 8.3, 187mM Glycine, 20% v/v Methanol) for 15 minutes. The 
proteins on the gel were then electrophoretically transferred to a nitrocellulose 
membrane using a BlO-RAD system for 1 hour at 100V. The nitrocellulose 
membrane was then blocked with blocking solution (5g Marvel in lOOml TBS: 20mM 
Tris, pH 7.5, 0.5M NaC1), for 1 hour at room temperature before being washed for 3 
x 5 minutes with TTBS (20mM Tris, pH 7.5, 0.5M NaCl, 0.05% v/v Tween-20). The 
membrane was then incubated with monoclonal mouse anti-hJFN-y antibody solution 
for 1 hour at room temperature. The TTBS wash procedure was repeated for 3 x 5 
minutes before the membrane was incubated in biotinylated secondary antibody for 30 
minutes. The membrane was then washed 3 x 5 minutes in TTBS followed by 
incubation in alkaline phosphatase conjugated ABC, diluted 1:30 in TTBS. After 
washing the membrane was incubated in the dark for 10-30 minutes with the enzyme 
substrate. The enzyme substrate was freshly prepared by adding 66.i1 NBT stock 
(Nitro Blue Tetrazolium, 50mg in lml 70% DMF) and 33p,l  BCIP stock (5 Bromo-4-
Chloro-3-lndoyl Phosphate, 50mg in lml 100% DMF) to lOmis alkaline phosphatase 
buffer (0. 1M Tris, pH 9.0, 0. 1M NaCl and 50mM MgCl). After incubating for 15 
minutes three dark bands had developed. Using the molecular weight marker lane 
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these bands were identified as approximately 1 7kDa (dhJFN-y requires 16. 8kDa) 
—34kDa (dimer of dhIFN-y requires 33.6kDa). 
Preparative glycine-SDS-PAGE of dhIFN-y (128) 
dhlFN-y/6M GdmCl solution (128) was desalted and lyophilised and dkWN-7 (0.5mg) 
dissolved in 5 x SDS reducing buffer (500t1). The sample was then heated at 90 °C 
for 5 minutes and loaded onto a 180mm x 150mm x 3mm 20% preparative 
polyacrylamide gel. Low molecular weight markers were loaded as a reference lane 
next to 10 sample elution lanes and the gel electrophoresed at 5mA at 4 °C overnight. 
After electrophoresis, the reference lane and the adjacent sample lane were cut Out 
stained with Coomassie Blue R-250 (0.1% w/v in an aqueous solution of 40% v/v 
methanol, 10% v/v acetic acid) for 1 hour, followed by destaining in an aqueous 
solution of 40% v/v methanol, 10% v/v acetic acid for 1 hour. During this procedure 
the unstained gel was kept moist with a small amount of running buffer. The stained 
and unstained gels were aligned and the pertinent area identified on the stained gel. 
The location of the appropriate band on the unstained gel was then estimated by 
extrapolating from the stained gel. The band of interest was excised and eluted into 
lml elution buffer (192mM glycine, 25mM Tris.HCI, pH 8.3 and 0.1% SDS) for 5 
hours at 40C using the Model 422 Electro-Eluter (Bio-Rad) according to the 
manufacturers instructions. 
After elution the sample was dialysed (centricon 3000) against 10mM sodium 
phosphate buffer, pH 7.5 to remove SDS and concentrate the protein. The eluted 
protein dhIFN-y (132) was examined by SDS-PAGE and a single band was visualised 
at 16.8kDa. Sequencing analysis from N-terminus: Found: residue(R) 1 =GIn, R2 Asp; 
dhIFN-y requires R 1 =Gln, R2=Asp. 
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